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Designed analogues of the aplyronines for use in antibody – drug conjugates 
Rachel Jayne Porter 
Summary 
The aplyronines are a family of structurally complex marine macrolides, isolated from the 
sea hare Aplysia kurodai, that exhibit picomolar growth inhibitory activity in the NCI 60 
cell line panel. An unprecedented heterotrimeric complex has been observed to form 
between aplyronine A and actin and tubulin together, resulting in disruption of cytoskeletal 
dynamics and subsequent cell death. This novel mode of action, coupled with their 
exquisite biological activity, renders the aplyronines compelling candidates for 
incorporation as payloads into antibody-drug conjugates provided the supply problem can 
be solved.  
Guided by structure-activity relationship (SAR) studies, a highly convergent route towards 
novel and simplified aplyronine structures has been designed. Routes to these function- 
oriented analogues should be more streamlined and efficient due to judicious structural 
editing, whilst functionality and potency are retained.  
Chapter 1 introduces marine natural products and illustrates their therapeutic potential 
alongside the challenges associated with these highly complex structures. The aplyronine 
family of natural products is introduced and a function-oriented approach towards analogue 
design is presented. The avenue of targeted therapies is discussed, with particular focus on 
the field of antibody–drug conjugates.  
Chapter 2 outlines the synthesis of our key simplified fragments. Significant optimisation 
efforts towards the synthesis of the side chain ketone are discussed, together with the 
synthesis of the northern fragment. Chapter 3 outlines two complementary fragment 
coupling strategies to access our designed analogues. Contrasting to the established 
sequence, an alternate approach is examined in which the southern and side chain fragments 
are first connected before the northern piece is appended. The strengths and shortcomings 
of each route are reviewed.  
Chapter 4 culminates in endgame manipulations to generate a range of simplified analogues 
and details their initial biological evaluation. Preliminary investigations into linker 
strategies using a quaternary amine approach are investigated. Chapter 5 summarises this 
work and presents suggestions for future directions of this research for the purpose of 
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Metal enolate stereochemistry 
 
According to accepted convention, the two metal enolates A and B will be referred to as 
(E)- and (Z)-enolates respectively (Figure 1). The metal–oxygen substituent is considered 









Syn- and anti-diastereoisomers 
 
The syn- and anti-convention introduced by Masamune for assigning the relative 
stereochemistry of vicinal stereocentres is used in this dissertation.1 A syn-relationship is 
defined by two substituents (R1 and R2) pointing in the same direction relative to the plane, 
defined by the main chain drawn in a zigzag confirmation, as shown in Figure 2. 
Conversely, an anti-relationship is defined by the two substituents occurring on opposite 





























Aldol adduct stereochemistry 
In aldol reactions where an a-chiral ketone directs the stereochemical outcome, the aldol 
adduct is referred to as shown in Figure 3. Here, the pre-existing ketone a-stereocentre is 
labelled as “1”. This convention recognises the origin of the stereochemistry whilst also 








Figure 3 Aldol adduct stereochemistry 
 
Compound numbering 
The naming and numbering of compounds is in accordance with the priorities set out by 
IUPAC. The numbering system for aplyronine analogues and intermediates follows that of 
Yamada and co-workers in their original publication detailing the isolation and 
characterisation of the aplyronines.2  It is used in the assignments of 1H NMR spectra and 
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1.1 Bioactive natural products throughout history 
Nature represents a vast, fertile source of structurally diverse biologically active 
compounds and offers inspiration for the development of novel therapeutic agents. Arising 
from secondary metabolite pathways, many natural products exhibit extremely high 
potencies and selectivities to ensure survival in extreme habitats and offer defence 
mechanisms against potential predators. Natural products, especially those from terrestrial 
origins, have historically been a source of drug molecules, with plants in particular forming 
the basis of these traditional medicines.3,4  
The use of plant-based drugs, rich in bioactive natural products, has been well described 
throughout history in the form of oils, infusions, potions and remedies for the treatment of 
a range of diseases. Clay tablets from Mesopotamia (2600 B.C.) documented oils from 
Cupressus sempervirens (cypress) and Commiphora species (myrrh) for the treatment of 
coughs, colds and inflammation, which are still in use today. This is believed to depict the 
earliest record of natural products as therapeutic agents.5 Several well-known milestones 
in drug discovery from natural products followed, including the isolation of morphine from 
Papaver somniferum (opium poppy) and  the anti-inflammatory acetylsalicyclic acid 
(aspirin) from the bark of the willow tree Salix alba in the 1800s.6,7 Their structural 
diversity and biological activity render natural products the most valuable source of new 
drugs and drug leads. In fact, over the last twenty years, more than one third of all FDA-
approved therapeutic agents were derived from or inspired by natural products with more 
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than 50% of small molecule drugs originating from natural products and their mimics, 
during 1981 to 2014.8 
 
1.1.1  Marine natural products 
Despite covering more than 70% of the surface of the earth, the world’s oceans remain a 
vastly underexplored resource. The flora and fauna within the marine environment are a 
rich and valuable source of biodiversity. Advancements in underwater exploration 
technology, enabling the improved collection of marine organisms and isolation of their 
metabolites, have fuelled the discovery of thousands of bioactive marine natural 
products.8,9 The ocean is a biologically challenging environment, with many sedentary 
marine organisms (e.g. sponges) relying on chemical means of defence against predation 
and competition. To counteract dilution effects from the sea, these marine metabolites have 
evolved into exceptionally potent cytotoxic agents. Many of these compounds appear to 
show superior molecular diversity compared to their terrestrial counterparts and belong to 
completely novel chemical classes.10  
Prized sources of natural products from the marine environment include algae, sponges, 
corals and molluscs. Algae alone account for a vast array of structurally diverse natural 
products, with over 30,000 algal species worldwide.11 In particular, red algae are an 
unrivalled source of chemically unique halogenated sesquiterpenes and have been 
investigated since 1970.12–14 Comprising approximately 60% of all marine animals, marine 
invertebrates are another highly valued source with over 11,000 novel natural product 
structures discovered between 1990 and 2014.15,16 Finally, microorganisms such as marine 
cyanobacteria, fungi and bacteria have received increased attention as a fertile sources of 
bioactive metabolites, with many natural products originally isolated from marine 
macroorganisms having now been attributed to metabolic products of symbiotic 
microorganisms.17–19  
Whilst exhibiting unique architectural complexity, many marine natural products also 
display novel modes of action in biochemical systems. These molecules have become 
validated starting points for the targeted development of drug-like molecules for the 
treatment of human diseases, especially in the field of cancer therapy.20,21 Common 
strategies for the treatment of cancer involve the interference and disruption of cellular 
processes such as signal transduction, microtubule assembly and DNA interactions, 
ultimately leading to apoptosis of the proliferating cancer cells.22 
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The first FDA-approved marine derived anticancer drug was cytarabine (1) (Figure 5) in 
1969.  From the Caribbean sponge Cryptotheca crypa, Bergmann isolated and identified 
the nucleosides spongouridine (2) and spongothymidine (3).23 These antiviral compounds 
guided the development of an analogue (Ara-C, 1) as a clinical anticancer agent for the 




Figure 5 Structure of cytarabine (1) and related nucleosides  
 
Today, several other notable anticancer drugs derived from marine origins are on the 
market (Figure 6), with many more undergoing clinical trials. Trabectedin (4, YondelisÒ) 
is an anti-neoplastic marine alkaloid which was approved for the treatment of advanced 
soft tissue sarcoma in 2007. In 2010, the microtubule targeting agent eribulin mesylate (5, 










Figure 6 ‘Drugs from the sea’, trabectedin (4) and eribulin mesylate (5) 
 
A major obstacle in the evaluation and development of a natural product through to a viable 
drug candidate is the sustainable supply of highly precious material. The synthesis of these 
intricate structures is demanding and uncompromising, thus offering a tantalising challenge 
to the synthetic organic chemist. Consequently, elegant yet highly selective and 
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Accessing multigram quantities of complex material exclusively through synthesis has 
been exemplified through the combined Novartis–Smith–Paterson synthesis of the 
anticancer agent discodermolide (6, Figure 7) on a 60 g scale.26–30 This remarkable 
sequence illustrates the power of contemporary organic synthesis and the link between total 
synthesis in academia to the process chemistry field. Despite this synthetic success, Phase 
I clinical trials were halted due to issues with off-target toxicity and clinical development 
was ultimately discontinued, an all too common outcome in the case of highly cytotoxic 





Figure 7 Marine natural product discodermolide (6) 
 
 
1.1.2 Synthetic analogues of natural products 
Total synthesis offers the opportunity to develop novel, simplified analogues or hybrids of 
natural products, with the anticipation of enhancing or maintaining biological activity, 
whilst greatly simplifying the synthesis. This tailored approach circumvents the low 
chemical tractability displayed by natural products as lead structures in drug development. 
These refined structures have also yielded crucial information on modes of action and 
biological activities.32 
This “function-oriented” strategy33 focusses on function by design with an emphasis on 
synthetic economy, and has been applied to numerous natural products.34–36 In particular, 
the development of bryostatin 1 (7) analogues or “bryologs” by Wender and co-workers 
resulted in the generation of a range of simplified and clinically superior analogues (Figure 
8).37–39 In addition, fragment-oriented synthesis has been applied to the anticancer natural 
product families the migrastatins (8) and anguinomycins (9, Figure 8).40,41 The potent 
biological activities of the natural products are retained in these structurally simplified 
analogues (as deemed by the reduction in molecular weight, MW), whilst the synthetic 
effort required is greatly reduced by the elimination of a number of non-essential 















Figure 8 Function-oriented synthesis of simplified analogues: a) bryostatin 1 (7) and “bryolog” 
(10) (PKC = protein kinase C); b) Migrastatin (8) and the core analogue (11) (IC50 values are for 
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43% reduction in MW
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Anguinomycin D (9) Anguinomycin D analogue (12)
Maintains bioactivity




























bryostatin 1 analogue (10)
PKC Ki = 0.25 nM
19 steps LLS
20% reduction in MW
C7H15
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Perhaps the most notable example of truncating a highly complex natural product is 
represented by the anticancer drug eribulin mesylate (5), a simplified analogue of the 
marine natural product halichondrin B (13, Figure 9). Scarce supply from the marine 
source necessitated formidable synthetic efforts and the first total synthesis of halichondrin 
B was reported by Kishi in 1992 in over 90 steps.42 Biological testing on numerous 
intermediates and analogues from the synthesis revealed its activity hinged upon the 
macrocyclic lactone moiety alone.43 This resulted in the development of a scalable 37-step 
industrial synthesis by Eisai of the structurally simpler analogue eribulin (5), which was 





Figure 9 Halichondrin B (13) and its simplified analogue eribulin mesylate (5) 
 
 Overall, eribulin (5) represents a vast simplification in structure through the exclusion of 
the seven polyether rings, remarkably resulting in halving the number of synthetic steps, 
whilst conserving the potent anticancer activity exhibited by the parent compound.  
 
1.2 Targeted cancer therapy 
Traditional chemotherapeutic drugs primarily target and inhibit cell division. However, 
these cytotoxic agents affect not only proliferating cancer cells, but other rapidly dividing 
healthy cells and tissues. This off-target toxicity, stemming from a lack of specificity, 
results in many unpleasant and dangerous side effects such as hair loss, nausea and myeloid 
suppression.45 The inherent toxicities of potent natural products at doses required for 
efficacy results in a narrow therapeutic index and limits their progress towards clinical use. 
Increasing potency, thereby decreasing the minimum effective dose, alongside improving 


























































Figure 10 Maximising the therapeutic window of drugs 46 
 
More than one hundred years ago, Paul Ehrlich first articulated the notion of combining a 
toxic entity together with specific binding to a diseased cell or organism within a single 
molecule and coined the term “magic bullets” to describe molecules such as these. Targeted 
medicine which sets the goal of aiming precisely with highly potent drugs dominates 
contemporary drug discovery. Indeed, it could be said that the development of personalised 
and tailored drugs is the ultimate goal within modern oncology research. 
The development of “magic bullet” therapeutics that selectively deliver cytotoxic agents to 
the tumour site has greatly progressed over the last few decades.47,48 These revolutionary 
medicines aim to inhibit essential biochemical targets and molecular pathways that are 
critical for the growth and maintenance of cancer cells.49 Targeting mutant kinases with 
small molecule tyrosine kinase inhibitors has seen success through the approval of Imatinib 




Figure 11 Imatinib (14), a small molecule tyrosine kinase inhibitor 
 
Other approaches involve conjugated species consisting of cytotoxic effectors that are 
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Monoclonal antibodies, which can specifically recognise antigens on the surface of cancer 
cells, offer another avenue for targeted therapy. In particular, antibody‒drug conjugates 
(ADCs) have emerged as promising and clinically validated leads for the treatment of 
cancer.52 
 
1.3 Antibody–drug conjugates 
 
Antibodies, or immunoglobins, are large Y-shaped proteins produced by plasma cells and 
are utilised within the immune system to identify and neutralise pathogens such as bacteria 
and viruses. The antibody specifically recognises a unique antigen expressed on the surface 
of the pathogen and binds to it through non-covalent interactions. By exploiting their 
specific binding properties, monoclonal antibodies can act as a mechanism for the selective 
delivery of cytotoxic agents to cancer cells. This new frontier in cancer therapy has grown 
rapidly, with four commercial ADCs on the market and more than sixty under investigation 
in clinical trials.53–57 
 
Antibody‒drug conjugates consist of a cytotoxic drug (often referred to as the payload or 
warhead) linked to a monoclonal antibody, as illustrated in Figure 12. This linkage should 
mask the cytotoxicity of the drug during transport but effectively release it when the 
conjugate reaches its intended antigen binding target. These three components together give 
rise to a powerful therapeutic agent guided by the exquisitely selective antibody, capable 







Figure 12 Generalised structure of an antibody–drug conjugate 
Once bound, the conjugate is then internalised into the cell via endocytosis and undergoes 
chemical or enzymatic cleavage to release the therapeutic agent. The drug then enters the 
cytosol and reaches its cellular target, eventually resulting in apoptosis (Figure 13). 
Additionally, if the cytotoxic agent is released into the extracellular tumour environment 
before internalisation, there is potential for neighbouring cancer cells to be killed in a 
Antibody Cytotoxic drug
Linker
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process known as the “bystander effect”. This effect could be significant in solid tumours 









Figure 13 Mechanism of action of an ADC 59 
 
The use of antibody‒drug conjugates brings with it many advantages due to the large 
contact surface area relative to small molecules. Humanised antibodies display long half-
lives of up to three weeks in circulation and therefore are practical for clinical use.46 The 
high affinity in antibody‒antigen interactions should result in the accumulation of the 
antibody at the tumour site, avoiding delivery to healthy tissues. Wastage of the precious 
cytotoxic agent is also reduced through decreased metabolism and excretion. Highly potent 
warheads are required, meaning previously rejected natural products that displayed off-
target toxicity can now be reconsidered. Antibody‒drug conjugates can therefore offer a 
viable and prolonged treatment option in cancer therapy. However, numerous challenges 
remain in the design and production of these new modalities. 
 
1.3.1 The antibody 
The antibody must selectively bind to target antigens that are solely or overexpressed on 
the surface of tumour cells to convey the highest degree of targeted delivery.60 This is 
achieved by capitalising on accessible tumour-associated markers and proteins which are 
abundantly expressed at the site of the disease in a homogeneous fashion but have little 
expression in normal cells. Alongside specificity for a target, the antibody should have 
sufficient binding affinity for retention and accumulation at the tumour site. However, 
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antibodies with extremely high antigen affinity can result in reduced efficiency for tumour 
penetration.61–63 Thus, an ADC with high antigen affinity does not necessarily translate to 
a treatment with high clinical efficacy. 
First generation ADCs made use of murine or chimeric antibody sequences, which elicited 
an immunological response to the foreign proteins and resulted in rapid clearing of the 
murine antibody from circulation.46,64 This problem has since been overcome in current 
ADCs with the incorporation and development of fully human antibodies.65  
 
1.3.2 The linker  
The choice and design of linkers for immunoconjugates is paramount. The linker must 
remain stable in circulation, avoiding uncontrolled leakage of the precious cytotoxic agent, 
yet precisely release the drug upon delivery to the cell. Consequently, the linker can play a 
profound role in defining the selectivity, pharmacokinetics, therapeutic window and even 
the overall success of the ADC. There are two main types of linkers currently in use: 
cleavable and non-cleavable linkers.  
Cleavable linkers contain labile functional groups that are easily broken down in the cell, 
such as hydrazones or disulfide and amide bonds (Figure 14). This process relies on the 
differences between the intracellular and plasma environments, such as acidic pH ranges 
and reduction potentials. However, these linkers have been observed to slowly release the 
drug into plasma, leading to systemic toxicity. A further cleavable linker strategy is to rely 
on intracellular proteases or esterases found in the lysosome to elicit hydrolytic enzymatic 
cleavage of peptide amide or ester bonds, typically used in combination with a self-
immolating spacer unit. The dipeptide valine-citrulline (Val-Cit) motif is an example of 
this and undergoes specific cleavage upon exposure to the lysosomal protease cathepsin 
B.66 
In most cases, these linkers are designed to release the parental toxin in a chemically 
unmodified, fully active form. This traceless approach is the main advantage of cleavable 
linkers and the cytotoxic potency of the conjugated payload can thus be estimated from the 
known pharmacological parameters of the free payload.   
Conversely, non-cleavable linkers rely upon complete proteolytic degradation of the 
antibody component of the ADC within the lysosome. This liberates a modified payload 
containing the amino acid residue derived from the antibody, typically a cysteine or lysine 
motif. With these linkers, any differences in activity between parent drug and potential 
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ADC metabolites must therefore be considered. Structurally, these linkers are typically 
alkyl or polyethyleneglycol (PEG) chains terminally appended with functionality to 
facilitate conjugation to the toxin and antibody. Non-cleavable linkers therefore confer the 
advantage of enhanced plasma stability and thus avoid non-specific release of the drug. 
This stability, however, limits the propensity for bystander killing of neighbouring cells.  
 
The linker is an integral structural aspect in designing a successful ADC therapeutic and 
current work in the field is largely focused on developing more sophisticated linker 












Figure 14 Cleavable linker strategies used in ADCs 
 
1.3.3 Conjugation methods 
One of the main difficulties associated with antibody‒drug conjugates is achieving 
homogeneity through conjugation methods. Zero to eight drug molecules can typically be 
conjugated to an antibody and heterogeneous mixtures of species with varying drug to 
antibody ratios (DAR) have usually been produced.67 Controlling the number and position 
of drug molecules attached to an antibody has important consequences for its 
pharmacokinetics. Unconjugated or poorly conjugated (e.g. with the payload localised in 
antigen binding sites) species can offset the benefit of drug-loaded ones, resulting in 
diminished activity. In addition, there is some evidence to suggest that a larger DAR leads 





































Cleavage in the lysosome
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heterogeneity by utilising site specific conjugation through techniques such as 
bioorthogonal chemistry and protein engineering.69 Conjugation can occur through native 
nucleophilic residues on the antibody scaffold or non-native functionality introduced 
through genetic engineering. In either case, these chemically reactive sites on the antibody 
surface must be utilised without impacting on the biophysical integrity of the antibody 
framework.70,71  
Conventionally, the naturally occurring reactive lysine and cysteine residues on the 
antibody have been used as conjugation sites through acylation and alkylation reactions. 
These are an attractive option due to the ease of reactivity without any processing or 
modification of the antibody required. Most ADCs are built on immunoglobin scaffolds 
(IgG) possessing over 80 lysine residues, 20 of which are found at highly solvent accessible 
sites, resulting in products with greatly variable DARs. This non-specific conjugation 
results in heterogeneous mixtures that can be prone to aggregation.72 Conversely, cysteine 
residues within an antibody exist as disulfide pairs and are more uniformly distributed with 
4 inter-chain disulfides and 12 intra-chain pairs. Selective reduction of the inter-chain 
disulfides produces eight possible sites for bioconjugation, again leading to a mixture of 
products (Figure 15).  
Modern advancements in genetic engineering have enabled site-selective antibody 
modification through artificially engineered cysteine residues on the antibody surface, e.g. 
Genentech’s THIOMAB technology. Further methods of site specific linkage to produce 
ADCs with precise DAR include engineering to introduce unnatural amino acid residues 
for orthogonal bioconjugation, e.g. azide click chemistry.73–75 
Cysteine conjugation takes advantage of fast Michael addition reactions with maleimides, 
resulting in succinimide thioethers. A major problem with this approach is the tendency of 
thiosuccinimide linkages to undergo a retro-Michael reaction, thereby resulting in non-
specific deconjugation. However, it has been reported that hydrolysis of the 
thiosuccinimide ring can prevent this elimination from occurring, circumventing the loss 
of drug‒linker unit from the ADC.76 As disulfide bonds are an integral structural element 
of the antibody scaffold, techniques involving developing re-bridging linkers have evolved 
for ADC production. The idea is simple: a bis-reactive drug-linker moiety undergoes 
reaction with both thiol residues produced from disulfide cleavage, leading to covalent re-
bridging of the protein in tandem with drug attachment (Figure 16).77,78 Ultimately, the 
combination of conjugation and linker chemistry must be customised to the antibody, the 
cytotoxic molecule and the profile of the disease to be treated in order to create an effective 
ADC.   




















Figure 15 Antibody conjugation using native amino acid residues; A) lysine conjugation, 
B) cysteine conjugation from reduced disulfides, C) cysteine conjugation through 




Figure 16 Conjugation of a payload to a disulfide bridge 78 
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1.3.4 The payload  
The core requirement for the payload is cytotoxicity. For an ADC to be therapeutically 
active, the number of drug molecules required to kill the cell should be well below the 
delivery threshold of the antibody. Combined with limited delivery of the cytotoxin caused 
by poor internalisation of the conjugate or inefficient payload release, the potency 
commanded is that of the sub-nanomolar range. Indeed, it has been reported that very few 
drug molecules actually reach the cell with studies suggesting only 0.01–0.1% per injected 
dose per gram of tumour mass is internalised.79 
The drug has to be amenable to selective functionalisation and attachment to the linker 
under physiologically compatible conditions. These non-trivial modifications should not 
negatively affect the potency of the parent drug. The conjugate should also be stable and 
soluble enough to store in aqueous media and to allow for controlled reactions with 
antibodies.  
Currently, the vast majority of ADCs in the clinic or in trials fall within two main 
categories: microtubule inhibitors (auristatins, tubulysins, maytansines) or DNA-damaging 
agents (calicheamicin, duocarmycin and pyrrolobenzodiazepine dimers). All these natural 
products were previously excluded as single use therapeutics due to the potential for off- 
target toxicities, but guided by the impeccable cell-targeting ability of an antibody they 
have resurfaced as viable drug candidates.46 Arguably, these payloads are somewhat 
limited in their mechanisms of action and future advances in the field should gear towards 
novel payload classes with diverse mechanisms of action to help combat resistance. 
The viability of antibody‒drug conjugates as therapeutic agents has been clinically 
demonstrated through the approval of ADCs for cancer treatment. Adcetris (brentuximab 
vedotin 15, Figure 17) is currently on the market for the treatment of Hodgkin lymphoma. 
This ADC features monomethyl auristatin E (MMAE), a microtubule inhibiting natural 
product derived from the marine natural product dolastatin 10, originally isolated from the 
sea hare Dolabella auricularia, as the cytotoxic warhead.80,81 Conjugation occurs through 
a cysteine residue via a maleimide group attached to the peptide-cleavable valine‒citrulline 
linker containing a self-immolative spacer. Kadcyla (ado-trastuzumab emtansine 16, 
Figure 17), approved for the treatment of metastatic breast cancer, uses the plant-derived 
drug maytansine which also targets microtubule assembly.82 This ADC contains a non-
cleavable linker conjugated via a maleimide onto the antibody through lysine residues. 
Maytansine and MMAE were previously excluded as anticancer drugs due to unacceptably 
high toxicity in human trials but have now seen clinical success through incorporation into 
immunoconjugates.  
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Derivatives of the calicheamicins, a family of bacterial-derived antitumour antibiotics, 
are prevalent in multiple ADCs.83–85 Their biological activity is elicited through binding 
of DNA leading to strand scission and resulting in cell death. Besponsa (inotuzumab 
ozogamicin 17, Figure 17) was approved in 2017 for the treatment of acute 
lymphoblastic leukaemia and contains a calicheamicin based payload. Mylotarg 
(gemtuzumab ozogamicin), also containing a calicheamicin payload, was re-introduced 
to the market for acute myeloid leukaemia in 2017 after previously being excluded due 
to issues surround toxicity. 
 
 
1.3.5 Summary and outlook 
ADCs have paved the way to revive highly potent compounds as cancer chemotherapeutic 
agents that were too toxic to be clinically useful on their own. Current conjugates make use 
of antibodies that are of human origin, and therefore not immunogenic, and linkers that are 
designed to be stable in circulation yet precisely release the toxin upon internalisation into 
the cell.  
 
ADCs rank among the most actively pursued classes of therapeutics in oncology, yet many 
challenges still remain in their development. Low to moderate preferential accumulation of 
the antibody at the tumour site has been reported in a number of cases with wide variations 
in tumour uptake observed.86 Processes such as antibody-tumour localisation in vivo also 
remain largely underexplored. Furthermore, the development of more homogeneous and 
stable conjugate systems is of paramount importance for the success of next-generation 
antibody therapeutics. 
 
Additionally, the high cost of bringing an ADC to market must be considered. Many rounds 
of optimisation are usually required to deliver an effective therapeutic. Nevertheless, with 
many more ADCs currently in various stages of clinical testing, this is a field that is rapidly 
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1.4 The aplyronines  
1.4.1 Isolation and structural determination 
The aplyronines are a family of polyketide marine natural products isolated by Yamada and 
co-workers from the sea hare Aplysia kurodai, collected of the coast of the Mie prefecture 
in Japan. This marine mollusc has proven to be a fertile source of bioactive natural products 


















Figure 18 Selected bioactive molecules isolated from Aplysia kurodai 
 
Aplyronine A (21), together with its two congeners aplyronines B (22) and C (23), was 
originally isolated in 1993 through an eight-step chromatographic sequence guided by 
HeLa–S3 cytotoxicity assays.2 An improved isolation procedure led to the discovery in 
2000 of the minor congeners aplyronines D-H.90 Isolation yields remained prohibitively 
low however, with 300 kg of wet sea hare yielding only 75 mg (10-5 %) of aplyronine A 

























Table 1 Structure and activity of the aplyronine family. a mg per 300 kg sea hare; b in vitro 













Congener R1 R2 R3 Isolation yield a / mg IC50b /nM 
A (21) 
 
TMSer H DMAla 75 0.45 
B (22) 
 
H TMSer DMAla 4.3 2.9 
C (23) 
 
H H DMAla 0.9 22 
D (24) 
 
TMSer H DMGly 2.6 0.071 
E (25) 
 
= 22-methylaplyronine A 4.0 0.18 
F (26) 
 
TMSer H MMAla 0.7 0.18 
G (27) 
 
DMSer H MMAla 1.6 0.12 
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Elucidation of the key structural features was determined by analysis of IR, UV and 1D 1H 
and 13C NMR data. Each congener features a 24-membered macrolactone with an eleven-
carbon side chain, terminating in an N-methyl-N-vinyl formamide moiety. Fifteen 
stereocentres append the carbon backbone, arranged in three stereotetrads (C7–C10, C23–
C26 and C29–C32) with three isolated stereocentres (C13, C17 and C19). The absolute and 
relative configuration of aplyronine A was determined by detailed 2D NMR studies and 
stereocontrolled synthesis of various degradative fragments. This assignment was further 
supported by the completion of the first total synthesis of aplyronine A by the Yamada 
group in 1994.92–97 
The structural variation in the aplyronine congeners is chiefly seen in the identity and 
positioning of the amino acid residues between the C7, C9 or C29 hydroxyls. The 
configuration of the stereogenic amino acids is noteworthy, as they present as scalemic 
mixtures of the corresponding (R)- and (S)-epimers. These ratios seem to always favour the 
naturally occurring (S)-configuration. It is postulated that this stereocentre could undergo 
epimerisation in the biosynthesis of these molecules or during the isolation procedure.2  
 
1.4.2 Biological activity  
The cytotoxicity of the aplyronines in the HeLa-S3 cell line is nothing short of exceptional, 
with IC50 values in the low to sub-nanomolar range across the family. Furthermore, on 
testing in the NCI human tumour 60 cell line primary screen, aplyronine A displayed 
excellent activity, with a GI50 of less than the 0.1 nM minimum threshold being observed 
across the majority of cell lines.98,99   
The main difference between the congeners of the aplyronine family lies in the amino acid 
residues. It is notable that these seemingly small differences yield such strong variations in 
their biological activities (Table 1). For example, aplyronine A is approximately 50 times 
more cytotoxic than aplyronine C, which lacks the methylated serine ester group at C7. 
Other congeners that contain this trimethyl serine residue in the same position also exhibit 
high toxicities, but their full biological evaluation has been hampered due to low isolation 
yields.  
On top of this excellent in vitro activity, the most abundant congener, aplyronine A exhibits 
promising growth inhibitory activity in vivo against a range of implanted tumour types in 
mouse xenographs as summarised in Table 2. Remarkable dose-dependent antitumour 
activities and high survival rates were observed in the case of Lewis lung carcinoma and 
P388 leukaemia.91 
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Table 2 In vivo antitumor activity of aplyronine A in mice. a Schedule: intraperitoneally (i.p) days 1-5; 
aplyronine A was dissolved in DMSO (0.08 mg mL-1) and then diluted with a physiological solution 
of NaCl 
 
These results are extremely promising and have propelled the aplyronines into serious 
contention as potential preclinical candidates.100  
 
1.4.3 Interaction with actin 
Actin was identified as the target biomolecule of the aplyronines by fluorescence-based 
measurements by Karaki and co-workers in 1996. Aplyronine A was observed to bind to 
G-actin in a 1:1 ratio.101 Actin is an extremely important and abundant protein, found in 
almost all eukaryotic cells, and is one of the main classes of cytoskeletal proteins within 
the cytoplasm. Actin is involved in the regulation of a variety of cellular processes 












Figure 19 Structure of uncomplexed actin in the ADP state104 
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Actin exists in two forms: monomeric G-actin (globular) and in the form of microfilaments 
in polymeric F-actin (filamentous). Polymerisation of G-actin to F-actin can occur under 
physiological conditions and it is this dynamic equilibrium which is essential for actin to 
exert its cellular function. The unidirectional process of filament growth takes place in a 
head-to-tail manner at the barbed ends of G-actin and is mediated by the interconversion 











Figure 20 Dynamic equilibration between G- and F-actin and the actin treadmilling process106,107 
 
 
Aplyronine A has been found to intercalate via its side chain into a narrow hydrophobic 
cleft of G-actin. This complex causes sequestering of G-actin monomers and thus inhibition 
of treadmilling and polymerisation to F-actin. Additionally, rapid depolymerisation of F-
actin can occur through capping and resulting severing of the actin filaments.101,108 
Disruption of this normal actin modulation pathway can lead to accelerated 
depolymerisation and apoptosis. The aplyronine binding mode described has subsequently 
been confirmed by X-ray analysis (Figure 21).108 This side chain binding occurs between 
subdomains 1 and 3, with the amino acid residues in actin participating in hydrophobic 
interactions with the aliphatic tail regions, ensuring the extended conformation. The 
macrolide core also forms important contacts with a large hydrophobic area on the surface 
of actin. In contrast, the polar terminus is located in a hydrophilic environment and forms 
key stabilising contacts in this region.  
A striking structural resemblance is borne between the aplyronine side chain and other actin 
binding natural products. A highly conserved motif terminating in the same N-methyl-N-
vinyl formamide moiety is present many actin binding natural products including 
reidispongiolide A (29), mycalolide B (30), scytophycin C (31) and rhizopodin (32) 
(Figure 22).109–112 Interestingly, the 80 known actin-binding natural products encompass 
just 8 major skeletal types. The aplyronines, possessing an 11-carbon aliphatic side chain 
coupled with the hydrophobic macrolide core, represent one class of such compounds.113 
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1.4.4 Structure–activity relationship studies  
It has been well established that the side chain motif in the aplyronines is crucial for actin 
binding. A wide range of side chain analogues, based on the aplyronines or the related 
reidispongiolide A (29), have been prepared by the Yamada115–117 and Paterson118–121 
groups to investigate this effect.  
However, actin binding alone cannot account for the variance in biological activity 
displayed by the aplyronine family. It is evident that actin depolymerising ability does not 
mirror the cytotoxicity of the aplyronines. For example, aplyronine A possesses an actin 
depolymerising IC50 value of 31 µM, whereas cytoxicity towards HeLa–S3 cells occurs 
with an IC50 of 0.45 nM.116 Furthermore, aplyronines A and C have identical side chains 
and bind actin with equal affinity, yet aplyronine A is 50 times more cytotoxic, confirming 
that actin depolymerisation alone is not sufficient to confer cytotoxicity. An early insight 
into the structure–activity relationships at play can thus be gleaned from this observation; 
the only difference between these congeners is the presence of the trimethyl serine residue 
at C7 in aplyronine A. This C7 trimethyl serine residue must therefore be profoundly 
important in conveying strong levels of cytotoxicity.  
Extensive structure–activity relationship studies have been carried out on aplyronine A and 
derivatives to gain a better understanding of the structural features which are necessary to 
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The presence of the C7 trimethylserine residue, the conjugated diene moiety and hydroxyl 
groups at C9 and C29 are features necessary to impart toxicity and very little variation is 
tolerated with regards to cytotoxicity compared with actin binding. Actin depolymerisation 
is strongly associated with the side chain, and is enhanced when combined with the 
macrocycle. From all this, we see that the parameters of actin depolymerisation ability and 
cytotoxicity are not always correlated. From crystal structures of the aplyronine–actin 
complex, it is evident that the trimethylserine residue protrudes solely into the surrounding 
bulk solvent. This indicates that its critical influence on cytotoxicity is not due to 
interactions with actin and suggests the possibility of binding to another protein target.  
Kigoshi and co-workers have invoked tubulin binding as an additional mode of action and 
reported that aplyronine A forms an unprecedented 1:1:1 heterotrimeric complex with actin 
and tubulin (Figure 24).124 Tubulin is another abundant cell protein and its monomers 
polymerise to form microtubules, which are important components of the cytoskeleton, 
especially during cell division. Aplyronine A therefore appears able to mediate a protein–







Figure 24 Proposed 1:1:1 heterotrimeric complex between aplyronine A, actin and tubulin; PB = 
protein binding, DPB = duel protein binding 124 
 
Through photoaffinity labelling and fluorescence microscopy measurements, the actin–
aplyronine A complex was found to synergistically bind to tubulin. Interestingly, without 
actin, no binding to tubulin was observed. This suggests actin binding may induce a 
conformational change to create a new tubulin binding site, possibly mediated by the 
trimethylserine residue on the aplyronine molecule. Aplyronine C, in the presence of actin, 
did not bind to tubulin at all, further cementing the importance of the trimethylserine ester 
moiety for interactions with tubulin.124 Kigoshi has further studied these proposed 
interactions and binding affinities using surface plasmon resonance (SPR).125  
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It is unclear exactly how this ternary complex induces cytotoxicity. Consistent with other 
antimitotic agents, such as vinblastine or paclitaxel, the mechanism of action may be 
disruption or blocking of the microtubule spindle organisation and dynamics during 
mitosis, ultimately leading to apoptosis.126,127 
Synergistic binding to two biomacromolecules is rarely seen in natural products and could 
offer enormous therapeutic potential.128,129 Furthermore, with this completely novel 
mechanism of action, there is the possibly of overcoming drug resistance pathways.  
Returning to the numerous criteria for a suitable ADC payload, we see that the aplyronines 
meet many of the fundamental requirements and as such are compelling candidates for this 
targeted therapy. Firstly, they exhibit exquisite cytoxicity in the sub-nanomolar range 
across a range of cell lines, and have even proven to be remarkably effective in vivo. 
Through extensive SAR studies and analysis of the aplyronine pharmacophore, suitable 
sites for functional handles can be identified to facilitate linker attachment. A highly 
promising feature of these bioactive natural products is their exciting and unique 
unprecedented mechanism of action, lending support to the aplyronines tremendous 
promise as an anticancer therapeutic. Antibody conjugation would not only limit off-target 
toxicity issues that could be associated with these highly potent molecules, but also reduce 
the amount of these scarce natural products required for clinical development.  
The realisation of the incorporation of the aplyronines and their analogues into antibody–
drug conjugates hinges upon the supply issue being solved. The current supply of these 
highly precious natural products is minute and thus ADC development is reliant on total 
synthesis to deliver an efficient and scalable route. 
 
1.5 Synthetic efforts  
 
Due to their structural complexity, the aplyronines represent an impressive synthetic target 
and have garnered the interest of a number of research groups. To date, three total syntheses 
have been reported, beginning with the pioneering work of Yamada and co-workers. In 
1994, Yamada reported the first total synthesis of aplyronine A (21) in 98 steps (47 LLS) 
with an overall yield of 0.39%. This lengthy route was justified given the need for flexibility 
within the synthesis to rigorously confirm the structure and absolute configuration of 
aplyronine A (21).92 The synthesis of aplyronines B (22) and C (23) quickly followed, along 
with simplified fragments for SAR studies.97,130 More recently, Kigoshi has reported a 
second-generation synthesis of aplyronine A (21) in 38 steps LLS and an improved 1.4% 
overall yield.131 Fragments have additionally been synthesised by Calter, Marshall and 
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Fuchs, generally following the main disconnections used by Yamada and Paterson.132–136 
The Paterson group has had a longstanding interest in the aplyronine family and synthetic 
efforts are summarised below.  
 
 
1.5.1 Paterson approach to the aplyronines 
Efforts towards the total synthesis of the aplyronines in the Paterson group first began in 
1995. Notable highlights of this ongoing work include the total synthesis of aplyronine C 
and novel tail analogues in 2013, and the completion of aplyronines A and D in 2015.137,138 
Refined coupling strategies and revised synthetic steps have led to improved routes to 
advanced fragments and deeper knowledge about the chemistry of the aplyronines. The 
highly stereocontrolled and convergent route offers the opportunity to access multiple 
congeners of the aplyronine family through late-stage functionalisation with the appropriate 
amino acid residues.  
Controlled installation of the dimethylalanine residue at C29 can be achieved through a 
selective Keck esterification at this position. Subsequent esterification at C7 over C9 is 
dependent on the less hindered hydroxyl conferring increased reactivity at this position. 
Common intermediate 33 (Scheme 1) therefore represents a diversification point, allowing 
access to multiple analogues. The C28–C34 region could be disconnected from the main 
chain through a sequence of aldol‒dehydration‒reduction steps starting from ketone 34 and 
C1‒C27 aldehyde 35. The (E)-trisubstituted olefin could be installed through a Horner‒
Wadsworth‒Emmons (HWE) reaction and Yamaguchi macrolactonisation would assemble 
the macrocycle from two advanced fragments: the northern C1‒C14 phosphonate 36 and the 
southern C15‒C27 aldehyde 37.  
In the forward synthesis, a series of substrate-controlled aldol reactions and 
diastereoselective 1,3-anti reductions were used to efficiently construct the C7‒C10, C23‒
C26 and C29‒C32 stereotetrads. Reagent-controlled reduction was responsible for installing 
the isolated C13 and C19 stereocentres. A key step in the Paterson approach was the strategic 
installation of the N-methyl-N-vinyl formamide side chain terminus. A modified Wittig 
reaction, using methodology developed within the group, proved successful in introducing 
this delicate moiety.139 Overall this route gave aplyronine C (23) in 28 steps LLS (47 total 
steps) in an overall yield of 3.6%.  
Further improvements were implemented in the group’s synthesis of aplyronines A and D 
and include a more streamlined protecting group strategy to deliver a route more amenable 
to scale up.138 
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1.5.2 Aldol methodology 
The stereotetrads found within the aplyronines are a common motif found in polyketide 
natural products. Biosynthetically, under the control of polyketide synthase enzymes, these 
originate from iterative addition of malonyl CoA or methylmalonyl CoA to the growing 
carbon chain. Depending on the type of condensation, one or two stereocentres can be 
introduced per cycle and the resulting b-hydroxy ketone unit can be further manipulated 
through reduction or dehydration reactions. This process is the source of the 1,3-
oxygenation pattern ubiquitously found in polyketides.140 
 
The Paterson approach to the aplyronines calls for construction of the stereotetrads using 
powerful boron aldol methodology largely developed in our laboratory. Enolisation of 
methyl (acetate type) or ethyl ketones (propionate type) and subsequent reaction with 
aldehydes can generate b-hydroxy ketones in a regio-, stereo- and enantioselective fashion 
(Figure 25). Comprehensive understanding of this aldol chemistry coupled with 














Figure 25 General acetate- and propionate-aldol reactions using methyl or ethyl ketones 
 
The relative configuration of the adducts arising from aldol reactions with boron enolates 
can be reliably predicted from inspection of the Zimmerman–Traxler transition state 
models (Figure 26).141 These chair-like transition structures are energetically favourable 
through minimisation of unfavourable 1,3-diaxial interactions. For this reason, (E)-enolates 
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High levels of stereoinduction are observed in boron-mediated aldol reactions. This can be 
attributed to short boron-oxygen bond lengths, ensuring the formation of tight, cyclic 
transition states that exacerbate the effects of unfavourable 1,3-diaxial interactions.143 Thus, 
the formation of geometrically pure enolates is of paramount importance to control the 
stereochemical outcome of these reactions. Numerous powerful methods have therefore 
been developed to enable the stereoselective formation of boron enolates.145–148 
Enolisation at low temperatures (e.g. –78 °C) with dialkyl boron triflates (e.g. n-Bu2BOTf) 
and a sterically demanding tertiary amine base (e.g. i-Pr2NEt) results in the selective 
formation of (Z)-enolates. Conversely, a combination of bulky ligands (e.g. cyclohexyl), a 
poor leaving group (e.g. chloride) and a small amine base (e.g. NEt3) favours the formation 
of (E)-enolates (Scheme 2).148 Formation of (Z)-enolates with dialkyl boron triflates is 
primarily governed by sterics, with both complexes 38 and 39 theoretically possible. 
Ultimately, the steric clash arising from the large triflate substituent and the incoming bulky 
base disfavours the formation of 38, resulting in the generation of the (Z)-enolate. However, 
for (E)-enolates the formation of complex 40, with boron directed towards the less 
substituted side of the carbonyl group, is favoured for both steric and electronic reasons. 
An energetically favourable interaction has been found to exist between the chlorine atom 
and the hydrogen cis to the carbonyl lone pair. This induces a partial negative charge on 
the adjacent carbon and thus activates the cis-hydrogen for deprotonation, selectively 
generating the (E)-enolate.  
Enolate geometry dictates the required relative stereochemistry of an aldol adduct. 
However, there is inherently no control of absolute stereochemistry unless a chiral element 
is present on either the enolate or aldehyde substrate. In particular, chiral ketones are able 
to furnish aldol adducts with high stereeocontrol through control of p-facial selectivity. 
Within our laboratory, Roche ester derived ethyl ketones 42 and 43 are frequently used to 
induce the desired absolute stereochemistry through boron and titanium-mediated aldol 
reactions (Figure 27). The selectivity in these cases will be discussed as they are 






Figure 27 Roche ester derived ethyl ketones 42 and 43 
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1.6 Analogue design and project aims 
 
1.6.1 Analogue design 
The aplyronines, through their exquisite potency and novel biological activity, have 
surfaced as a compelling candidate for incorporation into antibody‒drug conjugates. As 
discussed previously, truncating complex natural products whilst retaining their 
pharmacophore brings with it many advantages. Developing simpler analogues that 
preserve the aplyronines’ function and potency, whilst greatly shortening the synthesis of 
these complex structures, allows for investigations towards a viable and accessible ADC 
payload. Generating structurally simplified analogues also offers the opportunity to create 
more efficient and streamlined syntheses.  
 
A proposed function-oriented analogue scaffold is illustrated in Figure 28. Structure–
activity relationship studies of the aplyronines have indicated that the southern region of 
the macrocycle does not make any significant contact interactions for actin binding or 
cytotoxicity, other than conferring overall shape (Figure 28). Therefore, we propose that 
modifications in this area should not detrimentally affect bioactivity and offers potential to 
simplify the synthesis. Replacing the C17‒C21 chain with a simple hydrocarbon backbone 
removes two stereocentres and an olefin, drastically shortening the synthesis of this 
fragment.  
Additional modifications include the replacement of the C31 acetoxy group with a methyl 
ether, thereby reducing the potential for elimination and the need to manipulate protecting 
groups in subsequent steps. The substitution of the C25 hydroxyl by a methoxy group would 
ensure selective macrolactonisation at C23, avoiding the need to isomerise the undesired 
26-membered ring formed through reaction at C25 that had previously caused difficulties 
within the synthesis.149 Methoxy groups in these positions are present in other natural 
products that exhibit comparable binding affinity to actin and so these modifications are 
anticipated to be well tolerated in analogue 44. With modifications predominantly located 
in the southern fragment, the route towards these simplified analogues intersects well with 
the established Paterson synthesis.  
The Paterson group is not alone in our attempts to truncate the aplyronines to produce novel 
analogues or hybrids. Kigoshi and co-workers have reported the synthesis of hybrid 
structures with the aim of enhancing actin-depolymerising activity or cytotoxicity. 
 

















Figure 28 Function-oriented aplyronine D analogue (44) 
 
 
The first hybrid compound (45, Figure 29) was reported by Kigoshi in 2012. Here, the 
macrolactone core of aplyronine A was appended with the side chain of mycalolide B (30, 
Section 1.4.3, Figure 22), a macrolide natural product isolated from a Japanese sea 
sponge.110,123 Whilst this hybrid compound showed somewhat more potent actin-
depolymerising activity than aplyronine A, the cytotoxicity towards HeLa–S3 cells was 
disappointingly around 1000-fold lower. This result served to once again confirm that there 
is no direct correlation between actin-depolymerizing activity and cell growth inhibitory 
activity. The researches postulated that inversion in configuration at C25 causes a change in 
the conformational relationship between the macrolactone and side chain, as seen from the 
X-ray crystal structure (Figure 29) between the actin–aplyronine A complex and an actin–
karbiramide C (a mycalolide B related compound) complex. Whilst both compounds bind 
readily with actin, the change in angle and thus directional orientation of the macrolactone 
means that hybrid 45 cannot maintain a strong interaction to tubulin to confer cytotoxicity.  
 
In an effort to create a hybrid that is able to induce the desired protein–protein interaction, 
the Kigoshi group subsequently reported the synthesis of an aplyronine A–swinholide 
hybrid. In this case, the macrolide core of aplyronine A was combined with the side chain 








































































Figure 29 Aplyronine hybrid compounds. Superimposed conformations of actin–aplyronine A and –
kabiramide C or –swinholide A complexes based on X-ray analyses are shown. The arrows indicate the 
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This new hybrid 46 retained sub-nanomolar cytotoxicity towards HeLa–S3 cells. Inspection 
of the X-ray crystal structure confirms that this compound adopts a similar actin-binding 
conformation to the parent aplyronine A, and thus may be inferred to induce the postulated 
PPI between actin and tubulin.  
 
Guided by molecular modelling studies, the Kigoshi group have recently reported the 
synthesis of vastly simplified aplyronine analogues 47–49 (Figure 30).152 This bold 
approach consists of only the C1–C9 northern region coupled with the C23–C34 side chain. 
Perhaps unsurprisingly, these heavily truncated structures do not show sufficient PPI 
inducing effects or cytotoxicity. These oversimplified analogues demonstrate that the 
macrolactone portion of the aplyronines is indeed necessary to confer rigidity to fix the 








Figure 30 Kigoshi’s simplified aplyronine analogues152 
 
 
Together, these results from Kigoshi and co-workers demonstrate that simplified hybrid 
aplyronine structures that retain biological activity are synthetically tractable, yet also serve 
as a stark warning that over-simplification can lead to serious deleterious effects on 
cytotoxicity.  
 
1.6.3 Project aims 
The overall goal of this work is to develop novel bioactive analogues of the aplyronine 
family of natural products that can be incorporated into antibody‒drug conjugates. The 
intention is to design and synthesise unique, yet simplified hybrid structures that are more 
accessible than the current routes to the aplyronines but retain the functionality and potency 
of the parent molecules. These streamlined and more efficient syntheses ideally would be 
amenable to large scale production and industrial development, thus saving overall time, 














47: R1 = TMSer, R2 = H
48: R1 = R2 = TMSer
49: R1 = R2 = H
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Importantly, this work also allows for investigation into an alternative coupling strategy. 
Typically, the macrocycle is constructed before attachment of the side chain to limit the 
risk of any degradation of the delicate N-vinyl formamide moiety. A complementary 
approach would be to couple the southern C15‒C27 aldehyde fragment 50 with the side chain 
moiety 51, before addition of northern fragment 36 and finally macrolactonisation. These 
coupling strategies are outlined in Scheme 3. We therefore set the aim of bolstering the 
efficiency of the Paterson synthetic route through this alternative coupling strategy.  
The flexibility of this approach allows for the construction of numerous different analogues 
and hybrids. The option to vary amino acid residues and modify functionality on the side 
chain opens up avenues for diversification. By fine-tuning these parameters, it is anticipated 
that a superior warhead for an ADC can be produced, with the potential for diversity in 







































































































































































































Synthesis of advanced fragments 
 
 
2.1   C1-C14 northern phosphonate 36 
 
As discussed in Section 1.6.1, the northern fragment 36 for analogue synthesis is equivalent 
to that used in the synthesis of the parent natural products. This reflects the importance of 
this region in governing the exquisite cytoxicity displayed by the aplyronines. The dienoate 
moiety and the C7 trimethyl serine ester form key interactions and are crucial for promoting 
tubulin binding, with their removal leading to detrimental effects on the potency of these 
compounds.153  
This fragment features a 1,4-syn-3,4-anti stereotetrad and a (2E,4E)-diene, terminating in 
a phosphonate moiety to facilitate a Horner–Wadsworth–Emmons olefination for extension 
of the carbon skeleton. The potentially sensitive dienoate is initially masked as an alkynoate 
and exposed through a triphenylphosphine-promoted isomerisation. A substrate-controlled 
boron-mediated aldol reaction and 1,3-anti reduction sequence sets the configuration of the 
stereotetrad, revealing Roche ester-derived ethyl ketone 42 and aldehyde 55 as key 
fragments (Scheme 4). 
 










Scheme 4 Retrosynthetic analysis of the C1-C14 northern fragment 36 
 
2.1.1 Anti-aldol coupling 
The synthesis of the C1-C14 northern fragment 36 commences with a selective boron aldol 
reaction that is utilised to set the required 1,4-syn-3,4-anti relationship within the 
stereotetrad. The required ethyl ketone coupling partner 42 was easily accessed in three 
steps from commercially available (R)-Roche ester 58. Following PMB protection, ester 59 
was converted to the corresponding Weinreb amide 60 and subjected to ethylmagnesium 
bromide. After initial attack of the Grignard reagent, the stability of the resulting metal-
chelated intermediate prevents further addition, thereby minimising the formation of the 
tertiary alcohol byproduct. Chiral ethyl ketone 42 could reliably be produced in good yields 








Scheme 5 Synthesis of ethyl ketone 42 
 
Aldehyde 55 was prepared via Parikh–Doering oxidation of the corresponding alcohol 
precursor which had been synthesised in four steps from 5-hexyn-1-ol by Dr Mike Housden 
(Scheme 6). With the requisite aldol coupling partners in hand, ketone 42 could be treated 




















































(a) PMBTCA, PPTS, CH2Cl2; (b) Me(OMe)NH·HCl, i-PrMgCl, THF, —20 ℃; (c) EtMgBr, Et2O
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enolate 62 (Scheme 7). Subsequent addition of aldehyde 55 afforded aldol adduct 57, 
following oxidative workup, in excellent yield and diastereoselectivity on multigram scale 



















Scheme 7 Boron mediated aldol coupling of ketone 42 with aldehyde 55 
 
 
The stereochemical outcome of this reaction can be rationalised by the control of enolate 
geometry and consideration of the competing transition states as illustrated in Scheme 8. 
The hydroxyl configuration ultimately derives from the facial selectivity of the a-chiral 
enolate while the 3,4-anti geometry can be ascribed to the (E)-enolate (Section 1.5.2). 
Through density functional theory studies (DFT), the high levels of stereoinduction 
observed in aldol reactions of b-alkoxy borinates has been rationalised by Paton and 
Goodman where reactions with (Z)-enol borinates proceed through chair transition states, 
whilst (E)-enol borinates proceed via boats.148,154 These boat like transition structures are 
energetically more favourable and relieve the unfavourable 1,3-diaxial interactions 
between the ligand on boron and the side chain of the enolate. Notably, the boat 
conformation is stabilised by a formyl hydrogen bond between the aldehydic proton and 
the electron rich alkoxy oxygen substituent. Although this necessitates folding the alkyl 
chain towards the incoming aldehyde, which would appear to be a sterically unfavourable 
situation, the stabilising C-H-O interaction more than compensates for this.155 The facial 
preference of enolate attack is therefore controlled by the minimisation of 1,3-allylic strain 
(A1,3) between the a-methyl group and the enolate substituent. Consequently, Re-face 






























(a) BCy2Cl, NEt3, Et2O, 0 ℃; (b) 55, —78 ℃ → —20 ℃ then MeOH, H2O2, pH 7.0 buffer
(88%)
>95:5 dr
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interactions whilst Si-face attack, via TS-1, is more energetically favoured, leading to the 




















Scheme 8 Competing transition states for aldehyde addition of the (E)-enol borinate derived from 
Roche ester ethyl ketone 42 
 
 
2.1.2 1,3-Anti reduction and alkynoate isomerisation 
An Evans–Tishchenko reduction was successfully employed to install the required 1,3-anti 
relationship, setting the configuration of the full C7-C10 stereotetrad (Scheme 9).156 This 
hydroxyl-directed reduction of ketone 57 utilising SmI2 proceeded in excellent yield (98%) 


































































(a) SmI2, EtCHO, THF, 0 ºC
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Mechanistically, this transformation is thought to involve the generation of a catalytically 
active samarium (III) pinacolate 64, via reductive homocoupling of the excess aldehyde 
(Scheme 10).156 This is evidenced by the colour change of the reaction from dark blue-




Scheme 10 SmI2 mediated pinacol coupling of EtCHO 
 
This species acts as a Lewis acid, promoting hemiacetal formation followed by 
intramolecular hydride transfer via a 6,6-chair transition state. High levels of 
diastereoselectivity are observed due to the coordinating ability of the oxophilic samarium, 
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Due to the extreme sensitivity of SmI2, this reagent was always freshly prepared by 
sonicating a mixture of samarium metal and 1,2-diiodoethane in THF, taking care to 
rigorously exclude air and moisture. This method reliably produced a deep blue solution of 
SmI2 for use in reduction reactions with a 10 mol% loading and excess of propionaldehyde. 
The 1H NMR spectrum of 63 was identical to that previously reported, with the anti-
configuration between C7 and C9 having previously been confirmed using the Rychnovsky 
13C NMR method following acetonide formation.157  
Following Evans-Tishchenko reduction, ester 63 was then submitted to alkynoate 
isomerisation. Utilising conditions reported by Rychnovsky,158 exposure to 
triphenylphosphine and phenol for a prolonged period of time (48 h) cleanly afforded the 
desired (2E,4E) diene 65 in 93% yield (Scheme 12). Diagnostically large coupling 
constants between the olefinic protons (3JH–H = 15.2–15.7 Hz) confirmed the presence of 





Scheme 12 Isomerisation of alkynoate 63 
 
A mechanistic description for this thermodynamically driven transformation is outlined in 
Scheme 13. Nucleophilic attack of triphenylphosphine onto alkynoate 63 results in an 
allenic enolate which can be protonated by phenol at the a-position to yield conjugated 
olefin 66. Subsequent proton transfer and isomerisation of the olefin yields 67 which is 
additionally stabilised as a phosphorus ylid. Protonation of the ylid intermediate followed 
by E1cB elimination furnishes the thermodynamically favoured (E,E) diene. The use of 
phenol as a cocatalyst is crucial in this reaction; its inherent acidity facilitates the initial 
addition of triphenylphosphine to the alkyne, whilst its strong conjugate base (PhO-) can 
















(a) PPh3, PhOH, C6H6
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As differential protection of the C7 and C9 hydroxyl groups was not required, methanolysis 
of ester 65 (K2CO3, MeOH) yielded diol 68 as a single diastereoisomer in 93% yield 
(Scheme 14). At this point, it was necessary to decide on a suitable protecting group 
strategy to advance material towards our aplyronine analogues. In the first generation 
Paterson approach to the aplyronines, a cyclic para-methoxyphenyl (PMP) acetal had been 
used, in anticipation of the increased conformational rigidity associated with this group 
biasing the macrolactonisation to favour the desired 24-membered macrocycle.159 
Alongside this, a more recent strategy had been developed in the group involving a bis-
TES ether protection of the hydroxyl groups. 
Whilst both protecting group strategies on this fragment were initially investigated by the 
author, informative results came from Talia Pettigrew which indicated that bis-TES 
protection would ultimately be superior to the PMP route. Pettigrew had advanced material 
with both protecting groups to the macrolactone core and found that the PMP variant 
encountered more problems and complications compared to the bis-TES version. 
Consistently lower yields plagued the PMP route, together with purification difficulties at 
the HWE coupling stage.158 Based on these observations it was ultimately decided to move 
forward with the bis-TES approach for continued work towards analogue development.  
An additional advantage of this route is the early installation of the TES ethers which are 
utilised in the endgame of the aplyronine total synthesis. With only one site for 
macrolactonisation in our analogues, this circumvents the need for a more rigid protecting 
group and ultimately avoids a now unnecessary protecting group swap, streamlining the 
route overall.  
Resultingly, treatment of diol 68 with an excess of TESOTf afforded 69 in 92% yield 
(Scheme 14). Overall this fully protected northern fragment precursor 69 could be accessed 
in 9 steps and 37% yield from (R)-Roche ester. Additional plentiful stocks of this fragment 
were generously supplied by Dr Mike Housden for studies towards the aplyronine total 
synthesis and analogue development. With this key intermediate in hand, attention then 
turned to elaborating this material into the required northern phosphonate 36 for advanced 
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2.1.3 Elaboration into C1-C11 iodide 56 
From 69, the required northern fragment 36 could be accessed in a further 5 steps. In 
preparation for the subsequent alkylation step (vide infra, Section 2.1.4), the terminal C11 
PMB ether would need to be elaborated to a primary iodide and the C1 ester reduced and 
protected as a TBS ether.  
 
The C11 alcohol could be revealed by a DDQ mediated, oxidative cleavage of the PMB 
group. Mechanistically the deprotection proceeds via initial formation of a charge transfer 
complex through a series of single electron transfer (SET) steps between the electron rich 
PMB aromatic ring and the electron accepting DDQ. This is followed by benzylic 
dehydrogenation, affording the desired deprotected alcohol and PMB aldehyde as 
illustrated in Scheme 15.160 
 
Pleasingly, this transformation proceeded smoothly under neutral conditions (pH 7.0 
buffer) to afford alcohol 70 in 89% yield with no identifiable byproducts detected or 
migration of the silyl groups observed. In the analogous transformation, carried out by the 
author, with C7 and C9 protected as a PMP acetal the yield was significantly lower at 67%. 
This drop in yield can be attributed to migration of the acetal group to the terminal position 
and overoxidation of the PMP group leading to benzoate byproducts.159 These side 
reactions were thought to be promoted by the production of the weakly acidic DDQH 
(Scheme 15) and could not be fully suppressed, even with the use of pH 9.2 buffer. This 
outcome further cemented the choice of the bis-TES protection strategy moving forward.  
 
At this stage, alcohol 70 represented a stable intermediate that could be safely stored at  
-20 °C for prolonged periods of time with no obvious degradation. Therefore, major stocks 
of material were stored at this point as the ensuing intermediates containing the primary 
iodide or phosphonate moiety were observed to degrade over time and were best used 
immediately.  
 
Alcohol 70 could then be converted to iodide 71 under standard Appel-like conditions 
(PPh3, imidazole, I2) in good yield (Scheme 16).161,162 Due to the potential for interference 
in the subsequent alkylation step, the carbonyl moiety at the C1 ester was reduced to the 
primary alcohol and masked as a TBS ether. Treatment of ester 71 with excess DIBAL, 
followed by protection with TBSCl afforded 56 in 96% yield over two steps (Scheme 16). 
This completed the synthesis of the full C1-C11 iodide segment 56 and set the stage for the 
final alkylation step and completion of the northern fragment.  
 
























































11 OR 69: R = PMB
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2.1.4 Alkylation to C1-C14 phosphonate 36 
The Paterson approach for advanced fragment coupling necessitates the installation of a b-
ketophosphonate moiety to engage in an HWE reaction to forge the C14-C15 trisubstituted 
olefin. Homologation of the carbon chain of iodide 56 can be accomplished by a chain 
extension alkylation with 72, utilising conditions developed by Grieco and Pogonowski.163 
 
Synthesis of the C12-C14 b-ketophosphonate linker 72 can be achieved through 
deprotonation of commercially available diethyl ethylphosphonate with n-BuLi, followed 
by quenching with ethyl acetate (Scheme 17). This process is amenable to large scale; the 
product 72 can be isolated cleanly via distillation under reduced pressure in good yield. 
Additionally, this product can be stored at -20 °C for prolonged periods of time with no 













Sequential deprotonation of 72 with sodium hydride followed by n-BuLi generated a pale-
yellow solution of the required dianion for alkylation with iodide 56. Under kinetic control 
at low temperatures, dianions derived from b-ketophosphonates have been found to react 








Scheme 18 Regioselective alkylation of dianions derived from b-ketophosphonates 
 
 
However, the selectivity of this reaction proved challenging to control. As expected, there 
is to be no stereoselectivity at C14, with a 1:1 mixture of diastereoisomers formed at this 






























(a) n-BuLi, THF, —78 ºC, 1h; then EtOAc
(62%)
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from reaction at the a-position was a significant constituent of the isolated material (ca. 
20-30%).157 This branched regioisomer is inseparable from the desired product by column 
chromatography, but fortunately does not engage in the subsequent HWE reaction and can 
be readily separated after that stage. 
 
The regioselectivity of the alkylation shows marked differences depending on the identity 
of the iodide electrophile. Reaction with PMP protected iodide 74 at -50 °C resulted in the 
formation of desired phosphonate 75 alongside the undesired regioisomer 76 in a 6:1 ratio. 
Conversely, with the more hindered bis-TES protected iodide 56 no reactivity was observed 
below 0 °C and as a result the regiomeric ratio was a disappointing 3:1 (Scheme 19). 
Interestingly, the addition of HMPA to encourage deaggregation of the dianion did not 
appear to affect the outcome. 
 
Significant optimisation studies on this challenging reaction were first undertaken by Lee 
(on the PMP system) and more recently by Anžiček and Pettigrew (on the bis-TES 
variant).157,164,165 A wide variety of conditions were trialled, including choice of solvent, 
order of addition of reagents, the influence of HMPA, concentration and scale. However, 
the reaction remained capricious and no significantly improved conditions were ultimately 
found. The best results for the bis-TES system moving forward seemed to be an 
approximately 3:1 ratio of regioisomers and a modest yield (60-70%) on multigram scale. 
This outcome was considered reasonable and, for the purposes of advancing material 
towards our designed aplyronine analogues, no additional time was spent in further 
optimisation of this reaction.  
 
This alkylation step concludes the synthesis of the C1-C14 northern phosphonate 36 which 


























































Scheme 19 Contrasting results for the alkylation of PMP and bis-TES protected iodides 74 and 56 

















NaH, THF, 0 °C;
n-BuLi; then
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77: R = TES
PMP
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2.2 C28-C34 side chain ketone 51 
 
The necessary side chain fragment 51 for our designed aplyronine analogues possesses one 
modification: replacement of the C29 acetoxy by a methyl ether moiety. A third-generation 
approach to access a variant of this ketone coupling partner was developed by Dr Sarah 
Fink in the synthesis of aplyronine C and is outlined in Scheme 20 below.137 Our planned 
modification lends itself well to incorporation via this route. 
 
Key structural features of this fragment include the terminal N-vinyl formamide 
functionality, which can be installed from aldehyde 78 under modified Wittig conditions 
with subsequent isomerisation to the (E)-olefin. The 1,3,4-syn stereotetrad is set in a 








Scheme 20 Retrosynthetic analysis of the C28-C34 side chain ketone fragment 51 
 
 
The groundwork on this fragment was undertaken by Talia Pettigrew, who proved the 
validity of Fink’s route for incorporation of the methyl ether functionality. Initial work by 
Pettigrew bore out a titanium-mediated aldol coupling to set the requisite syn 
stereochemistry. Preliminary investigations into N-vinyl formamide installation via a 
double Swern oxidation and Wittig reaction sequence was met with reasonable success, 
albeit on small scale (9 mg, 21% yield). For completeness, Fink and Pettigrew’s work is 
summarised in Scheme 21. 
 
The aim of the author was therefore to build on Pettigrew’s initial results and access 
multigram quantities of key intermediates to deliver a sizeable stockpile of side chain 
ketone 51 for advanced fragment coupling.  In particular, the modified Wittig approach 
was targeted as a step that required optimisation and further investigation. Synthetic efforts 






































































































































For natural product synthesis
34
3 steps
(78%, > 20:1 E/Z)
3 steps
(93%)
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2.2.1 Titanium-mediated aldol coupling 
Fink’s original protocol to construct the C29-C30 bond relied upon a tin (II) triflate mediated 
aldol reaction to set the desired syn stereochemistry. However, recent work within the 
Paterson group on titanium-mediated aldol methodology has superseded this 
approach.164,165 Compared to their tin counterparts, titanium-mediated aldol reactions 
convey a number of advantages. For example, asymmetric aldols utilising tin Lewis acids 
appear to be highly dependent on reagent quality.120 Additionally, the preparation of these 
reagents is often lengthy and necessitates the use of hazardous materials, ultimately 
generating a significant amount of toxic tin waste.  
 
Urpí and Romea have demonstrated the feasibility of titanium (IV) enolates in asymmetric 
aldol reactions to assemble polypropionate motifs in polyketide natural products.166,167 
Titanium Lewis acids such as TiCl4 and the softer Ti(i-PrO)Cl3 have been found to 
selectively generate (Z)-enolates, which upon addition of an aldehyde result in the 
formation of the syn-product. Based on this discovery, this methodology has been 
incorporated into the aplyronine project as a desirable alternative to tin mediated aldol 
reactions.  
 
Attractively, the required ethyl ketone 42 required for the side chain fragment is identical 
to that utilised previously in the northern fragment synthesis (Section 2.1.1). In this case 
ketone 42 could be enolised upon treatment with Ti(i-PrO)Cl3 and diisopropylethylamine 
at -78 °C to afford the desired (Z)-enolate 79 (Scheme 22). Treatment with excess 
acetaldehyde forged aldol adduct 80 in 77% yield and 17:1 dr. This reaction was extremely 
amenable to scale up and was reliably reproducible, which was exemplified with a 12 g 
batch yielding 77% of 80 in 14:1 dr in a single manipulation. This further highlights the 
robustness and operational ease of the titanium aldol method. 
 
The reaction between titanium enolates and aldehydes is understood to proceed via a 
chelated Zimmerman-Traxler transition state as illustrated in Scheme 23.168 This chair-
like conformation is facilitated by strong titanium-oxygen interactions between the 
electron-rich PMB group and the highly oxophilic titanium centre. The stereoselectivity is 
conveyed from the stereogenic centre on the enolate, with the major all-syn aldol product 
arising from the less sterically crowded transition structure TS-3.  
 
Pleasingly, upon inspection, NMR comparisons between the titanium (IV) and tin (II) aldol 
products were identical.137 
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Subsequent Evans-Tishchenko reduction of aldol adduct 80 yielded ester 82 and set the 
configuration across the full stereotetrad. This reaction again exhibited very high yields 
and excellent diastereoselectivity (97%, >95:5 dr) for the 1,3-anti product with no 
appreciable loss of selectivity on multigram scale (Scheme 24). Ultimately, through this 
aldol reaction and reduction sequence, over 12 g of intermediate 82 was efficiently prepared 













2.2.2 Elaboration to diol 83  
Alcohol 82 represents the point of divergence between the natural product and the analogue 
aplyronine projects (Scheme 21). Protection of the C31 hydroxyl with a TES ether, before 
a protecting group swap after the Wittig reaction, ultimately leads to the natural product 
fragment with the acetoxy functionality. This switch was necessary as the acetate group 
was found to be prone to elimination in the subsequent Wittig step. For analogue 
development, the desired methyl ether moiety could instead be installed at this point as we 
anticipated that it would be more robust and less susceptible to elimination. This tactic 
would save us two synthetic steps and the associated processing time and effort by avoiding 
the protecting group exchange. 
 
Methylation could be achieved by treatment of alcohol 82 with Meerwein salt (Me3OBF4) 
and proton sponge which proceeded smoothly. Cleavage of the PMB ether with DDQ, 
followed by DIBAL reduction revealed diol 83, as illustrated in Scheme 25. This set the 
stage to begin investigations into the challenging Swern oxidation and Wittig sequence to 



















(a) SmI2, EtCHO, THF, —20 ºC
(97%)
>95:5 dr















Scheme 25 Synthesis of diol 83 
 
 
2.2.3 N-vinyl formamide installation 
With diol 83 in hand, the two termini could be concurrently advanced to their desired 
oxidised forms. Kinetically, oxidation at C33 is expected to be more rapid, risking the 
formation of a cyclic byproduct through intramolecular hemiacetal formation through the 
C29 hydroxyl group. This issue could be circumvented by the use of a double Swern 
oxidation, as demonstrated by Fink.120 Mechanistically, this activates both hydroxyls as the 
corresponding alkoxysulfonium salts before the addition of triethylamine triggers carbonyl 
formation, thus limiting the potential for nucleophilic attack. Resultingly, formation of the 
sensitive keto-aldehyde 78 could be achieved under these conditions, with no discernible 
epimerisation of the a-stereocentres observed (Scheme 27). This material was found to be 
extremely unstable on silica and was therefore best used crude with minimal purification. 
During work-up, the combined organics could be washed carefully with dilute acid (0.5 M 
HCl), base (NaHCO3) and finally brine to successfully remove the triethylamine 
hydrochloride salt produced in the Swern oxidation, which would inevitably quench the 
ylid formed in the following Wittig olefination. Additionally, aldehyde 78 was always 
cautiously concentrated in vacuo to minimise losses due to volatility. 
With aldehyde 78 in hand, attention turned to the installation of the sensitive N-vinyl 
formamide subunit. The modified Wittig protocol discussed here was developed within the 
Paterson group in earlier studies towards aplyronine A (21)139 and has since been employed 
in our total synthesis of reidispongiolide A (29).169 The necessary phosphonium salt 84 
could easily be prepared in a two-step sequence. Following the protocol of Couture,170 N-
methyl formamide and paraformaldehyde were reacted with TMSCl in refluxing 
chloroform to give N-(chloromethyl)-N-methylformamide 85, which could be treated with 
triphenylphosphine to precipitate phosphonium salt 84 in 32% yield. Despite the low yield, 











(a) Meerwein salt, proton sponge, CH2Cl2; (b) DDQ, CH2Cl2/pH 7.0 buffer (2:1), 0 ºC; 
(c) DIBAL, CH2Cl2 —78 ºC
82 83
(73%)
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reagent, which could be stored at -20 °C indefinitely with no obvious degradation. To 
access this fragment Fink utilised an alternative protocol which employed thionyl chloride 
as the chlorinating agent.171 However, this has the disadvantage of producing large volumes 
of hydrochloric acid and sulfur dioxide as gaseous byproducts on scale and necessitates the 
distillation of 85. Couture’s procedure is therefore operationally simpler and delivers 84 in 




Scheme 26 Synthesis of phosphonium salt 84 
Treatment of phosphonium salt 84 with LiHMDS generated the required ylid. However, 
upon addition of keto-aldehyde 78, the desired enamide 86 was formed in a disappointing 
30% yield (3:1 Z/E) over the two steps (Scheme 27). Whilst this represents an improvement 
on Pettigrew’s preliminary results, this was in stark contrast to Fink’s outcome with the C31 
TES protected variant (75% over two steps, 8:1 Z/E).120 Despite numerous attempts, the 
poor result could not initially be improved upon, with yields consistently in the range of 
25-35%.  
No identifiable byproducts could be detected by TLC, nor isolated via column 
chromatography of the crude material. The Wittig olefination was judged to be the problem 
step, with the oxidation apparently proceeding reasonably well (80-90%) as judged by the 
crude 1H NMR, with good mass recovery of aldehyde 78. Interestingly, no elimination 
products were ever observed in this reaction, lending a degree of confidence to our initial 
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Frustratingly, the low mass balance after the Wittig reaction could not be accounted for and 
an alternative approach was therefore sought. An examination of the literature, particularly 
within the syntheses of related natural products possessing this N-vinyl formamide 
terminus, revealed varying approaches for incorporation of this challenging subunit. In 
Yamada’s total syntheses of aplyronines A, B and C (21-23), this moiety is installed 
classically via the condensation of aldehyde 87 with N-methyl formamide under mildly 





Scheme 28 Yamada’s condensation approach to install the terminal N-vinyl formamide97 
Paterson’s alternative protocol utilises P2O5 to promote the condensation and act as 
dehydrating agent. This was successfully implemented in the total synthesis of scytophycin 













However, these condensation reactions require the preparation of a homologated aldehyde, 
which would require significant synthetic effort with a new retrosynthetic approach. Thus, 



































(a) P2O5, MeNHCHO, CH2Cl2
3189
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Advances in metal-catalysed N-alkenylation reactions have expanded the chemist’s toolbox 
and can be useful for installing N-vinyl formamide moieties. Takai olefination of an 
aldehyde or hydrozirconation of a terminal alkyne can generate (E)-vinyl halides with good 
levels of stereoocontrol.173,174 With the desired (E)-geometry pre-installed, a metal-
catalysed cross coupling can then deliver the required N-vinyl formamide.175  
 
In particular, Miyashita and co-workers applied a Takai olefination and Buchwald 
amidation sequence to great success in their synthesis of scytophycin C (31, Scheme 
30).176,177 Importantly, scytophycin C (31) bears a remarkably similar side chain to that of 
our designed aplyronine analogues. The N-vinyl formamide terminus was introduced in 
59% yield over the two steps from aldehyde 90 – a marked improvement on Paterson’s 
20% yield for the condensation reaction (Scheme 29). Notably, Miyashita additionally 
reported extreme difficulties in utilising the Wittig method to complete this transformation, 
with elimination of methanol being the predominant outcome and no desired product 














Scheme 30 Miyashita’s Takai–Buchwald sequence for terminal amidation of aldehyde 90 177 
 
 
Encouraged by this successful example and noting that this sequence conveniently 
intersected our developed route well, the Takai olefination–Buchwald amidation approach 
was investigated as a potential solution to the difficulties previously encountered. However, 
disappointingly this was not to be the case. Attempted Takai olefination of aldehyde 78 led 
to a mixture of elimination products whilst the desired (E)-vinyl iodide 91 was not detected 























(a) CrCl2, CHI3, THF, 0 ºC; (b) trans-1,2-cyclohexanediamine, CuI, K3PO4, MeNHCHO, dioxane








Scheme 31 Attempted Takai olefination to produce (E)-vinyl iodide 91 
 
On balance, it was decided to follow Fink’s original protocol with a TES ether in place at 
C31, and to undertake a protecting group swap to install the new methoxy group after the 
Wittig reaction, thus mirroring the approach used to construct the natural products. Whilst 
this route would not save any synthetic steps in this sequence, it should result in a greater 
overall yield and allow for a smoother and higher throughput of material. This strategy 
would be dependent on the resulting methylation proceeding efficiently and without 
elimination, nor degradation of the N-vinyl formamide. The viability of this approach was 
investigated and is outlined in Scheme 32.  
 
Returning to intermediate 82 at the diversification point (Scheme 21), TES protection could 
be cleanly accomplished by exposing alcohol 82 to TESOTf and 2,6-lutidine at -78 °C to 
furnish TES ether 92. DDQ mediated PMB cleavage and deprotection of the propionate 








Scheme 32 Elaboration of alcohol 82 to TES protected intermediate 93 
 
Gratifyingly on this TES substrate, the double Swern oxidation and Wittig olefination 
protocol following the previously utilised sequence delivered formamide 94 in a much-
improved yield of 71% on multigram scale. Subsequent TES deprotection under neutral 
conditions using AcOH-buffered TBAF yielded alcohol 95 in 99% yield (Scheme 33). 
With intermediate 95 in hand, attention turned to the methylation to yield our desired 






































(a) TESOTf, 2,6-lutidine, CH2Cl2, —78 ºC; (b) DDQ, CH2Cl2/pH 9.2 buffer (4:1); (c) DIBAL, CH2Cl2, —78 ºC










Scheme 33 Swern–Wittig sequence on TES protected diol 93 
 
 
In the event, this seemingly trivial transformation on alcohol 95 proved to be highly 
troublesome. Initial results using our previous conditions (Meerwein salt and proton 
sponge) were tantalisingly promising, with the methylation apparently proceeding 
smoothly on test reaction scale (10 mg, 64%, Table 3, entry 1). However, attempts to 
replicate this result on a preparative scale revealed significant reactivity problems, with 
minimal conversion observed in all attempts. Further optimisation efforts for this step are 
outlined in Table 3.  
 
Increasing the equivalents of Meerwein salt and proton sponge in an attempt to promote 
the conversion to methylated product 86 was unsuccessful. Significant starting material 
remained, combined with a variety of spots on TLC and a complex crude 1H NMR (Table 
3, entry 3). On the other hand, decreasing the equivalents of reagents, in order to combat 
unwanted side reactions potentially inhibiting the reaction, again led to no reactivity (Table 
3, entry 4).  
 
Moving away from the Meerwein system, the classical Williamson ether synthesis (NaH, 
MeI) was trialled (Table 3, entry 5).178 Perhaps unsurprisingly, significant decomposition 
was observed during this reaction, presumably via a retro aldol-type mechanism. Late stage 
methylation utilising methyl triflate and 2,6-di-tert-butylpyridine has seen some success 
within complex natural product syntheses, as demonstrated by Evans and co-workers in 
their synthesis of ionomycin A. However, the authors do report that this reaction can be 
“quite substrate dependant.” 179 Nevertheless, these conditions were applied to our N-vinyl 
formamide system but returned poor results (Table 3, entry 6). No discernible product (or 
byproduct) could be isolated from the complex mixture. 
 
A survey of the literature directed us towards the avenue of carbohydrate methodology and 
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Kuhn.180,181 Standard procedures called for the use of a polar solvent and 3 equivalent of 
MeI and 2 equivalents of Ag2O per alcohol to be methylated. Application of this protocol 
in acetonitrile at room temperature yielded only starting material as judged by TLC 
analysis. Upon gradual warming of the reaction to 80 °C, trace amounts of desired 
methylated product were observed (Table 3, entry 7). Encouraged by this result, the 
material was re-submitted and reacted at 80 °C from the beginning. Puzzlingly, despite 
refluxing for a prolonged period of time, no methylated product 86 was detected and 
starting material was returned quantitively upon work-up (Table 3, entry 8). Switching the 
reaction solvent to DMF at 80 °C was destructive and led to a mixture of elimination 
products (Table 3, entry 9). 
 
 











Conditions Result Comment 
1 10 
 
Me3OBF4 (4 eqv.) 
proton sponge (5 eqv.) 
64% 86  
2 50 Me3OBF4 (4 eqv.) 
proton sponge (5 eqv.) 
Starting material Faint by-
products on TLC  
3 50 Me3OBF4 (10 eqv.) 
proton sponge (12 eqv.) 
Starting material Messy TLC and 
crude NMR 
4 50 Me3OBF4 (2 eqv.) 
proton sponge (3 eqv.) 
Starting material  
5 10 MeI 
NaH 
Decomposition Assumed retro 
aldol 
6 25 MeOTf (10 eqv.) 
2,6-di-tert-butylpyridine (20 eqv.) 
Decomposition No byproducts 
isolated 
7 50 MeI, Ag2O, MeCN 
rt ® 80 °C 
Trace product Mainly starting 
material 
8 50 MeI, Ag2O, MeCN 
80 °C 
Starting material  
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Based on these vexing results, it was clear that this post-Wittig methylation strategy was 
not a viable route to access our desired fragment. In the end, with limited options available, 
attention returned to the originally planned Wittig olefination on aldehyde 78 with the C31 
methyl ether already installed.   
 
The nature of the alcohol protecting group at C31 appears to have a significant effect on the 
outcome of the Wittig olefination, with drastic differences in yield observed under identical 
conditions (Table 4). 
 
 








a Reaction performed by Dr Sarah Fink 120 
 
 
Elimination tends to be the main reported problem and seems to account for the reduction 
in yield, especially for the PMB variant (Table 4, entry 3). Fink noted that PMBOH made 
up 25% of the crude material, presumably caused by the excess ylid competitively acting 
as a base in an E2 or E1cB reaction.120 As previously discussed, no elimination products 
were ever observed by this author in the methyl ether system. 
 
Reidispongiolide A (29) possess a very similar side chain to our targeted analogues. During 
their total synthesis, Paterson and co-workers applied this modified Wittig olefination to 
deliver enamide 96 in a respectable 52% yield (Scheme 34).169 This result further highlights 
that the methyl ether system does appear to suffer from reduced yields compared to the 
TES equivalent. Aldehyde 97 is almost identical to our substrate: the only difference is the  
lack of a methyl group at C32, therefore rendering it not a-chiral. This could explain the 
greater efficiency of the reaction on this less delicate substrate. In an effort to optimise this 
challenging reaction, we returned to our initial protocol for the Wittig olefination. 
 
Entry R Yield (over two steps) 
1 TES 71% (8:1 Z/E) 
2 Me 35% (3:1 Z/E) 






























Scheme 34 Installation of the enamide functionality in reidispongiolide A (29) 
 
The procedure reported in the original publication shows marked differences to that used 
in recent syntheses within the group.139 The aplyronine and reidispongiolide systems both 
make use of a slight excess of both phosphonium salt 84 and LiHMDS (1.5 and 1.4 
equivalents respectively), with the excess base ensuring full deprotonation of the salt.  
Upon addition of the base to generate the ylid, the system is warmed from -78 °C to 0 °C 
over 30 min, during which time the white suspension turns bright yellow, before being re-
cooled to -78 °C for the addition of the aldehyde. Contrastingly, Paterson’s original 
protocol calls for a much higher excess of reagents (2 equivalents of phosphonium salt 84 
and 3 equivalents of base). An additional difference between the two procedures is the 
work-up protocol. Initially this made use of a neutral quench (pH 7.0 buffer) which had 
been replaced to by acidic quench (NH4Cl) in the aplyronine project.  
 
With some trepidation, we returned to original protocol. Fearing that 3.0 equivalents of 
LiHMDS might promote unwanted side reactions, the loading was dropped to 2.1 
equivalents in conjunction with 2.0 equivalents of phosphonium salt 84. Progressively 
warming the system from -78 °C to 0 °C over 2 h, instead of only 30 min, was also 
introduced. A much slower generation of ylid was observed, as evidenced by a very gradual 
change in reaction colour from white to bright yellow over this warming period. Pleasingly, 
initial results from quenching with pH 7.0 buffer were good, with the reaction delivering 
much improved yields on scale (Table 5). Ultimately, this reaction could reliably deliver 
enamide 86 in 50-60% yield over two steps. This was evidently a drastic improvement on 
previous results for this difficult transformation.  
 
Upon close inspection, the 1H NMR spectrum revealed that this reaction delivered enamide 
86 as an inseparable mixture of (Z)- and (E)-isomers in a 3:1 ratio. The spectrum is further 
complicated by the presence of rotamers within each isomer (7:1 and 2:1 respectively), 
arising from the restricted rotation around the N-vinyl formamide bond (Figure 31, 














































Equivalents  Ylid generation conditions 
(temperature range and time) 
Yield 
(over two steps) 
1 100 1.5 LiHMDS 
1.4 salt 84 




2 200 2.1 LiHMDS 
2.0 salt 84 




3 450 2.1 LiHMDS 
2.0 salt 84 




4 1000 2.1 LiHMDS 
2.0 salt 84 
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The ratio of double bond isomers was inconsequential as the mixture was to be isomerised 
to the required (E)-geometry in the next step. Consequently, enamide 86 could be converted 
into the thermodynamically favoured (E)-olefin 51 via treatment with molecular iodine in 
CH2Cl2 for 24 h.139,169,182 This reaction was carried out in the absence of light and is thought 
to proceed via an ionic mechanism under these conditions (Scheme 35). The proposed 
mechanism involves electrophilic attack of iodide at C33, followed by rotation about the 












Scheme 35 Mechanistic proposal for the iodine mediated (Z)- to (E)-enamide isomerisation  
 
 
Gratifyingly, 5 mol% of iodine could be used to deliver (E)-enamide 51 as a single 








Scheme 36 Iodine mediated (Z)- to (E)-isomerisation of enamide 86 
 
This completes the synthesis of our modified side chain ketone 51. Overall, more than 1g 
of this fragment was synthesised in 8 steps and 30% yield from ethyl ketone 42. This 
fragment brought unanticipated challenges in the Swern–Wittig sequence, but careful 





















































(a) I2, CH2Cl2, dark
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2.3 C15–C27 southern fragment 98 
 
The simplified southern fragment 98 contains two of our planned modifications for 
designed aplyronine analogues: the C17–C21 hydrocarbon chain and the C25 methyl ether. 
Synthetic work on this fragment was exclusively undertaken by Talia Pettigrew and, for 
completeness, her work is summarised in Scheme 37.165 
 
Pettigrew further extended the applications of titanium (IV) mediated aldol methodology 
to construct the C23–C26 stereotetrad in this fragment. The simplified aldehyde 99 for aldol 
coupling could be accessed in two steps from 1,9-nonanediol and the ketone partner 43 was 
derived from (S)-Roche ester. Compared to the tin variant, the titanium approach was again 
found to be more favourable and provided the aldol adduct 100 in good yield and 
diastereoselectivity (85%, 17:1 dr) on multigram scale. The fully protected southern 
fragment 98 was delivered after a further two steps: an Evans–Tishchenko reduction and 




























































(a) (i-PrO)TiCl3, (i-Pr)2NEt, CH2Cl2, —78 ºC; (b) SmI2, EtCHO, THF, —20 ºC; 
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Pettigrew’s simplified fragment 98 was synthesised in 8 steps and 20% yield from (S)-
Roche ester. Compared to the equivalent fragment in the group’s synthesis of aplyronines 
A and D, this represents a considerable saving of 8 synthetic steps.138 Pettigrew estimated 
that to make 1 g of this fragment via this route would take 8 working days, compared to 
approximately 16 days for the full natural product fragment. This further demonstrates the 
reliability and efficiency of Pettigrew’s synthetic approach.  
 
 
2.4 Summary  
 
This chapter has outlined the synthesis of our advanced modified fragments for 
incorporation into our designed ‘aplyrologues’. The northern phosphonate 36 has been 
synthesised in 14 steps and 18% yield from (R)-Roche ester (Scheme 38). In advancing 
this material, the bis-TES protected variant was selected to move forward in place of the 














Scheme 38 Summary of northern phosphonate 36 synthesis 
 
 
Titanium (IV) Lewis acid aldol methodology was used with great success in the side chain 
synthesis, providing multigram quantities of the required aldol adduct with the correct all 
syn-stereochemistry. This is an operationally easier procedure than the corresponding tin 
aldol route which was used in earlier iterations of the aplyronine synthesis.120 Overall, side 
chain ketone 51 with the necessary C31 methyl ether moiety, has been synthesised in 8 steps 
and 30% yield from ethyl ketone 42 (Scheme 39). This represents a saving of two steps by 
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Significant optimisation of the challenging Swern–Wittig sequence was carried out to 
successfully deliver reliable experimental conditions for this reaction. Additionally, this 
work has provided insight into the stability of the methyl ether moiety; it has demonstrated 
its robustness towards elimination, thus validating the incorporation of this functionality 















Scheme 39 Summary of side chain ketone 51 synthesis 
 
 
With plentiful stocks of all three advanced fragments, attention now turned to exploring 

































































Fragment coupling strategies 
 
 
The southern fragment 98 is orthogonally protected at each terminus: C15 bears a silyl ether 
whereas a benzylic ether lies at C27. This differentiation allows for selective removal of 
each protecting group to allow for fragment coupling to either the northern or side chain 
fragments after oxidation to the aldehyde. A Horner–Wadsworth–Emmons olefination 
forges the C14–C15 northern-southern connection, whilst an aldol reaction unites the 












































oxidise for HWE 
reaction
OTBS
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Traditionally, the aplyronine scaffolds have been constructed by first connecting the 
northern and southern fragments via a HWE reaction, then closing of the macrolactone at 
C23, before the side chain is finally appended using an aldol coupling.137,138,149 This strategy 
was deliberately designed for late stage introduction of the sensitive N-vinyl formamide 
moiety. Within the natural product system, with the acetoxy substitution at C31, the 
formamide was prone to decomposition through hydrolysis or elimination pathways under 
a variety of conditions.120 Thus, careful handling of all late stage intermediates was required 
after the installation of this delicate functionality. Furthermore, compounds containing the 
N-vinyl formamide exists as stable rotamers, leading to complications in purification and 
NMR analysis of all subsequent intermediates. 
 
Encouraged by our results during the synthesis of side chain ketone 51, we were optimistic 
that our methyl ether variant would not exhibit the same sensitivity issues as its acetoxy 
counterpart. Therefore, we could consider exploring an alternative coupling strategy to 
offer more flexibility in the synthesis of our designed aplyronine analogues and expand the 
range of analogues generated via late-stage transformations.  
 
 
3.1 Alternative coupling strategy  
 
Based on previous observations, early introduction of the N-vinyl formamide moiety could 
be tenable. This opens up the possibility for a reversed coupling sequence where the 
southern and side chain fragments are first connected, before the northern portion is joined. 
This would complete the full C1–C34 backbone before macrolactonisation.  
 
This approach would convey a number of advantages. Firstly, the chemistry used to attach 
the side chain ketone usually is carried out on highly precious, late stage intermediates thus 
limiting optimisation efforts. For example, in the synthesis of aplyronines A and D, the 
aldol coupling sequence to connect the C27–C28 bond was found to occur in a moderate 
65% yield by Dr Simon Williams.121,138 Williams' optimisation efforts were frustrated by a 
lack of material given the valuable nature of the intermediates. Similarly, the zinc 
borohydride reduction to set the configuration at C29 has been afflicted by highly variable 
yields and dr. Improvements have analogously been prohibited by the limited quantity of 
substrate available. Furthermore, this alternative sequence opens up the possibility of new 
sites of linkage for ADC development. Hence, by coupling the side chain and southern 
fragments together at an earlier stage, we gain the opportunity to undertake optimisation 
studies on these challenging reactions to potentially deliver a more efficient route to our 
designed analogues.  
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3.1.1 Aldol–dehydration–reduction sequence 
With side chain ketone 51 in hand, the required aldehyde coupling partner was revealed in 
two steps. Deprotection of PMB ether 98 with DDQ proceeded smoothly, followed by 






Scheme 41 Deprotection and oxidation sequence to aldehyde 50 
 
A boron-mediated aldol reaction had previously been successful in joining analogous 
fragments together in the aplyronine natural product syntheses.138 Williams and Fink had 
both noted that an excess of enolate is required to push the reaction to completion, coupled 
with a mild non-oxidative work-up procedure. 
 
Ketone 51 was therefore enolised with dicyclohexylboron chloride and triethylamine at        
0 °C, before the addition of aldehyde 50 at -78 °C. Aldol adduct 101 was obtained after a 
non-oxidative work up (MeOH, pH 7.0 buffer) as an inconsequential mixture of 
diastereoisomers, along with excess ketone 51. This mixture was directly subjected to a 
Burgess dehydration protocol, at which point the diastereoisomers converged to enone 102. 
At this point ketone 51 could be separated more easily via column chromatography.183 
Initial results using these standard conditions yielded a result comparable to that of 
Williams (Table 6, entry 1).  
 
Theorising that incomplete breakdown of the boronate species under the non-oxidative 
conditions could be responsible for the relatively low yield, an oxidative work up using 
hydrogen peroxide was trialled. However, under the harsher conditions, complete 
decomposition of the product was observed (Table 6, entry 2). This stands in contrast to 
results obtained during our group’s synthesis of reidispongiolide and rhizopodin. Both 
routes employed a hydrogen peroxide oxidative work-up with great success on arguably 
more delicate substrates.169,184 
 
Hence, a milder work up procedure was sought. Taking inspiration from the group’s work 




















(a) DDQ, CH2Cl2/pH 7.0 buffer (2:1); (b) (COCl)2, DMSO, NEt3, —78 ºC → 0 ºC
Chapter 3 – Fragment coupling strategies  
 
 76 
intermediate boron aldolate.185 Pleasingly, an improved yield of 70% was achieved using 
this procedure (Table 6, entry 3), further highlighting the mild nature of boron-mediated 
aldol reactions within complex natural product synthesis.  
 
Whilst the majority of the excess ketone can be easily recycled after the Burgess 
elimination step, it would be preferable to lower the number of equivalents if possible. 
Gratifyingly, employing only 1.5 equivalents of ketone 51, enone 102 could be isolated in 
an excellent 90% yield over three steps (Table 6, entry 4). On scale this could be further 
reduced to just a slight excess of 1.2 equivalents without appreciable loss in efficiency 
(Table 6, entries 5 and 6).  
 
 
















Entry Scale / mg Ketone 
eqv. 
Work-up Yield 
(over 3 steps) 
1 60 2 Non-oxidative 
(MeOH, pH 7 buffer) 
 
58% 
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The second key step of this fragment coupling sequence is elimination of the newly formed 
C27 hydroxyl. This relies on the extremely mild and selective nature of the Burgess reagent, 
which exists as the inner salt. Mechanistically, initial formation of the sulfamate ester is 
followed by an Ei-type elimination. Intramolecular syn-elimination of the b-hydrogen 
occurs via a cyclic six-membered transition state to generate the olefin product with high 
stereoselectivity.183,186 As illustrated in Scheme 42, the (E)-selectivity stems from the 
preference for the large groups (R1 and R2) to minimise unfavourable steric interactions in 
the transition state. The Burgess reaction has therefore found widespread use as a mild and 









Scheme 42 Mechanism for dehydration reactions using the Burgess reagent 
 
 
The reaction was operationally simple and generally proceeded well at room temperature. 
Aldol adduct 101 was simply added to a slight excess of Burgess reagent in THF and the 
reaction left to stir for 16 h. Monitoring by TLC analysis was straightforward due to the 
large differences in polarity of the starting alcohol and product enone. However, on larger 
scales it became apparent that the reaction was sluggish, and a considerable amount of 
starting material would remain, even with warming to 40 °C. In these cases, it was best to 
work-up and purify the product, before re-submitting the recovered starting material. 
Interestingly, within the field of natural product synthesis, there are instances where the 
Burgess dehydration has been successfully carried out in refluxing toluene, with no 
degradation products observed.190,191 Although these conditions were not trialled on our 
system, this might represent a possible solution for future optimisation of this reaction.  
 
Conjugate reduction of enone 102 was achieved through treatment with Stryker’s reagent: 
triphenylphosphine copper hydride hexamer.192 For the purpose of the Paterson group's 
studies into the aplyronines, Dr Simon Williams developed a convenient method to freshly 
prepare a solution of Stryker’s reagent for use in conjugate reduction reactions.138 This 
solution is operationally much simpler to use than the solid reagent which is highly air 
sensitive, laborious to prepare and must be stored and manipulated within a glovebox.193 
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organosilanes, designed to produce copper hydride species in situ.194–197 Following the 
procedure of Yun, a solution of Stryker’s reagent in toluene could be prepared from copper 
(II) acetate, triphenylphosphine and an excess of tetramethyldisiloxane (TMDS). A 
characteristic colour change from blue-green to bright red over 8-10 h signifies the 
formation of the desired copper hydride species.198 Conveniently, the solution was 
amenable to storage at -20 °C for up to a month.  
 
Mechanistically, conjugate addition of the soft hydride nucleophile produces copper 
enolate 103 which can react with the excess organosilane to regenerate the active catalyst. 
In this step, the product becomes masked as the silyl enol ether 104, which upon protonation 
furnishes ketone 105 (Scheme 43). Employing a catalyst loading of 20 mol% copper, 
ketone 105 could be delivered in excellent yield (93%), as evidenced by the loss of the 
characteristic enone signals by 1H NMR analysis. No extra precautions such as solvent 
degassing were necessary. Due to the similarities in retention factor between enone 102 
and ketone 105 on TLC, the reaction mixture was often left overnight (16-24 h) to ensure 
full conversion to the product. Once complete, the mixture was simply applied directly to 
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With this sequence thoroughly optimised, and the first goal within our alternative coupling 
sequence met, attention turned to the diastereoselective reduction of ketone 105.  
 
3.1.2 Reduction of ketone 105 
The final step to construct the stereotetrad within the side chain required the 
diastereoselective reduction of ketone 105. Previous work had identified zinc borohydride 
as a useful reducing agent for this transformation. However, yields and dr had been found 
to vary significantly (50-90%, 3:1-10:1 dr) and were seemingly dependent on the quality 
of the reagent and scale of the reaction.120,138 Fink’s best result on the natural aplyronine 
side chain was a promising 90% yield and 10:1 dr, albeit this was an isolated result on 
small scale. The diastereoselectivity has been proposed to arise from an eight membered, 
zinc-chelated transition state involving the ketone and acetyl carbonyl groups.199 
 
This transformation was first trialled on side chain ketone 51 as a simpler model system. 
In this trial, reduction of ketone 51 with freshly prepared zinc borohydride solution yielded 
a mixture of diastereoisomers (1.5:1 dr) in a moderate 70% yield (Scheme 44). 
Gratifyingly, the diastereoisomers were separable through careful column chromatography.  
 
A Mosher ester analysis was carried out to determine the absolute configuration of C29 in 
the major diastereoisomer of 106.200,201 Esterification with (R)- and (S)-a-methoxy-a-
(trifluoromethyl)phenyl acetic acid (MTPA-OH) under Keck conditions (DCC, DMAP, 
DMAP×HCl) afforded the (R)- and (S)-Mosher ester derivatives 107 and 108 in 81% and 
76% yield respectively (Scheme 45).202 The Mosher method relies on the assumption that 
the ester derivatives predominantly adopt the conformation in which the methine proton, 
ester carbonyl and trifluoromethyl group are coplanar, as depicted in Figure 32. The 
presence of a phenyl ring results in diamagnetic shielding of the protons that reside on the 
same side of the plane as the ring (i.e. Ha, Hb and Hc). These proton signals in the (R)-
MTPA ester will be therefore shifted upfield relative to the analogous set of protons in the 
(S)-MTPA ester. The reverse is true for protons Hx, Hy and Hz. By analysing the difference 
in chemical shifts Dd = dS - dR for as many protons as possible, it is possible to determine 
the absolute configuration of the carbinol centre. The sign of this difference is expected to 
be negative for protons on one side of the hydroxyl and positive for those on the other.203 
 
Analysis of 1H NMR spectra for both compounds showed that the DdS – R signs for protons 
in the vicinity of the carbinol centre corresponded to the pattern, in agreement with the (R)-
configuration at C29 (Scheme 45). 
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106 107: (R)-MTPA ester 81%
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With these results to support our assignment of the major diastereomer as the desired (R)-
configuration, these conditions were next investigated on our real system, ketone 105.  
 
Initial results to generate alcohol 109 were pleasing with a reasonable yield of 68% together 
with an increase in stereoinduction to 6:1 dr (Scheme 46). However, this result was not 
always reproducible, and we were troubled with variations in yield and dr similar to those 
observed by Williams. Puzzlingly, each batch of reagent was prepared in an identical 
manner, but there appeared to be no consistency of results between each reaction with 
different batches yielding different results. Lowering the temperature to -10 °C, in the hope 
of improving the dr, led to the reaction stalling. This reaction currently remains capricious 





Scheme 46 Zinc borohydride reduction of ketone 105 
 
Again, the diastereoisomers were separable via column chromatography. This fortunately 
permitted recycling of unwanted diastereoisomer 110 by oxidising back to starting material 
ketone 105 and re-subjecting this to the reduction conditions (Scheme 47). This provided 






Scheme 47 Re-oxidation of unwanted diastereoisomer 110 
 
 
The stereochemical outcome of this reduction is noteworthy. Due to the superior 
coordinating ability of Zn2+, high levels of stereoinduction have been observed in zinc 
borohydride mediated reductions.199,204 Dr Sarah Fink had screened a variety of reducing 
agents to effect this transformation and zinc borohydride surfaced as the only reagent 
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As our compounds differ sufficiently from the natural product to make stereochemical 
comparisons difficult, once again a Mosher ester analysis was carried out to rigorously 





Scheme 48 Formation and analysis of Mosher esters 111 and 112 
 
Further optimisation of this reduction reaction is ultimately required; however, it was 
deemed prudent at this stage to continue to push forward towards coupling the northern 
fragment to construct our designed analogues.  
 
3.1.3 Elaboration to aldehyde 54 
To assemble the full carbon skeleton via HWE coupling to the northern C1–C14 
phosphonate 36 (Section 2.1), the aldehyde functionality had to be revealed at C15 (Scheme 
49). To avoid undesired oxidation, the newly formed hydroxyl at C29 was masked as a TBS 
ether (TBSOTf, 2,6-lutidine) in good yield. Gratifyingly, the potentially sensitive N-
methyl-N-vinyl formamide moiety remained untouched under these Lewis acidic 
conditions. Contrary to the established coupling sequence, where the C29 hydroxyl is 
revealed at a late-stage and directly esterified, alcohol protection is necessary at this earlier 
point in the synthetic route.  
 
Removal of the primary TBS ether at C15, in the presence of the more sterically hindered 
secondary centre, could be achieved through treatment of 113 with TBAF. Careful 
monitoring of the reaction by TLC analysis ensured clean conversion to the desired primary 
alcohol 114, with no doubly deprotected byproduct observed. Subsequent DMP oxidation 
of alcohol 114 proceeded smoothly to generate aldehyde 54 which was used crude in the 
ensuing HWE olefination reaction. Thus, with the required aldehyde in hand, our focus 





































112: (S)-MTPA ester 78%
CH2Cl2














Scheme 49 Elaboration of C15–C34 fragment 109 to aldehyde 54 
 
 
3.1.4 HWE coupling and C13 reduction 
The Horner–Wadsworth–Emmons olefination is a powerful method for the stereoselective 
olefination of aldehydes and ketones with stabilised phosphonate carbanions leading to 
products with high (E)-selectivity.205,206 A variant on the Wittig reaction, the use of 
phosphoryl-stabilised carbanions has many advantages over the traditional triphenyl-
phosphorous ylids and offers great synthetic utility.207,208 
 
Mechanistically, deprotonation of b-ketophosphonate 36 leads to the stabilized 
phosphonate carbanion 115 (Scheme 50). This can reversibly add into aldehyde 54 to form 
an oxaphosphetane intermediate that irreversibly decomposes to generate the enone product 
116. The thermodynamic driving force for this reaction is the loss of the phosphate ester 
moiety.   
 
The stereoselectivity of the Horner–Wadsworth–Emmons olefination derives from both 
kinetic and thermodynamic control through the reversible addition of the phosphonate 
carbanion to the carbonyl group.208–210 Although minimisation of steric interactions 
between the aldehyde proton and bulky phosphonate is preferred (Scheme 50, TS-5), this 
ultimately leads to an oxaphosphetane intermediate that places the aldehyde R group and 





















































(a) TBSOTf, 2,6-lutidine, CH2Cl2, —78 ºC; (b) TBAF, THF; (c) DMP, NaHCO3, CH2Cl2
(85%)
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enone is slow. Contrastingly, whilst reaction through TS-6 is initially less favourable due 
to destabilising steric interactions, this pathway eventually leads to the corresponding anti- 
oxaphosphetane intermediate. Resultingly, collapse of this adduct is fast to generate the 


























Scheme 50 The origin of selectivity in the Horner–Wadsworth–Emmons olefination 
 
 
As b-ketophosphonate 36 was more readily accessible (10 steps) than aldehyde 54 (15 
steps) it was used in slight excess (1.1 equivalents) and as a mixture of regiosiomers 
(Section 2.1.4). Deprotonation of 36 with Ba(OH)2 in anhydrous THF, followed by the 
addition of aldehyde 54 in wet THF (THF/H2O, 40:1) generated enone 116 in 85% yield 
(Scheme 51). Analysis of the 1H NMR confirmed the excellent E/Z selectivity (>20:1) with 
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77 could easily be separated from the product via column chromatography. Conveniently, 
this extremely mild reaction could be left to run for an extended period of time (i.e. > 72 h) 
without detrimental effects.  
 


























The construction of the trisubstituted olefin in this complex intermediate is noteworthy. 
This class of olefins represents a challenging target to build via the HWE reaction, but the 
unique barium hydroxide variant of this methodology has proved to be extremely efficient 
in this regard. Our group demonstrated that barium hydroxide could be utilised under very 
mild conditions (wet THF, rt) to efficiently furnish substituted olefins from base-sensitive 
and structurally complex aldehydes.211 This methodology has since been successfully 
applied to highly functionalised substrates in complex natural product syntheses.212–214 
 
Having successfully completed our final fragment coupling and forged the full carbon 
skeleton of our analogues, the next step was the installation of the final stereocentre at C13. 
A chiral reducing agent is necessary for this transformation due to the lack of inherent 
substrate bias in 116 for installation of this isolated carbinol stereocentre. The Corey–
Bakshi–Shibata (CBS) reduction is able to circumvent this issue by utilising a chiral 
catalyst to sterically differentiate between the substituents on a carbonyl group. 



































(a) Ba(OH)2, THF, then 54, THF/H2O (40:1)
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proline derived oxazaborolidine coordinating with the Lewis acidic borane reducing agent.  
This coordination forms a well-defined chiral complex between the reactants and activates 
borane as a hydride donor for intramolecular hydride transfer to the carbonyl. Additionally, 
the Lewis acidity of the endocyclic boron is enhanced, thus promoting ketone coordination 
via the sterically more accessible oxygen lone pair. The face-selective hydride transfer is 
thought to proceed through a boat-like transition structure in which the large substituent 
(RL) is orientated pseudo-equatorially away from the methyl group on boron to minimise 
unfavourable steric interactions.  
 
The absolute stereochemistry of the newly formed carbinol can thus be predicted from the 
transition state structure TS-7 illustrated in Scheme 52. In this particular case, the ‘large’ 











Scheme 52 Transition state model for ketone reduction with (R)-CBS catalyst 
 
 
Enone 116 was subjected to standard CBS reduction conditions ((R)-Me-CBS catalyst, 
BH3×SMe2, -10 °C) and delivered alcohol 117 in 30% yield on small scale. Despite 
employing stoichiometric amounts of ‘catalyst’ the reaction would not go to completion, 
with mostly starting material returned upon work up. Initially, this was taken as a positive 
sign: whilst conversion was low, no byproducts were detected and it was hoped that with 
optimisation the yield would improve. However, despite multiple attempts, this reaction 
remained troublesome (Table 7, entries 1–2). On larger scales, it became apparent that side 
reactions were occurring, as evidenced by the disappearance of the N-vinyl formamide 
signals in the 1H NMR of the crude material. These byproducts were tentatively attributed 
to the catalyst or reductant interacting with the N-vinyl formamide moiety, leading to 
hydrolysis or reduction byproducts. The reaction remained puzzlingly unreliable and 
irreproducible, with seemingly identical conditions returning any combination of starting 














































Entry Scale / mg Conditions Result 
1 10  (R)-Me-CBS catalyst (1.3 eqv.),  
BH3×SMe2 (1.2 eqv.), -10 °C 
 
30% 117 
2 35 (R)-Me-CBS catalyst (1.3 eqv.),  
BH3×SMe2 (1.2 eqv.), -10 °C 
 
116 or unidentified byproducts 
or trace 117 
3 10 (R)-Me-CBS catalyst (2 eqv.),  
catecholborane (2 eqv.), -78 °C ® 0 °C 
 
116 
4 10 (R)-Me-CBS catalyst (2 eqv.),  
catecholborane (2 eqv.), -20 °C ® rt 
 
Trace 117 
5 30 (R)-Me-CBS catalyst (2 eqv.),  
Catechol borane (2 eqv.), -10 ® rt 
 
Unidentified byproduct 
N-vinyl formamide signals lost 
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It is noteworthy to mention that in all previous CBS reductions within the aplyronine 
projects in our group, none had been attempted on a substrate containing the N-vinyl 
formamide functionality, perhaps foreshadowing these observed disappointing results. In 
the hope of gaining a reproducible result, varying the hydride source from borane to 
catechol borane215,216 at a range of temperatures was investigated. These attempts were not 
successful, and we were plagued by similar reactivity problems (Table 7, entries 3–5).  
 
Given the failure of the CBS reaction, a Noyori asymmetric transfer hydrogenation reaction 
was next investigated (Table 7, entry 6). This approach utilises a chiral ruthenium catalyst 
together with either 2-propanol or formic acid as the hydrogen source to enact the 
asymmetric reduction.217,218 In our case, formic acid was avoided as it was expected this 
would promote the hydrolysis of the sensitive N-vinyl formamide moiety. Interestingly, the 
product isolated from this reaction showed the characteristic downshift of H15 expected 
upon reduction of the carbonyl, but curiously no corresponding signal for H13 could be 
detected. Mass spectrometry results additionally provided no insight into the identity of this 
byproduct.  
These results reveal a serious disadvantage in this alternative coupling approach and it soon 
became apparent that gambling on the outcome of this reaction was not the best use of 
material or a reliable way to enact this transformation.  
Consequently, we decided to continue our synthesis with the enone functionality in place. 
The C13 methoxy has proved to be crucial to help anchor and position the trimethyl serine 
moiety as required for interaction with tubulin. Whilst the carbonyl moiety could still 
conceivably pick up these interactions (e.g. through hydrogen bonding), it is unclear if 
changing the hybridisation state from sp3 to sp2, and thus changing the angle of the 
interaction, would have detrimental effects on the cytotoxicity. An analogue containing the 
enone moiety would therefore allow for further probing of the protein binding interactions 
and could deliver crucial SAR data. Thus, we decided to move forward towards closing the 
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3.1.5 Removal of the propionate ester 
The propionate moiety in 116 had proved to be a judicious and robust choice of protecting 
group, demonstrating stability under a variety of conditions. However, the stage was now 
set for its removal and to reveal the C23 hydroxyl group for subsequent macrolactonisation. 
Due to the delicate nature and limited stocks of our advanced intermediate 116, this 
transformation was first investigated on a model system. The undesired minor diastereomer 
110 from the zinc borohydride reaction seemed an ideal choice, as our main concern was 
once again side reactivity of the N-vinyl formamide terminus.  
 
A metal hydride reduction approach using DIBAL was employed by Pettigrew to effect 
this transformation in the established coupling sequence.165 Theorising that DIBAL could 
readily cause reductive cleavage of the N-vinyl formamide moiety, these conditions were 
first investigated without anticipation of success. As expected, cleavage occurred even at 
low temperatures and the N-vinyl formamide signals disappeared from the crude 1H NMR 
(Table 8, entry 1). Use of lithium borohydride or lithium tri-tert-butoxyaluminium hydride 
as alternative hydride sources led to similarly poor results (Table 8, entries 2 and 3). New 
mild and selective deprotection conditions were therefore sought. 
 
Precluding the use of metal hydrides and acidic conditions, due to the instability of the N-
vinyl formamide, we were left with only one approach – hydrolysis under basic conditions.  
A variety of bases were screened with very little success. Methanolysis under standard 
conditions (K2CO3, MeOH) returned starting material, even with prolonged stirring at 
elevated temperatures (Table 8, entries 4 and 5). Frustratingly, this result turned out to be 
a common occurrence in this reaction screen. Despite the use of seemingly harsh 
conditions, the propionate ester remained stubbornly intact and starting material was 
returned quantitively each time under various conditions (Table 8, entries 6–10). Within 
our group, barium hydroxide had proven to be an effective reagent to enact ester hydrolysis 
under mild conditions and was next trialled (Table 8, entry 11).219,220 Whilst some 
reactivity was observed, no desired product could be isolated. Intriguingly, an unidentified 
byproduct was produced, containing 1H NMR signals corresponding to both the propionate 
ester and the N-vinyl formamide moieties. The use of a Grignard reagent also failed to 
produce any desired product (Table 8, entry 12). 
 
It was clear from these discouraging results that a more forceful approach was necessary. 
Remarkably, treatment with sodium hydroxide in refluxing methanol resulted in the desired 
hydrolysed product 118 in moderate yield (Table 8, entry 13). The production of a lower 
polarity spot was evident after a few hours and it was best to stop the reaction before starting 
material was completely consumed to avoid this.  

























Entry Conditions Result 
1 DIBAL, -78 °C Hydrolysis of N-vinyl formamide 
 
2 LiBH4, 0 °C Hydrolysis of N-vinyl formamide 
 
3 LiAlH(Ot-Bu)3, 0 °C Hydrolysis of N-vinyl formamide 
 
4 K2CO3, MeOH, rt 110 
 
5 K2CO3, MeOH, 65 °C 110 
 
6 LiOH, THF 110 
 
7 NEt3, MeOH 110 
 
8 NaOMe, MeOH 110 
 
9 KOH, THF 110 
 
10 Me3SnOH, CH2Cl2 110 
 
11 Ba(OH)2, MeOH Unidentified product 
 
12 MeMgBr (3 eqv.) 110 
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Before moving to the real system, these conditions were trialled on northern iodide 56 and 
gratifyingly, no elimination or deprotection reactions were observed at the silyl ethers. 
Pleasingly, these conditions translated well into the real system. The modest result of 55% 
yield (87% yield brsm) was deemed reasonable with the majority of unreacted starting 
material recovered (Scheme 53). Hence, a sufficient quantity of advanced material could 




















Scheme 53 Propionate ester cleavage in advanced fragment 116 to form C23 alcohol 119 
 
3.1.6 Advancement towards the macrocycle 
Successful cleavage of the propionate left us two oxidation steps away from accessing the 
necessary seco-acid 120 for macrolactonisation. A serendipitous discovery during our 
group's studies towards the aplyronines was the concomitant deprotection and oxidation of 
an allylic silyl ether to the corresponding aldehyde upon exposure to DDQ.159 The proposed 
mechanism commences with oxidation at the allylic position and  hydride transfer from the 
activated methylene through single electron transfer steps. The aldehyde is then 





























(a) NaOH, MeOH, 60 ºC












Scheme 54 DDQ mediated allylic oxidation of TBS ether 119 
 
 
Silyl ether 119 was therefore treated with DDQ in biphasic CH2Cl2/pH 7.0 buffer (1:1) 
solution at 0 °C to generate aldehyde 120 in 74% yield (Scheme 55). Oxidation to the 
required seco-acid followed by macrolactonisation would then furnish our fully protected 
aplyronine analogue precursor. This sequence was to be completed through a Pinnick 
oxidation and Yamaguchi esterification, analogous to the real aplyronine system.222,223 
Preliminary results indicated that macrolactonisation had occurred on test reaction scale (2 
mg), however this result could not be replicated, and all subsequent attempts resulted in 
destruction of the material to unidentifiable byproducts (Scheme 55). Due to the small scale 
of these reactions, it is unclear which of the two steps proved incompatible with our 
substrate but, once again, the 1H NMR signals from the N-vinyl formamide moiety had 
disappeared. 
 
At this stage of the project, stocks of advanced intermediates were low. In the course of 
this route, we had faced unforeseen difficulties and encountered challenging reactions with 
poor yields. Furthermore, the crucial macrolactonisation had failed and the path towards 
successful optimisation was unclear.  Hence, it was decided to abandon this alternative 




3.2 Established coupling sequence 
 
Whilst the alternate coupling sequence was under investigation by the author, Pettigrew 
was simultaneously advancing material towards analogues through the route borne out in 
the natural product synthesis. With plentiful stocks of northern and southern fragments to 
hand, the goal was therefore to obtain a sizeable stockpile of macrocyclic intermediate 




































































































(a) DDQ, CH2Cl2/pH 7.0 buffer (1:1), 0 ºC; (b) NaClO2, NaH2PO4, t-BuOH, 2-methyl-2-butene, H2O; 
(c)TCBC, NEt3, THF; then PhMe, addition into DMAP, PhMe
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3.2.1 Coupling of northern and southern fragments 
This well precedented coupling strategy commences with the Horner–Wadsworth–
Emmons reaction of b-ketophosphonate 36 and aldehyde 52. The required aldehyde could 
be accessed through selective deprotection of the TBS ether at C15 under acidic conditions, 
















By an analogous procedure (Section 3.1.4), the HWE reaction proceeded smoothly to 
generate enone 121 in 85% yield (Scheme 57). In this case, aldehyde 52 was viewed as the 
less precious fragment (accessible in 5 steps) compared to phosphonate 36 (10 steps) and 
thus was used in slight excess (1.05 equivalents). Again, the phosphonate minor 
regioisomer 77 could be separated cleanly at this stage. With the two fragments coupled, 
the next step was the introduction of the allylic alcohol through asymmetric reduction of 
the C13 ketone. Pleasingly, without the N-vinyl formamide moiety present, the CBS 
reduction proceeded smoothly to generate alcohol 122 in excellent yield (93%) as a single 
diastereoisomer. The stereocontrol can be rationalised by inspection of the transition state 
as previously discussed (Section 3.1.4, Scheme 52). Stoichiometric quantities of the CBS 
‘catalyst’ were employed to ensure high reaction rates and selectivity. The 13S alcohol was 
assigned by comparison to Pettigrew’s analysis, wherein the configuration was determined 
through Mosher ester analysis.165 Ensuing methylation with Meerwein salt (Me3OBF4) and 
proton sponge proceeded smoothly in 87% yield. The propionate ester cleavage, which had 
caused such difficulties in the presence of the N-vinyl formamide could now simply be 
achieved through treatment with DIBAL at low temperature. Alcohol 123 could be quickly 
and efficiently formed in this way in almost quantitative yield (Scheme 57).  
 
This sequence of steps could reliably be carried out on larger quantities of material and 
delivered over 2 g of alcohol 123 for further studies, further highlighting the efficiency of 




















(a)THF/H2O/HCl 3M aq. (5:2:1); (b) (COCl)2, DMSO, NEt3, CH2Cl2, —78 ºC → rt




















Scheme 57 Northern and southern fragment coupling and elaboration to generate alcohol 123 
 
 
3.2.2 Towards the macrocycle  
As previously discussed in Section 3.1.6, the 24-membered macrolactone could be 
accessed through oxidation at C1 to expose the carboxylic acid for subsequent 
esterification. This sequence begins with the elegant DDQ mediated deprotection and 
oxidation of the allylic TBS ether 123. However, careful handling was required for this 
compound. Unlike the previous DDQ substrate 119, our current intermediate possesses a 
PMB ether at C27 which is usually labile under the oxidative DDQ conditions. Preferential 
macrolactonisation to forge the undesired 26-membered macrolactone had been observed 
to occur on material with the C27 alcohol, hence its protection remained essential at this 
stage.165 Woodrow observed that the allylic oxidation occurred faster than PMB cleavage 
to deliver the desired kinetic aldehyde product.221 Pettigrew witnessed similar results and 
delivered optimised conditions for this transformation.  
 
Moving forward, TBS ether 123 was exposed to solid DDQ in biphasic CH2Cl2 and aqueous 























































(a) Ba(OH)2, THF, then 52, THF/H2O (40:1); (b) (R)-Me-CBS, BH3·SMe2, THF, —10 ºC; 
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chemoselectivity issues with the PMB ether. In this way, aldehyde 124 could be formed in 
a respectable 75% yield and unreacted starting material could easily be recovered and 
resubmitted. Pettigrew reported optimum results with the use of pH 9.2 buffer solution. It 
was surmised that under neutral conditions (pH 7.0 buffer), the acidic DDQH generated 
during the reaction was promoting undesired protecting group migrations, leading to 
apparent recovered ‘starting material’ that was not synthetically useful. Gratifying, under 
the basic buffered conditions, the recovered material proved to be spectroscopically 
identical to the starting material. Overall, aldehyde 124 could reliably be produced with a 
















The seco-acid for macrolactonisation can be obtained through a chemoselective Pinnick 
oxidation of the aldehyde at C1. The strengths of the Pinnick oxidation lies in the mild 
reaction conditions, rendering it applicable for use on complex substrates with a broad 
range of sensitive functional groups. Under conditions of sodium chlorite in combination 
with hypochlorous acid and scavengers, Lindgren and Nilsson first reported the oxidation 
of aldehydes to carboxylic acids.223 Kraus and co-workers developed the methodology 
further by introducing 2-methyl-2-butene as the scavenger under buffered conditions.224,225 
Pinnick successfully generalised this process and demonstrated its application to a wide 
range of a,b-unsaturated aldehydes.226 
 
The active oxidant in this transformation is believed to be chlorous acid (HClO2), produced 
from sodium chlorite under the mildly acidic dihydrogenphosphate-buffered conditions. 
Addition of this species into the aldehyde produces an adduct that undergoes hydride 
abstraction through a pericyclic transition state. In this process, the carboxylic acid product 






















(a) DDQ, CH2Cl2/pH 9.2 buffer (4:1), 0 ºC
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reactive species and can react with the starting sodium chlorite to generate chlorine dioxide 
(ClO2), thus inhibiting the reaction. Additionally, any olefins present in the aldehyde 
substrate risk reaction with electrophilic HOCl, resulting in the creation of unwanted 
halohydrins. Consequently, a sacrificial additive, such as 2-methyl-2-butene, is added in 



















Scheme 59 Mechanism for the Pinnick oxidation of an aldehyde 
 
 
In this case, Pinnick oxidation of aldehyde 124 proceeded smoothly upon exposure to a 
large excess of reagents, to yield seco-acid 125 after a simple aqueous workup (Scheme 
60). Typically, the material was clean enough to be subjected directly to the esterification 




With the required seco-acid 125 in hand, attention turned to the pivotal macrolactonisation 
step. The method of choice was the Yamaguchi protocol as this had been successfully 
implemented in the aplyronine natural product synthesis to form the C1–C27 macrocycle. In 
the method developed by Yamaguchi, upon treatment with 2,4,6-trichlorobenzoyl chloride 
and triethylamine, the carboxylic acid functionality is first converted to the reactive mixed 
anhydride species (Scheme 61). The mixed anhydride solution is then diluted and added 
slowly (e.g. via syringe pump) to a solution of DMAP which acts as a nucleophilic catalyst 





























(side reaction) 2ClO2 +   Cl   + HO
HPO42
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to promote the intramolecular condensation. Classically, the reaction is conducted under 
conditions of high dilution and slow addition to minimise intermolecular coupling and 
suppress the formation of oligomers.222 Investigations by Dhimitruka and SantaLucia have 
























Scheme 60 Pinnick oxidation and Yamaguchi macrolactonisation sequence to form the fully 








































































(a) NaClO2, NaH2PO4·2H2O, t-BuOH, 2-methyl-2-butene, H2O; (b) TCBC, NEt3, THF; then PhMe, addition into DMAP, PhMe
Chapter 3 – Fragment coupling strategies  
 
 99 
Seco-acid 125 was treated with TCBC and NEt3 before the mixed anhydride solution was 
diluted with toluene and added to a large excess of DMAP over 2-12 h via syringe pump. 
This delivered macrolactone 126 in good yield (70% yield over two steps, Scheme 60) on 
a 500 mg batch. Through this procedure, over 1 g of key macrocyclic intermediate 126 was 
generated. The fully protected macrocycle was a convenient point to store advanced stocks, 




3.3 Side chain installation 
 
With plentiful stocks of protected macrocycle 126, the planned sequence to construct our 
aplyronine analogues could continue with the final fragment coupling to attach the side 
chain. Having fully optimised this reaction in the alternative coupling sequence, we were 
optimistic that these conditions would translate well into our current system.  
 
 
3.3.1 Aldol coupling 
Deprotection of PMB protected macrocycle 126 could be achieved under standard 
conditions (DDQ, CH2Cl2, pH 7.0 buffer), and the resulting alcohol 127 was oxidised with 
DMP. This delivered the macrocyclic aldehyde 53 necessary for subsequent aldol coupling 






































(a) DDQ, CH2Cl2/pH 7.0 buffer; (b) DMP, NaHCO3, CH2Cl2
(80%)
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Due to the highly precious nature of the intermediates, we proceeded with caution for this 
final fragment coupling. Frustratingly, the previously developed conditions (1.5 
equivalents of enolate, silica gel work-up) did not translate well into these more advanced 
substrates. All initial attempts at the boron-mediated aldol reaction failed, with starting 
material aldehyde 53 and ketone 51 returned quantitatively. Reflecting that poor-quality 
reagents might have caused the reaction to fail, fresh dicyclohexylboron chloride was 
prepared, but to no avail. The reaction remained troublesome. Puzzlingly, Pettigrew 
reported no similar difficulties at this stage and successfully forged the coupled product.  
 
In an attempt to encourage conversion, the excess of side chain ketone 51 was vastly 
increased to 6 equivalents, alongside a change in experimental procedure. Previously, the 
Lewis acid and triethylamine base had been added neat to a solution of ketone 51 in diethyl 
ether. Contrastingly, in this case it was found that pre-mixing the BCy2Cl and NEt3 and 
generating a 1 M solution of ‘enolising reagent’ was crucial for a successful reaction. 
Whilst the high loading of ketone is not ideal, the differences in molecular weight between 
this small fragment and the larger macrocycle render this manageable. Additionally, excess 
enolate would regenerate ketone 51 upon workup and the surplus could be recovered almost 
quantitatively after the Burgess elimination. Pleasingly, it was found that on larger scales, 
the ketone loading could be reduced to 2 equivalents. 
 
To this end, the enolate derived from ketone 51 was added to aldehyde 53 at -78 °C and 
the reaction was slowly warmed to -20 °C over 1 h. Progression could be monitored by 
TLC analysis and once complete, the reaction was quenched by addition of silica gel and 
stirring with exposure to air. As before, incorporation of the N-vinyl formamide moiety 
results in a large increase in polarity of the aldol adduct product 128, rendering it 
inseparable from excess ketone at this stage.  
 
The Burgess elimination was employed once again to eliminate the newly formed C27 
hydroxyl to forge enone 129. As previously observed, the reaction was prone to stalling 
and best practice was to halt, work-up and resubmit the material to ensure full conversion. 
Through this aldol–dehydration sequence, the full C1–C34 aplyronine carbon skeleton was 
assembled in a good 65% yield over 3 steps from alcohol 127 (Scheme 63). 
 
3.3.2 Conjugate reduction of enone 129 
With the full carbon backbone in place, the final step in this sequence is the conjugate 
reduction of enone 129 to form ketone 130. This transformation is precedented within the 
aplyronine natural product synthesis and can be accomplished by treatment with Stryker’s  



















































































































(a) 51, BCy2Cl·NEt3 (1M in Et2O), 0 ºC, then 53, —78 ºC; (b) Burgess reagent, THF; 
(c) [CuH(PPh3)]6 (5 mol%), PhMe
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reagent. The reagent was prepared and used in an analogous manner to that previously 
discussed (Section 3.1.1). Notably, in this case, it is imperative to achieve chemoselectivity 
for the enone over the pentadienoate moiety. For this purpose, triphenylphosphine was 
crucially employed as a ligand to form a less active reagent through a modified Lipshutz 
protocol.229  
 
Treatment of enone 129 under standard conditions of 20 mol% of Stryker’s reagent solution 
led to a product initially identified as ketone 130 (Scheme 63). However, upon closer 
inspection of the 1H NMR it soon transpired that another component was present in the 
reaction mixture (ca. 50%). Significantly reduced integration values of the dienoate protons 
(H2–H5) indicated that side reactivity of the pentadienoate moiety was occurring alongside 
enone reduction. Byproduct 131 is surmised to have the structure shown in Figure 33, 
although this has not been rigorously confirmed through purification and full structural 












Figure 33 Hypothesised reduced dienoate product from Stryker’s reduction of enone 129 
 
 
Williams reported no evidence of this byproduct forming on the real aplyronine system and 
surprisingly, the reaction had to be pushed to completion with further aliquots of Stryker’s 
reagent solution needed.121 It therefore seems that on our simplified substrate, the 
pentadienoate moiety is much more susceptible to conjugate reduction. Re-examination of 
Pettigrew’s results indicate that 131 was also observed in this case. 
 
Optimisation of this reaction was carried out in an effort to suppress the formation of this 
unwanted byproduct (Table 9). Running the reaction at a lower temperature or in the dark 
did not improve the result (Table 9, entries 1–2). Lowering the loading required us to 
balance the reactivity with selectivity (Table 9, entries 3–4) with 5 mol% loading 






































With careful monitoring of the reaction together with the reduced catalyst loading, ketone 
130 could be cleanly furnished in a few hours in an excellent and reliable 89% yield, with 
no over-reduction observed (Scheme 63). Monitoring conversion by TLC analysis was 
futile since starting material enone 129, ketone 130 and byproduct 131 all possess the same 
retention factor on silica in a variety of solvent systems. Hence aliquots were taken every 
hour, filtered through a small plug of silica and analysed by 1H NMR spectroscopy. By this 
method it was possible to follow the disappearance of enone signals to judge when the 
reaction was complete, whilst minimising the formation of byproduct 131. At this point, 
the full carbon skeleton of our designed analogues was in place and the stage was set for 
late stage diversification to deliver a library of analogues for biological evaluation. 
 
Entry Conditions Result 








3 1 mol% [CuH(PPh3)]6, TMDS, rt No conversion 
 

































This chapter has outlined endeavours towards two complementary methods for advanced 
fragment coupling.  Firstly, we focused on connecting the southern and side chain 
fragments before the addition of the northern fragment (Scheme 64). Whilst this approach 
ultimately failed to deliver a reliable and efficient route towards analogues, its advantage 
lay in the early entry of the boron-mediated aldol reaction. Significant optimisation of this 
reaction was carried out with a noteworthy improvement in yield obtained. Furthermore, 
this route taught us much about the side chain chemistry and revealed the truly remarkable 
and impressive stability of N-vinyl formamide moiety to a variety of conditions. However, 
given the difficulties of the CBS reduction associated with the N-vinyl formamide and 
failures in macrolactonisation, efforts towards this route were deprioritised in favour of the 
established approach. 
 
The previously published Paterson strategy once again served well and proved to be a 
reliable method to unite complex fragments to assemble the C1–C27 macrolactone. 
Elaboration of the macrolactone to the full carbon skeleton was achieved through 
appendage of the side chain moiety. The late stage boron-aldol coupling in this route proved 
challenging to implement on more complex substrates but ultimately delivered the desired 
coupled product. Optimisation of the Stryker’s reduction yielded a reliable protocol to 
furnish ketone 130 efficiently (Scheme 65).  
 
Following this sequence, ketone 130 was prepared in 14 steps and 17% yield from southern 
fragment 98. The highly anticipated conversion of ketone 130 into designed aplyronine 





























































































































































Towards antibody–drug conjugates 
 
Our ultimate goal is to develop structurally simplified analogues of the aplyronines, that 
retain the exquisite potency of the corresponding natural products, to incorporate into next 
generation antibody–drug conjugates. At this point, in order to achieve this aim, three 
outcomes needed to be accomplished: (1) completion of the synthesis of these highly 
complex molecules through a late stage diversification strategy, thus generating a small 
library of analogues, (2) biological testing of our analogues to critically assess the effects 
of our structural modifications, and (3) investigations into suitable linker chemistry for 
bioconjugation to an antibody.  Each of these efforts will now be described.  
 
 
4.1 Completion of analogue synthesis 
 
With ketone 130 in hand, the full analogue skeleton was in place and only few 
modifications were needed to complete the synthesis of these designed compounds. A late 
stage diversification strategy was envisaged to ultimately generate a focused library of 
analogues. With the C29 ketone in place, those analogues contain a side chain similar to that 
of scytophycin C (Figure 22, Section 1.4.3) and in the first instance these hybrid structures 
were targeted.  
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4.1.1 Scytophycin-type hybrid analogues 
Ketone 130 could be transformed into aplyronine–scytophycin hybrid analogues in two 
steps, deprotection and esterification. Esterification at C7 with N,N,O-trimethylserine 
(TMSer) is pivotally important for cytotoxicity and our attention turned to installing this 
crucial functionality. As previously discussed, this amino acid residue exists as a scalemic 
mixture of epimers (ca. 1:1) and it is unclear if this is a natural feature of these compounds, 
or an artefact of the isolation procedure. Due to subtle differences in the pharmacophore, 
each diastereoisomer could have a unique biological profile as one of the serine 
enantiomers could potentially promote stronger interactions with tubulin than the other. 
Hence, appending enantiomerically pure amino acids was a deliberate strategy designed to 
examine these effects. 
 
Towards this end, Pettigrew made significant progress, delivering two aplyronine–
scytophycin analogues (Figure 34). The first of these was the aplyronine C-like hybrid 132, 
bearing two free hydroxyl groups in the northern region. The second analogue 133 contains 
the naturally occurring (S)-TMSer amino acid group at C7.165 Close inspection of the 1H 
NMR spectrum, however, revealed that the over reduced dienoate byproduct 131 (Section 
3.3.2) was a significant contaminant of this material and thus could have consequences in 
modifying the biological activity of these compounds (vide infra, Section 4.2). Following 
this discovery, the goal of the author was therefore to re-synthesise these analogues to 
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Exposure of bis-TES protected 130 to conditions of buffered HF∙pyridine resulted in the 
formation of diol 132 in 85% yield (Scheme 66). Dr Simon Williams had prepared each 
enantiomer of TMSer for use in the aplyronine projects and had successfully demonstrated 
that acylation could be achieved site-selectively at C7 over the more hindered C9 position.121 
Yonemitsu esterification conditions proved to be the most reliable way to achieve this 
transformation. These conditions are a variant of the Yamaguchi method whereby all the 
reagents are combined simultaneously, bypassing the pre-formation of the mixed anhydride 
species.230  
 
Careful monitoring of the progress of the reaction was necessary to avoid bis-acylation, 
and by cautiously adding aliquots of reagent from a stock solution it was possible to push 
the reaction to an acceptable conversion. In this way, the (S)-epimer 133 was prepared in 
















































































(a) HF·py, py, THF, 0 ºC → rt; (b) (S)- or (R)-TMSer, DMAP, TCBC, NEt3, CH2Cl2/benzene, 0 ºC
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4.1.2 Aplyronine D analogue 44 
With the C29 ketone analogues in hand, the next stage of our project was to investigate the 
installation of the ester moiety at this position. As in the alternative fragment coupling 
sequence (Section 3.1.2), diastereoselective reduction of the ketone functionality would be 
necessary. Initial testing of the zinc borohydride reduction on highly advanced ketone 130 
once again highlighted the challenges associated with this reaction. In this case, 11B NMR 
analysis confirmed the zinc borohydride reagent had successfully formed (Zn(BH4)2        
11B: - 45 ppm).204 
 
As previously experienced, yields and dr were highly variable. Furthermore, on these more 
complex substrates, TLC analysis and column chromatography were more difficult. The 
compounds appear as two spots due to the stable N-vinyl formamide rotamers and have a 
tendency to streak due to their high polarity. Moderate yields of 50-60% were typically 
observed with a dr of 2:1 (Scheme 67). Interestingly, an attempt to carry out the reaction 
using sodium borohydride seemed to yield the undesired (S)-diastereoisomer exclusively, 
although due to the small scale of the reaction this product was not fully characterised. The 
(R)-configuration at C29 was unambiguously determined by Mosher ester analysis. Thus, 
the (R)- and (S)-MTPA esters 136 and 137 were formed, and the sign of DdS-R for protons 
on each side of the derivatised alcohol was consistent with the (R)-configuration as shown 
(Scheme 67).  
 
We first targeted an aplyronine D analogue with the N,N-dimethyl glycine residue in the 
side chain. Based on Yamada’s initial biological testing, aplyronine D exhibits greater 
cytotoxicity than aplyronine A and so was prioritised for analogue development. 
Additionally, the lack of stereogenicity in the amino acid somewhat simplifies the analysis 
of the products. 
 
Dimethyl glycine esterification of C29 in 130 could be achieved under Keck conditions, and 
the crude material immediately subjected to buffered HF×pyridine to enact the bis-TES 
deprotection. Through this sequence, diol 138 was formed in 69% yield over the two steps. 
Finally, esterification at C7 using the naturally occurring (S)-trimethyl serine residue under 
the previously discussed Yonemitsu conditions afforded aplyronine D analogue 44 in 65% 
yield (Scheme 68). This analogue was now ready to be submitted for biological evaluation 
(vide infra, Section 4.2), alongside our scytophycin hybrid analogues 133 and 134, to 
provide an insight into the effects of our modifications on cytotoxicity. Notably, these 
analogues have been designed to allow for a direct comparison of each epimer of TMSer, 
together with the effect of the ketone moiety at C29, thus providing valuable SAR data. 
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136 (R)-MTPA ester (63%)
MTPA
137 (S)-MTPA ester (72%)
(a) Zn(BH4)2, Et2O, 0 ºC; (b) (S)- or (R)-MTPA-OH, DCC, DMAP, DMAP·HCl, CH2Cl2
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Due to time pressures, the corresponding aplyronine A analogue containing a DMAla 
residue at C29 was not synthesised, but could easily be made via an analogous procedure in 
the future. With a small set of analogues in hand, the much-anticipated biological testing 



















































































(a) DMGly, DCC, DMAP, DMAP·HCl, CH2,Cl2; (b) HF·py, py, THF, 0 ºC → rt;
(c) (S)-TMSer, DMAP, TCBC, NEt3, CH2Cl2/benzene, 0 ºC
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4.2 Biological testing 
 
Biological testing of our aplyronine analogues was carried out by Steve Walsh in 
collaboration with the David Spring group from the Department of Chemistry and the Jay 
Carroll lab at Cancer Research UK Cambridge Research Institute. To allow for 
comparisons with Yamada’s original biological data for the natural products, the HeLa cell 
line was initially chosen with a view to expanding our testing to other cell lines after these 
initial studies. 
 
4.2.1 First phase 
The first round of biological testing was carried out using the material prepared by Talia 
Pettigrew.165 These constitute our scytophycin–aplyronine hybrid analogues with the C29 
ketone functionality (Figure 35, compounds 132 and 133). Alongside these simplified 
structures, synthetic samples of the aplyronines (Figure 35, compounds 21, 23 and 24) 
prepared by Williams were submitted to the cytotoxicity assay to provide a means of 
directly evaluating and assessing the outcome of our structural modifications. The 
microtubule stabilising marine natural product discodermolide (6, Figure 7, Section 1.1.1) 
was additionally included as a control across separate assays.  
 
The results of this assay are summarised in Table 10. Compounds were tested in three 
independent experiments, each consisting of three replicates of the same concentration of 
each drug. As anticipated, synthetic aplyronine A, C and D samples showed the expected 
picomolar antiproliferative activity. These results independently agree with earlier 
biological results obtained by Williams in collaboration with Professor Fernando Diaz in 
Madrid (Ap A 0.30 nM, ApD 0.40 nM, HeLa cell line).121 Interestingly, the activities of 
aplyronine A and aplyronine D appear to be approximately equal in this HeLa cell line. 
This is in contrast to Yamada’s  findings (ApA 0.45 nM, ApD 0.071 nM, HeLa–S3 cell 
line).2,90 HeLa cells are heterogeneous and contain more than one type of mutant cells, one 
of which is HeLa–S3.231–234 It is possible that aplyronine D is more selective for these cells, 
which could account for the stark difference in IC50 values. However, it is worth mentioning 
that Yamada’s 2012 paper disclosing the minor aplyronines contains no experimental 
procedures for the measurement of cytotoxicity. Alongside this, it is not clear if the 
cytotoxicity values quoted for aplyronines A-C were obtained in parallel assays alongside 
aplyronines D-H or if they are merely those measured upon their isolation in 1993. If the 
latter is true, it is reasonable to assume a degree of discrepancy between experiments run 
19 years apart.  
 









































TP01 133 (S)-TMSer 
TP02 132 H 
 R2 R3 
Ap A 21 TMSer (S:R, 1:1) (S)-DMAla 
Ap C 23 H (S)-DMAla 




































































Table 10 Antiproliferative activity of synthetic aplyronines and analogue samples against HeLa 
cells 
  
Compound IC50 / nM 
Ap A 21 0.31  
Ap C 23 3.67  
Ap D 24 0.26  
TP01 133 146  
TP02 132 n.d. 
Discodermolide 6 3.49 












Figure 37 Cell growth over 4 days for first phase compounds. Vehicle refers to 0.1% DMSO in 
DMEM (Dulbecco’s modified Eagle’s medium)  
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Two types of data are illustrated in Figures 36 and 37. Percentage viability illustrates the 
number of cells alive at a fixed point in time, in this case after 96 h. Alongside this, cell 
growth was monitored over the same time period. Our scytophycin hybrid analogues do 
not appear to mirror the picomolar antiproliferative activity of the parent natural products, 
with IC50 values over 100 nM. However, the differences observed between TP01 133 and 
TP02 132 serve as further proof of the necessity for the C7 trimethyl serine residue to 
promote increased cytotoxicity.  
 
As previously discussed (Section 3.2.3), the reduced dienoate product 131 is a constituent 
in Pettigrew’s material and it is possible that some of the reduced activity observed for 
TP01 133 stems from this byproduct either competitively binding or inhibiting the binding 
of the true analogue to actin and tubulin. Additionally, the amount and concentration of 
‘true’ analogue is reduced, leading to errors in obtaining an accurate value.  Previous SAR 
studies from the Yamada and Kigoshi groups have confirmed that the fully saturated 
dienoate results in a significant loss of activity.108 Hence it was necessary to re-synthesise 
analogue 133 as detailed in Section 4.1.1 and re-submit the pure sample for re-testing. 
 
4.2.2 Second phase 
Once our re-synthesised aplyronine–scytophycin analogues 133 and 134 and the aplyronine 
D analogue 44 were in hand, these compounds were submitted to a second round of 
biological testing against HeLa cells (Figure 38). These results would allow us to directly 
compare the importance of the configuration of TMSer at C7 and the ketone functionality 
at C29. Alongside these analogues, the actin-binding reidispongiolide A (29) and tubulin-
binding discodermolide (6) were submitted for control and comparison purposes.  
 
The results of this assay are summarised in Table 11. Compounds were tested in triplicate 
at the same concentration of each drug. The three analogue samples tested exhibit IC50’s 
greater than 100 nM, whilst discodermolide displayed an analogous value to that of our 
first assay (Figure 39). Disappointingly, our analogues do not appear to possess the sub-
nanomolar potency exhibited by the parent natural product. There could be a number of 
reasons for this. Firstly, loss of the pharmacophore could stem from our analogues biding 
to actin or tubulin in an altered conformation compared to the natural products. Removal 
of the olefin and the two stereocentres in the southern region may change the binding mode 
or binding direction. This could also alter the protruding conformation of the trimethyl 
serine residue for tubulin binding, thus negatively impacting the activity. Additionally, the 
increased conformational flexibility in the macrolide ring in our analogues may also 
contribute to this effect. All previous evidence suggests that the C13 methoxy, the C10 
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methyl and the C9 hydroxyl groups have important roles and function as anchors to retain 
the protrusive trimethylserine moiety.108 Perhaps one of the removed stereocentres forms 
an additional crucial interaction and its removal could be significant enough to change the 
binding mode of our analogues. Finally, an important consideration is the potential impact 
our alterations have on cell permeability. It may be that the modifications have rendered 
these molecules less permeable via the cell membrane than their natural counterparts. A 
surprising outcome of these results is the apparent lack of importance in the configuration 
of the trimethyl serine residue at C7 (compare RP-1 133 and RP-2 134). This effect would 
be valuable to explore in more detail, possibly with the parent aplyronine D structures.  
 
We had indeed hoped to see equal or higher potency in the analogues to further their 
potential for inclusion in ADCs. These biological results were therefore disappointing. One 
encouraging prospect is that whilst the native aplyronines are too toxic to be administrated 
as a standalone chemotherapeutic, the reduced potency of our analogues opens up the 






















Figure 38 Aplyronine analogue samples for second phase of biological testing 
 
 R1 
RP-1 133 (S)-TMSer 
























































Figure 39 Cell viability graph for second phase compounds in biological testing 
 
 









Despite these initially disappointing results, there is still a lot of underexplored potential 
for the development of aplyronine analogues for ADC development. Diversification of this 
preliminary small library would generate more ‘aplyrologues’ and we can make use of the 
SAR and protein binding knowledge that this gives us to find the best possible combination 
of activity and simplicity. Once an appropriate analogue is in hand, attention can turn to 
ADC construction where linker chemistry is of paramount importance.  
 
Compound IC50 / nM 
RP-1 133 164 
RP-2 134 192 
RP-3 44 125 
Discodermolide 6 3.4 
Reidispongiolide A 29 21 
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4.3 Linker strategies 
 
Since the ultimate goal of this work is to develop novel ADCs, it would also be necessary 
to develop chemistry to link our eventual warhead of choice to an antibody. To this end, in 
parallel with the ongoing aplyrologue synthesis, we set out to develop an aplyronine 
derivative suitable for bioconjugation to an antibody. This section will concentrate on 
identifying a suitable modification site within our analogues to which a linker could be 
attached. A discussion on possible bioconjugation strategies to antibodies will be presented 
in the next chapter.  
 
In identifying optimal linker attachment points, it is necessary to consider the effect the 
linkage may have on biological activity if a non-cleavable variant is used. Additionally, 
another important consideration is that the chemistry used to install the linker must be 
compatible with the wide range of functional groups present in our compounds.  
 
Kigoshi has demonstrated that the N-vinyl formamide terminus can serve as an attachment 
point to a variety of biological probes.114,124,235,236 SAR studies showed that replacement of 
this moiety with other polar functional groups such as alcohols, oximes, or hydrazones 
could be well tolerated with respect to cytotoxicity.116,117 Various derivatives could 
therefore be introduced through deliberate hydrolysis of the N-vinyl formamide moiety and 
subsequent condensation with a substituted hydroxylamine (Figure 40). Importantly, this 
work illustrated that biological activity could be retained upon installation of large groups 
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This approach initially seemed an attractive prospect: it was well precedented and signified 
a late stage modification so fitted in well with our synthetic route. However, we had spent 
considerable time and effort optimising the installation of the N-vinyl formamide moiety 
and to simply replace it at this stage seemed counterintuitive. Additionally, oxime linkages 
can be labile under physiological conditions, leading to reduced ADC stability in plasma 
and the possibility of issues due to off-target toxicity. As such, a focus on more stable 
linkers was deemed appropriate at this stage.  
 
Many methods have been reported in the literature for conjugation strategies of complex 
natural products.237–240 For our purposes, late stage approaches using functionality already 
in place within our analogues was highly desirable. To this end, our initial focus was 
conjugating through the pendant amino acid residues as these represent the final steps in 
our analogue synthesis. 
 
Williams validated this tactic through the synthesis of linker-modified derivative 139, 
extending from the dimethylglycine residue at C29 (Figure 41).121,138 The basis of this 
approach can be explained with the aid of the crystal structure of the 1:1 aplyronine A-actin 
complex, in which the C29 DMGly residue appears to protrude into the surrounding bulk 
solvent.108 Hence, elaboration of the amino acid moiety should not significantly impact the 
key ligand–protein binding interactions. Williams’ designed substrate 139 contains an 
Fmoc-protected primary amine group for non-cleavable bioconjugation to an antibody 











Figure 41 Aplyronine derivative synthesised by Williams for antibody conjugation extending 
through the dimethyl glycine ester residue121 
 
 
The disadvantages of non-cleavable linkers, namely the liberation of an unknown linker 
modified payload, led us to shift to a cleavable approach. Cleavable linkers are designed to 
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Hence, the well-characterised chemical entity with known potency is released through this 
more defined method.  
 
The field of cleavable linkers commonly encompasses hydrazones, disulfides, phosphate 
diesters and enzyme-cleavable dipeptides.108 Of these, the enzyme-cleavable dipeptide 
motif surfaced as a compelling candidate for use in our aplyronine analogues. Specifically, 
our system could be compatible with the elegant linker technology reported by Seattle 
Genetics242 and Pillow and co-workers at Genentech.243  The Genentech protocol converts 
tertiary amine residues found in drug molecules to the corresponding para-aminobenzyl 
quaternary ammonium salts (PABQs, Scheme 69). This is in combination with a protease 
cleavable valine-citrulline (Val-Cit) dipeptide unit to promote the intracellular cleavage. 
Upon exposure to the protease cathepsin B, the Val-Cit component is recognised and the 
aniline amide is cleaved. This triggers the self-immolating 1,6-elimination sequence of the 
PAB moiety, leading to traceless drug release.  
 
This methodology is an extension to the well-established para-aminobenzyl carbamate 
(PABC) self-immolating chemistry utilised in the clinically approved ADC Adcetris 
(Figure 17, Section 1.3.4) which contains a monomethyl auristatin E (MMAE) 
payload.81,244,245 The limitations to this chemistry are substrate specific in that the drug 
molecule must contain either a primary or secondary amine residue that is capable of 
forming a carbamate or amide connection. Auristatin E 140 (Figure 42) was initially not 
amenable to this protocol due to the terminal tertiary amine, prompting the synthesis of the 
desmethyl analogue, monomethyl auristatin E 141.81 In this example the biological activity 
was not detrimentally affected by this minor change. However, maintaining potency after 
small alterations is not always trivial, as demonstrated by the tubulysins. Here, the removal 
of a methyl group from tubulysin analogue 142 resulted in a greater than 40-fold drop in 
potency (Figure 42).81 The PABQ strategy is therefore a helpful extension of this 
methodology to allow us to derivatise tertiary amines directly. 
 
The quaternary amine approach conveys an additional benefit through the introduction of 
the charged species, leading to improved physicochemical properties of the corresponding 
conjugates through reduced ADC aggregation.246,247 Aggregation has been shown to 
decrease the therapeutic activity of the antibody and can elicit an immunological 
response.248  
 
Importantly, this class of linkers displayed remarkable stability in vivo with no loss of small 
molecule observed after seven days of ADC circulation in mice. The Genentech ADC 
conjugates are constructed in three efficient steps. Starting with valine-citrulline linker 144 
appended with a maleimide handle, the benzylic alcohol is first chlorinated, before SN2  












































































140 R = Me, auristatin E

















142 R’ = Me, tubulysin analogue IC50 0.8 μM (1A9 ovarian cancer cells)















144 X = OH




















(a) SOCl2, DMF; (b) NR3, TBAI, DIPEA
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displacement of the halide by a tertiary amine on the payload delivers the quaternised 
product 145. Ensuing bioconjugation through cysteine residues on the antibody affords the 
ADC (146, Scheme 70). Preliminary efforts toward the development of this linker strategy 
in the context of our aplyronine analogues will be now discussed.  
 
Although linker 144 is commercially available, the exceedingly high cost of this material 
(ca. £2500/g) precluded its use as a starting material for our synthesis. Consequently, we 
set out to synthesise a sizeable quantity of this key intermediate for use towards developing 
linker chemistry for our analogues. This work was carried out in the AstraZeneca 
laboratories in Macclesfield, UK.  
 
4.3.1 Synthesis of valine-citrulline linker 144 
The use of valine-citrulline linker 144 is extremely well documented in the literature for 
ADC design.249–251 Contrary to this, there is a distinct lack of publications that provide a 
detailed experimental procedure for the isolation and synthesis of this important linker 
motif.252–254 The original report was provided by Dubowchik and co-workers, who accessed 
linker 144 through a series of amide bond couplings, starting from the parent amino acid 
residues (Scheme 71).252 This approach is prevalent within the patent literature, but again, 














Scheme 71 Retrosynthesis of valine-citrulline linker 144 
 
 
Moving forward, this protocol was selected as the route to access linker 144, due to its 
apparent chemical simplicity and anticipated ease of scale-up. However, this deceptively 
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The synthesis commenced with conversion of commercially available Fmoc-protected-L-
valine 147 into the corresponding N-hydroxysuccinimide activated ester 148. Promoted by 
DCC, this transformation proceeded smoothly to deliver ester 148 in 90% yield (Scheme 
72). Pleasingly, this transformation could be scaled up to produce decagram quantities of 
intermediate 148.  
 
Investigations then began on the subsequent coupling reaction to install the citrulline 
residue. Following the literature protocol, simple addition of L-citrulline to a basic solution 
of ester 148 yielded the desired dipeptide 149 in a promising 78% yield on 500 mg scale 
(Scheme 72). Stirring for prolonged periods (ca. 48-72h) was necessary to achieve good 
conversion.  The work-up procedure for this reaction involved a citric acid quench followed 
by an organic extraction. The highly polar nature of these intermediates prohibits the use 









Scheme 72 Synthesis of Fmoc-Val-Cit-OH 149 
 
Upon application of this protocol to a preparative scale reaction (ca. 5 to 10 g), several 
unexpected problems arose. Firstly, on scale the material appeared to be highly hygroscopic 
and as a result had to be dried in a vacuum oven for extended periods of time (72-96 h) in 
order to drive off the excess water present. Additionally, close examination of the 1H NMR 
spectrum revealed that a significant quantity of citric acid, stemming from the work-up 
conditions, was contaminating the isolated material. All efforts to separate the citric acid 
from desired product 149 failed due to similarities in polarity and solubility. Alongside this, 
unreacted starting material Fmoc-Val-OSuc 148 had not been successfully removed and 
was present within the isolated material in meaningful quantities (ca. 5-10%). Hence, a new 
work-up procedure was developed to circumvent these issues.  
 
This new work-up procedure was designed to allow for easy removal of unreacted starting 
material. To this end, the reaction was quenched with aqueous potassium carbonate solution 
























(a) N-hydroxysuccinimide, DCC, THF, 0 ºC; (b) L-Citrulline, NaHCO3, DME/H2O/THF (2:2:1)
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potassium carboxylate and thus remains in the aqueous phase, allowing clean removal of 
the organic starting material. Next, acidification of the basic media was required for 
extraction of the product. Citric acid was completely removed from the procedure and 
replaced by hydrochloric acid, which can be easily removed in vacuo. Whilst the formation 
of the byproduct was alleviated, this improvement was compounded with a further 
operational issue. Upon acidification, a large volume of thick, gelatinous material was 
formed that was exceedingly difficult to manipulate. Best practice was to extract this ‘jelly’ 
material with large volumes of polar solvents (EtOAc and IPA), which upon concentration 
and drying yielded the desired product 149. Whilst the use of excessive volumes of solvent 
is not ideal, this sequence eventually proved reliable on scale (80-90% yield) and for the 
first time we had access to multigram quantities of pure dipeptide product 149 (Scheme 
73).   
 
The next step in this series was the installation of the self-immolating ‘trigger’, and the 
success of this reaction was found to hinge upon the quality of the 4-aminobenzyl alcohol 
(PABOH) reagent. This reaction was mediated by 2-ethoxy-1-ethoxycarbonyl-1,2-
dihydroquinoline (EEDQ), a well-known coupling agent in peptide synthesis.255–257 EEDQ 
allows the coupling of amino acids in a single operation with little or no racemisation. 
Mechanistically, activation of a carboxylic acid occurs via the formation of a mixed 
anhydride species 150 (Scheme 74). Displacement of the ethoxy group on EEDQ yields 
intermediate 151, which decomposes through a 6-membered transition state to generate the 
mixed anhydride 150 which acts as the acyl transfer agent. Amide 152 is subsequently 
furnished after nucleophilic attack of the amine moiety from the second amino acid. 
Anhydride formation is believed to be slow, but once formed is consumed very rapidly 












































































































































(a) PABOH, EEDQ, CH2Cl2/MeOH (2:1), dark
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In this case, exposure of acid 149 to EEDQ and para-aminobenzyl alcohol yielded the 
coupled product after 72 h. Purification via filtration of the crystallised product yielded 153 
in 74% yield (Scheme 75).  
 
Overall, this protected valine-citrulline linker 153 was synthesised in 3 steps and 59% yield 
from 147. With the Fmoc protecting group in place, this represented a convenient point to 
stockpile material and over 15 g of this intermediate was generated via this route. There is 
great potential for flexibility in advancing this material towards an ADC linker; the Fmoc 
group can simply be deprotected and a carboxylic acid-modified bioconjugation handle 
appended through a final amide coupling.  
 
4.3.2 Valine-alanine linker 154 and quaternisation studies 
Whilst the synthesis of Val-Cit linker 153 was explored and optimised, parallel 
investigations into quaternisation strategies were undertaken. For this purpose, we made 
use of the analogous Alloc-protected valine-alanine (Val-Ala) linker 154 which was kindly 







Figure 43 Valine-alanine linker 154 supplied by AstraZeneca 
 
 
The valine-alanine linker system is an alternative substrate for cathepsin B cleavage and 
has recently seen incorporation into antibody–drug conjugates.258,259 Compared to its Val-
Cit counterpart, the Val-Ala system may offer benefits of reduced hydrophobicity and 
therefore lower potential for aggregation.260,261 
 
Alloc deprotection was initially trialled using Pd(0) and pyrrolidine to act as the allyl 
scavenger.262 However, the pyrrolidine byproduct could not be separated from the desired 
amine product, and so an alternative approach was sought. Pleasingly, treatment of 154 
with catalytic tetrakis(triphenylphosphine)palladium(0) (Pd(PPh)3)4) in combination with 
potassium carbonate in methanol delivered the deprotected amine 155 in 74% yield 
(Scheme 76). The lower than anticipated yield can be attributed to the highly polar nature 























Scheme 76 Alloc deprotection of 154 with catalytic Pd(0) 
 
 
Mechanistically, this transformation proceeds via oxidative addition of Pd(0) into the 
allylic  carbonate to form a Pd(II) p-allyl complex. The resulting carbonate anion can 
undergo spontaneous decarboxylation to reveal the primary amine (Scheme 77). Pd(II) is 
reduced by attack of the scavenger species, presumed to be the methoxide anion in this 







Scheme 77 Mechanism for Alloc deprotection using Pd(0) 
 
 
With the free amine in hand, the bioconjugation handle could now be connected. For our 
purposes, the maleimide functionality was initially selected to align with the Pillow 
approach for reaction with a thiol-containing carrier. In principle, any antibody conjugation 
motif could be coupled at this point, provided it is appropriately substituted with a 
carboxylic acid to facilitate amide bond formation.  
 
Coupling of 6-maleimidohexanoic acid and amine 155 could be achieved under standard 
conditions by exposure to HATU and diisopropylethylamine (DIPEA) overnight. At this 
point, the polarity of the product was sufficiently reduced so that purification could be 
performed via column chromatography to deliver amide 156 in 70% yield (Scheme 78). 
Subsequent chlorination of 156 could be achieved through treatment with thionyl chloride 







































(a) Pd(PPh3)4, K2CO3, MeOH











Scheme 78 Amide coupling between amine 155 and 6-maleimidohexanoic acid 
 
 
This method generated the required benzyl chloride 156 in a reasonable 61% yield (Table 
12, entry 1). In an effort to improve the yield, additional chlorination conditions were 
screened. Limited optimisation was carried out due to the highly reactive nature of the 
intermediates and the potential for product degradation. We were further prohibited by the 
low organic solubility of the peptide linker and were limited to polar solvents such as DMF 
or DMSO. Attempted mesylation of the primary alcohol for subsequent substitution led to 
complete destruction of material (Table 12, entry 2). Chlorination using N-
chlorosuccinimide (NCS) led to the production of an unknown intermediate that was not 
characterised (Table 12, entry 3). 
 














Entry Conditions Result 
1 SOCl2, DMF 0°C 
 
61% 157 
2 MsCl, NEt3, DMF 0°C 
 
Decomposition 
























































(a) 6-maleimidohexanoic acid, HATU, DIPEA, DMF, 1h, then 155, DMF
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Thionyl chloride was thus selected moving forward. This reaction was strictly quenched 
after 5 min to suppress unwanted side reactions stemming from the highly reactive species 
in solution. Chloride 157 precipitated from the aqueous quench and was isolated by a 
simple filtration. This provided linker model 157 to act as a screening platform for 
quaternisation strategies. Quaternisation was initially trialled with N,N-
dimethylbenzylamine 158 or modified side chain fragment 159 as model systems for our 







Figure 44 Model tertiary amines used for quaternisation reactions 
 
 
Increasing the reactivity of the benzyl chloride was found to be necessary and this could be 
achieved through a Finkelstein reaction with an iodide salt such as KI or TBAI.243 
Preliminary results for the quaternisation reaction are presented in Table 13. Ultimately, 
within this first screen of conditions, no quaternised product was observed. The reaction 
proved difficult to follow by TLC analysis due to the high polarity of intermediates and the 
tendency for compounds to streak on silica. Time constraints precluded optimisation efforts 
for this reaction, which will therefore be a focus for further studies in the future.  
 
4.4 Summary  
This chapter has outlined our efforts towards constructing an antibody–drug conjugate 
based on an aplyronine payload. Completion of the synthesis of a small library of simplified 
analogues has been achieved and biological studies have been undertaken. The outcomes 
of the biological results indicate that this first round of analogues does not mirror the potent 
cytoxicities in the parent natural products. This reflects that our efforts to maximise both 
structural simplicity and cytotoxic potency have not yet come to fruition. However, these 
studies have delivered valuable information as to the necessity of certain functionalities for 
the activity of these compounds. In future studies, it will be possible to build on this 
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Linker strategies have been discussed with a focus on the quaternary amine approach, and 
preliminary investigations into this chemistry have been undertaken. The future directions 





























Entry NR3 Conditions Result 
1 158 KI, DMSO 
 
No reaction 
2 158 KI, DMSO, DIPEA 
 
No reaction 
3 159 KI, DMSO, DIPEA 
 
No reaction 














































5.1 Future work 
 
5.1.1 Evaluation and second-generation analogues 
Although our initial simplified analogues have not demonstrated the excellent cytotoxicity 
exhibited by the parent aplyronines, there is scope to probe the underlying reasons for this 
and utilise this information to glean further valuable insight into the structure–activity 
relationships of the aplyronines and their protein targets. To this end, additional data could 
come from actin binding studies of our analogues alongside aplyronine D. This would 
validate whether actin is still indeed a target of our analogues and allow us to critically 
assess the effect our modifications have on protein binding. Alongside this, if a crystal 
structure of our analogues bound to actin could be obtained, we could examine the 
directional binding mode of the simplified macrocycle and its resulting impact on tubulin 
binding through the positioning of the critical trimethyl serine residue. Based on this 
information, we could rationally design a new range of simplified analogues that are able 
to promote the desired PPI to impart cytotoxicity.  
 
Moreover, it would be necessary to explore the limit of structural simplicity whilst 
maintaining biological activity. Further modifications could be guided by computational 
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methods, especially if the crystal structure of the actin–aplyronine –tubulin ternary complex 
can be obtained. 
Our simplified analogues are synthetically more tractable than the natural products and as 
such could be useful candidates to undertake further studies to probe fine details related to 
protein binding.  
The late stage functionalisation strategy employed in our synthesis could deliver a second 
round of analogues possessing relatively minor modifications with ease. To this end, 
varying the pendant amino acid residues at C7 and C29 offers an attractive and simple means 
of diversification. At the C29 position we can take inspiration from other actin binding 
natural products such as mycalolide B, which exhibits stronger actin-depolymerising 
activity and possesses an O,O-dimethylglycerate ester at this position. Additionally, the 
degree of N-methylation at the amino acid residues at both C7 and C29 would be interesting 
to explore. To achieve this, several N-substituted variants of glycine and alanine could be 
appended at C29 in the side chain. Furthermore, the nature of the nitrogen atom could be 
also considered (e.g. basic, non-basic or absent altogether) by appending molecules such 
as N-acetyl-N-methylglycine or isovaleric acid. A schematic representing some of these 
proposed analogues is presented in Figure 45. 
With regards to tubulin binding, varying the pattern of N-methylation in the serine residue 
at C7 could offer insight into this interaction, which to date has not yet been fully elucidated. 
Each variant is expected to have a unique biological profile due to subtle differences in the 
pharmacophore in the northern portion of the macrocycle. Hence, dimethyl, monomethyl 
and unmodified serine motifs could be appended to probe this effect (Figure 45). Further 
biological testing of these analogues in assays against multiple cell lines will further guide 
the development of aplyronine derivatives as payloads in ADCs.  
 
5.1.2 Improvements to the synthesis 
The Paterson strategy to construct the aplyronines and their analogues has been designed 
to be highly efficient. Late stage diversification, through a common intermediate, allows 
access to multiple aplyronine congeners with relative ease. A streamlined protecting group 
strategy is in place alongside a comparatively simple endgame – all the relevant functional 
groups within the aplyronines are present once the side chain has been appended, apart 
from the pendant amino acids. Whilst many improvements have been made, there remain 
several steps which would benefit from further optimisation. This is especially true if the 
aplyronines and their analogues are to fulfil their potential as payloads for antibody–drug 
conjugates. Structurally simplified candidates ought to be amenable to large scale 
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manufacture to provide enough material for a clinical campaign. The most pressing matters 
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Firstly, within the northern fragment synthesis, the alkylation of iodide 56 remains a 
frustrating bottleneck (Scheme 79). Typically, on medium scale at least 25% of material, 
corresponding to several hundred milligrams, is lost at this stage in a single operation due 
to the undesired formation of the unproductive regioisomer 77 (Scheme 19, Section 2.1.4). 
Notably, this route contributes to the longest linear sequence of our synthesis. Significant 
further optimisation of this challenging reaction is thus required as a matter of priority. 
Removal of the C14 methyl group has been shown to be tolerable through SAR studies and 
















The second reaction requiring extensive optimisation is the reduction to set the desired (R)- 
configuration at C29 (Scheme 80). In this work, this reaction is mediated by zinc 
borohydride and is plagued by inconsistency in yields and dr (55–65% yield, 1:1–6:1 dr). 
In the author’s hands, the best result on advanced ketone 130 was a modest 58% yield and 
2:1 dr. These results are especially concerning given the position of this reaction in the 
overall synthetic route. With only three further synthetic manipulations required to reach 
our complete analogues, this serious hit in yield and efficiency is further compounded due 
to the wastage of highly precious material which has already passed through many previous 
steps. Efforts to improve this reaction could focus on a screen of alternative reducing 
agents. For example, if sodium borohydride was able to enact this transformation to deliver 
the unwanted (S)-diastereoisomer in good yield and dr, a Mitsunobu esterification could be 
employed to ultimately set the desired configuration.120,263 Additionally, reagent-controlled 
methods could be investigated, although efforts to develop the alternative coupling strategy 
during this work highlighted the incompatibility of the N-vinyl formamide moiety to CBS 

























(a) 72, NaH, THF, 0 ºC, then n-BuLi, then 56, 0 ºC


















If optimisation of these challenging reactions can be accomplished, the efficiency and 
scalability of the route to the aplyronines and analogues will be boosted, thereby increasing 
the likelihood of success in future scale up efforts. 
 
 
5.1.3 ADC development 
The continuation of this work constitutes further studies towards our ultimate goal of 
incorporating the aplyronines into antibody–drug conjugates. To this end, the immediate 
focus should be to build upon the preliminary linker chemistry discussed in Chapter 4.  The 
quaternary amine method is an attractive approach to release the free unmodified payload 
in a traceless fashion. Optimisation of the quaternisation reaction following the Genentech 
protocol should provide conditions to efficiently deliver an aplyronine-linker species for 
subsequent bioconjugation to an antibody.243 The chemistry towards this linker species has 
been successfully optimised and large stockpiles of dipeptide material are in hand to 
facilitate these further studies.  
 
Alongside developing the chemistry for a suitable linker species, reliable chemical means 
of bioconjugation that are compatible with our aplyronine payloads need to be realised. 
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An elegant cysteine re-bridging approach (vide supra, Section 1.3.3) has been realised 
through the development of a novel divinylpyrimidine linker platform, and has been 
validated through the generation of highly plasma stable antibody constructs.77 This 
technology has proven to be site-selective with predictable control over the drug to antibody 
ratio (DAR), without relying on antibody engineering. Further bioconjugation methods 
developed by the Spring group include novel enzymatically-cleavable linker 
methodologies and sequence-dependent bioconjugation.264,265 
 
Our goal is thus to construct an ADC derivative of the aplyronines based on a quaternary 
amine linkage in tandem with a site-selective bioconjugation method, to deliver 
homogeneous ADCs with controlled DAR (Figure 46). These could be based on a 
simplified aplyronine scaffold, which has been the focus of this work, or the parent natural 
product structures. Generally, a spacer unit is employed between the linker–payload and 
bioconjugation site, and this can be utilised to improve the pharmacokinetics of the 
conjugate. These spacers typically incorporate a hydrophilic element such as the uncharged 
polyethyleneglycol (PEG) unit. This brings the advantage of increased aqueous solubility 
and decreased hydrophobicity, thereby reducing the potential for aggregation. 
 
Ultimately, by this approach, we hope to accomplish our ambitious goal to create an 
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5.2 Overall conclusions 
 
In this work, a function-oriented total synthesis of a small library of simplified aplyronine 
analogues has been developed. This achievement signifies the endpoint of this work by 
meeting one of the key goals set out at the beginning of this work. 
 
The approach previously described by Paterson and colleagues is a highly efficient and 
convergent route to access these aplyronine derivatives and has been validated once again 
in the work detailed here. Through our late stage diversification strategy several congeners 
of the aplyronine family can be accessed with relative ease. This modular approach also 
paves the way for the creation of novel aplyronine hybrid structures which borrow elements 
from other natural products. 
 
In Chapter one, the potential for marine natural products to provide inspiration for the 
design of clinically relevant molecules was introduced. The function-by-design approach 
of truncating natural products was discussed, and this concept was applied to the aplyronine 
family. Antibody–drug conjugates are emerging as a highly promising class of anticancer 
agents and the aplyronines have resurfaced as compelling candidates for incorporation into 
these targeted therapeutics. 
 
Chapter two presented the synthesis of three key fragments, two of which contained 
modifications for construction of our simplified aplyronine scaffolds. Chapter three 
subsequently outlined two complementary coupling strategies to access complex advanced 
intermediates. 
 
In Chapter four, efforts towards crafting an antibody–drug conjugate were discussed. 
Completion of a small library of analogues and their biological evaluation was 
accomplished, alongside preliminary studies into linker strategies. In contrast to our hopes 
and predictions for these molecules, it was demonstrated that our analogues in fact showed 
reduced potency compared to the natural products. Further exploration of these effects will 
uncover additional SAR data to guide the re-design of future simplified analogues. 
 
Simplified aplyronine D analogue 44 has been synthesised in 1.7% overall yield and in 25 
steps LLS (40 steps total) from Roche ester derived ethyl ketone 42. For the purposes of 
applying this synthetic route to a promising scale up campaign, it compares favourably with 
the industrial manufacture of Halaven (eribulin mesylate 5, Section 1.1.1), a marine natural 
product inspired drug. The current route used in production by Eisai requires 30 steps LLS
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with 62 steps in total, demonstrating a high-profile success story in the combined efforts of 
both academia and industry to generate a viable solution to the supply problem purely by 
synthesis.  
 
Our future goal of combining the exquisite biological activity of the aplyronines with the 
impeccable targeting ability of an antibody could have tremendous potential for the 
treatment of a variety of cancers. This brings us one step closer to realising the hope of 
Ehrlich’s fabled magic bullet within modern medicine. 
 













6.1 General procedures 
All experiments were performed under anhydrous conditions and under an atmosphere of 
argon in oven dried glassware, employing standard techniques for handling air-sensitive 
materials, unless otherwise stated or when aqueous reagents were used.  
Reagents and solvents were purified according to standard procedures.266 Acetonitrile 
(MeCN), benzene (C6H6), dichloromethane (CH2Cl2) and dimethyl sulfoxide (DMSO) 
were distilled from calcium hydride (CaH2) and stored under an argon atmosphere. 
Tetrahydrofuran (THF) and diethyl ether (Et2O) were distilled from benzophenone ketyl 
radical and sodium or potassium wire, respectively, under an argon atmosphere. 
Triethylamine (NEt3), 2,6-lutidine and hexamethyldisilazane (HMDS) were distilled from 
and stored over CaH2. Diisopropylethylamine (i-Pr2NEt) was distilled from ninhydrin, then 
redistilled from and stored over CaH2. Oxalyl chloride ((COCl)2) and titanium tetrachloride 
(TiCl4) were distilled and stored at -20 °C under an atmosphere of argon. Propionaldehyde 
was distilled from calcium chloride (CaCl2) immediately prior to use. DDQ was 
recrystallised from chloroform, and proton sponge was recrystallised from methanol. 
Barium hydroxide (Ba(OH)2) was dried under high vacuum at 130 °C and stored under 
argon. 1,2-diiodoethane was washed with Na2S2O3 solution and stored at -20 °C under 
argon. 
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All other chemicals were used as received from the manufacturer unless otherwise stated.  
Solvents used in workup, extractions and flash column chromatography were distilled prior 
to use. Aqueous solutions of ammonium chloride (NH4Cl), brine (NaCl), sodium 
bicarbonate (NaHCO3), sodium thiosulfate (Na2S2O3) and sodium / potassium (Na+/K+) 
tartrate were saturated. Buffer solutions were prepared from stock tablets as directed.  
Purification by flash column chromatography was carried out using Merck Kieselgel 60 
(230-400 mesh) silica gel under a positive pressure of regulated compressed air. All solvent 
mixtures are reported as volume mixtures. Preparative thin layer chromatography was 
carried out using Merck Kieselgel 60 F254 plates.  
 
6.1.1 Biological studies 
Cell Line 
 
HeLa cells were obtained from the American Type Culture Collection (ATCC) and were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% 
heat-inactivated FBS and 2 mM L-glutamine. 
 
Cell Viability  
 
Cells were seeded at 2,000 cells/well in 96-well plates for 24 h at 37 °C with 5% CO2. 
Serial dilutions of aplyronine samples were added to the cells in complete growth 
medium and incubated at 37 °C with 5% CO2 for 96 h. Cell viability was measured using 
CellTiter-Glo viability assay (Promega) according to the manufacturer’s instructions. Cell 
viability was plotted as a percentage of untreated cells. Each measurement was taken in 
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6.2 Analytical procedures 
Analytical thin layer chromatography (TLC) was carried out using Merck Kieselgel 60 F254 
plates which were visualised using UV light (254 nm) and stained with potassium 
permanganate, vanillin, anisaldehyde or phosphomolybdic acid / cerium (III) sulfate 
Ce2(SO4)3 dips.  
Proton nuclear magnetic resonance (NMR) spectra were recorded using an internal 
deuterium lock at ambient probe temperature (298 K) on the following instruments: Bruker 
Avance BB, or Bruker Avance TCI (500 MHzand Bruker DPX400 (400 MHz). An internal 
reference of dH = 7.26 ppm was used for residual solvent protons in CDCl3 and dH = 7.26 
2.50 ppm for DMSO. All 1H NMR data are represented as: chemical shift (in ppm on the d 
scale relative to dTMS = 0 ppm), integration, multiplicity (s = singlet, d = doublet, t = triplet, 
q = quartet, m = multiplet, br = broad, obs = obscured, app = apparent), coupling constant 
(J in Hz), and assignment. Assignments were determined on the basis of unambiguous 
chemical shift or coupling pattern, 1H-1H COSY, HSQC and HMBC experiments, or by 
analogy to fully interpreted data for related compounds.  
Proton-decoupled 13C NMR spectra were recorded using an internal deuterium lock at 
ambient probe temperature (298K) on the following instruments: Bruker Avance BB and 
Bruker Avance TCI (125 MHz). An internal reference of dC = 77.0 ppm was used for 
carbons in CDCl3 and dC = 79.5 ppm for DMSO. All chemical shift values are reported in 
ppm on the d scale relative to dTMS = 0 ppm.  
Infrared spectra were recorded on a Perkin-Elmer Spectrum One FT-IR spectrometer. 
Absorbance frequencies (vmax) are reported in cm-1.  
Optical rotations were measured on an Anton Parr MCP100 polarimeter at 589 nm and are 
reported as follows: [!]"#$ 	 at 20 °C (unless otherwise noted), concentration (c in g dL-1) and 
solvent.  
Melting points are uncorrected. 
High resolution mass spectra (HRMS) were recorded at the EPSRC Mass Spectrometry 
Service (Swansea, UK) or at the departmental mass spectrometry service (University 
Chemical Laboratories, Cambridge) using electron impact (EI) and electrospray ionization 
(ESI) techniques. The parent ion is quoted with the indicated cation: [M+H]+, [M+Na]+ or 
[M+NH4]+. 
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6.3 Preparation of reagents  
 
Dicyclohexylboron chloride (BCy2Cl) 
Cyclohexene (40 mL, 400 mmol, distilled from CaH2) was dissolved in Et2O (200 mL) and 
cooled to −10 °C. Monochloroborane methyl sulfide complex (BH2Cl·SMe2, 20 mL, 200 
mmol) was added dropwise over 15 min, and the solution was stirred at 0 °C for 1 h, then 
at rt for 1 h. The solvent was removed by distillation at ambient pressure (35 °C) under 
argon. Distillation under reduced pressure (0.3 mBar, 89−92 °C) gave BCy2Cl as a 
colourless liquid, which was stored under argon at −20 °C.  
Samarium (II) iodide (0.1 M in THF)  
To samarium powder (108 mg, 0.72 mmol) and 1,2-diiodoethane (169 mg, 0.60 mmol) 
was added THF (6 mL). The mixture was sonicated for 1 h until a deep blue colour had 
developed. The resulting SmI2 solution was used immediately.  
Zinc borohydride (Zn(BH4)2, 0.175 M in Et2O)  
Zinc (II) chloride (1.49 g, 10.9 mmol) was dried under vacuum at 150 °C for 2 h then 
suspended in Et2O (50 mL) and refluxed for 2 h until all the solids had dissolved. The 
resulting solution was cooled to rt and transferred to a flask containing sodium borohydride 
(0.817 g, 21.6 mmol) suspended in Et2O (12 mL). The reaction was stirred vigorously for 
16 h and the supernatant solution of Zn(BH4)2 (0.175 M) removed via cannula.  
Stryker’s reagent ([CuH(PPh3)]6)   
Copper (II) acetate (25 mg, 0.125 mmol) and triphenylphosphine (66.0 mg, 0.25 mmol) 
were suspended in toluene (4.66 mL) under an argon atmosphere. Tetramethyldisiloxane 
(0.330 mL, 2.43 mmol) was added and the bright blue mixture stirred for 16 h to produce 
a deep red solution which was used directly in conjugate reduction reactions.  
i-PrMgCl (2.0 M in THF)  
To magnesium turnings (3.74 g, 154 mmol) in THF (70 mL) was added a portion of i-PrCl 
(2.00 mL, 21.9 mmol) and one bead of iodine. The brown reaction mixture turned 
colourless and the temperature rose as the reaction initiated. A further quantity of i-PrCl 
(10.8 mL, 118 mmol) was added dropwise over 1 h. The dark grey solution of i-PrMgCl 
was cooled to rt and used immediately.  
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EtMgBr (3.0 M in Et2O)  
EtBr (11.2 mL, 150 mL) was added slowly to a suspension of magnesium turnings (4.01 g, 
165 mmol) in Et2O (50 mL) over 1 h. The dark grey solution of EtMgBr was used 
immediately.  
Lithium hexamethyldisilazide (LiHMDS, 1.0 M in THF)  
To a solution of HMDS (0.576 mL, 2.75 mmol) in THF (0.94 mL) at 0 °C was added n-
BuLi (1.56 mL, 1.6 M in hexane, 2.5 mmol). The mixture was stirred for 1 h at 0 °C before 
being used immediately. 




To a solution of 4-methoxybenzyl alcohol (5.00 g, 36.2 mmol) and tetrabutylammonium 
hydrogensulfate (123 mg, 0.362 mmol) in CH2Cl2 (50 mL) at −10 °C was added 50% 
aqueous KOH solution (50 mL). Trichloroacetonitrile (3.99 mL, 39.8 mmol) was added 
dropwise over 20 min and the biphasic mixture was rapidly stirred for 1 h whilst warming 
to rt and stirred further 2 h. The organic phase was separated, and the aqueous phase was 
extracted with Et2O (3 × 100 mL). The combined organic phases were dried (MgSO4) and 
concentrated in vacuo. Purification by flash chromatography on neutral alumina (1:19 
EtOAc/PE) yielded PMBTCA as a colourless oil (9.35 g, 92%).  
Rf  0.33 (1:19 EtOAc/PE, alumina plate); 1H NMR (500MHz, CDCl3) &H 8.36 (1H, br s, 
NH), 7.37 (2H, d, J = 8.5 Hz, ArH), 6.91 (2H, d, J = 8.6 Hz, ArH), 5.28 (2H, s, OCH2Ar), 
3.82 (3H, s, OMe).  














To a stirred solution of paraformaldehyde (1.65 g, 55.0 mmol) in CHCl3 (150 mL) was 
added N-methylformamide (2.92 mL, 50.0 mmol) and TMSCl (19.0 mL, 150 mmol). The 
mixture was heated to reflux for 2 h then cooled to rt and concentrated in vacuo to give 
crude 85 as a pale yellow oil. The crude material was used directly in the next reaction.  
1H NMR (400 MHz, CDCl3) δH 8.29 (0.67H, s, NCHO), [8.07] (0.33H, s, NCHO*), 5.25 
(1.33H, s, CH2Cl), [5.24] (0.67H, s, CH2Cl*), [3.08] (1H, s, NMe*), 2.98 (2H, s, NMe).  
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 
assignments denoted with an asterisk.  
 
(N-methylformamido)methyl)triphenylphosphonium chloride, 84  
 
 
Crude N-chloromethyl-N-methylformamide 85 was added to a stirred solution of 
triphenylphosphine (14.4 g, 55.0 mmol) in Et2O (100 mL) and stirred at rt for 24 h. The 
resulting slurry was filtered and washed with anhydrous Et2O (3 × 15 mL), then dried under 
high vacuum to give a white solid (6.03 g, 32% over 2 steps).  
1H NMR (500 MHz, CDCl3) δH 8.16–7.64 (16H, m, NCHO, NCHO*, ArH), [6.60] (0.30H, 
d, J = 2.4 Hz, NCH2P*), 6.22 (1.60H, d, J = 4.1 Hz, NCH2P), 3.20 (2H, s, NMe), [2.80] 
(1H, s, NMe*). 
Distinguishable resonances of the minor rotamer (4:1 ratio) are given in brackets and 
assignments denoted with an asterisk.  
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Diethyl (3-oxobutan-2-yl)phosphonate, 72 
 
 
To a solution of diethyl ethylphosphonate (6.00 g, 36.1 mmol) in THF (50 mL) at −78 °C 
was added n-BuLi (24.8 mL, 1.6 M in hexane, 39.7 mmol). The mixture was stirred for 1 
h, then EtOAc (3.62 mL, 36.8 mmol, freshly distilled from CaH2) was added dropwise. 
After stirring for 1.5 h at −78 °C, the reaction was quenched with NH4Cl (50 mL) and 
warmed to rt. The layers were separated and the aqueous extracted with EtOAc (5 × 50 
mL). The combined organics were dried over MgSO4 and concentrated in vacuo. The 
residue was purified by distillation under reduced pressure (0.42 Torr, 88 °C) to afford 
phosphonate 72 as a colourless oil (3.89 g, 62%).  
Rf  0.13 (1:1 EtOAc/PE); 1H NMR (500 MHz, CDCl3) δH 4.18-4.08 (4H, m, 
P(OCH2CH3)2), 3.20 (1H, dq, J = 25.6, 7.1 Hz, H14), 2.34 (3H, s, Me12), 1.38 (3H, dd, J = 
21.3, 7.1 Hz, Me14), 1.33 (6H, m, P(OCH2CH3)2).  
These data are in agreement with those previously reported.138 
 
6.4 Experimental procedures for Chapter 2 
 
6.4.1 C1-C14 northern fragment 36 
Methyl (R)-3-((4-methoxybenzyl)oxy)-2-methylpropanoate, 59  
 
 
To a solution of methyl (R)-3-hydroxy-2-methylpropionate (4.00 g, 33.8 mmol) in CH2Cl2 
(40 mL) was added freshly prepared PMBTCA (9.50 g, 37.2 mmol). PPTS (817 mg, 3.25 
mmol) was added and the solution was stirred at rt for 2 h. The reaction was quenched with 
NaHCO3 (75 mL) and the aqueous layer was extracted with CH2Cl2 (3 × 30 mL). The 
combined organics were dried (MgSO4) and concentrated in vacuo. The crude mixture was 
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before being filtered through a plug of Celite and the filtrate was concentrated in vacuo. 
Purification by flash column chromatography (1:4 EtOAc/PE) afforded PMB-ether 59 as a 
colourless oil (6.99 g, 87%).  
Rf  0.40 (1:4 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 7.23 (2H, d, J = 8.5 Hz, ArH), 
6.87 (2H, d, J = 8.5 Hz, ArH), 4.45 (2H, s, OCH2Ar), 3.80 (3H, s, ArOMe), 3.69 (3H, s, 
OMe), 3.63 (1H, dd, J = 9.2, 7.3 Hz, H11a), 3.46 (1H, dd, J = 9.3, 6.0 Hz, H11b), 2.77 (1H, 
tq, J = 7.0, 6.0 Hz, H10), 1.17 (3H, d, J = 7.3 Hz, Me10).  





N,O-dimethylhydroxylamine hydrochloride (3.99 g, 41.0 mmol) was dried under vacuum 
for 3 h before being added to a stirred solution of methyl ester 59 (6.50 g, 27.3 mmol) in 
THF (55 mL). The resulting slurry was cooled to ‒20 °C and i-PrMgCl (41.0 mL, 2.0 M in 
THF, 81.8 mmol) was added dropwise over 30 min, ensuring that the internal temperature 
did not rise above ‒10 °C. The mixture was stirred at ‒20 °C for 2 h and quenched with 
NH4Cl (100 mL). After warming to rt the mixture was extracted with Et2O (3 × 75 mL) and 
the combined organic extracts were washed with brine (75 mL), dried (MgSO4) and 
concentrated in vacuo. Purification by flash column chromatography (3:7 EtOAc/PE) 
afforded amide 60 as a colourless oil (6.43 g, 88%).  
Rf  0.19 (3:7 EtOAc/PE) 1H NMR (500MHz, CDCl3) &H 7.23 (2H, d, J = 8.8 Hz, ArH), 
6.86 (2H, d, J = 8.8 Hz, ArH), 4.44 (2H, ABq, J = 11.5 Hz, OCH2Ar), 3.80 (3H, s, ArOMe), 
3.69 (3H, s, OMe), 3.68 (1H, dd, J = 8.8, 8.5 Hz, H11a), 3.40 (1H, dd, J = 9.0, 6.0 Hz, H11b), 
3.20 (3H, s, NMe), 1.55 (1H, br s, H10), 1.11 (3H, d, J = 6.8 Hz, Me10).  
















To a solution of amide 60 (6.00 g, 22.4 mmol) in Et2O (75 mL) at 0 °C was added dropwise 
EtMgBr (25 mL, 3.0 M in Et2O, 67.3 mmol). After stirring at 0 °C for 1 h, the reaction was 
carefully quenched by the slow addition of NH4Cl (100 mL). The mixture was warmed to 
rt and extracted with Et2O (3 × 50 mL), and the combined organic extracts were washed 
with brine (50 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash column 
chromatography (1:4 EtOAc/PE) afforded ketone 42 as a colourless oil (4.38 g, 82%).  
Rf 0.32 (1:4 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 7.21 (2H, d, J = 8.8 Hz, ArH), 
6.87 (2H, d, J = 8.8 Hz, ArH), 4.41 (2H, ABq, J = 11.5 Hz, OCH2Ar), 3.80 (3H, s, OMe), 
3.59 (1H, dd, J = 9.0, 7.8 Hz, H11a), 3.43 (1H, dd, J = 9.0, 5.5 Hz, H11b), 2.92-2.82 (1H, m, 
H10), 2.50 (2H, q, J = 7.3 Hz, H8 × 2), 1.06 (3H, d, J = 7.0 Hz, Me10), 1.03 (3H, t, J = 7.0 
Hz, Me8).  





To a solution of alcohol 61 (3.00 g, 19.2 mmol) in CH2Cl2 (30 mL) was added DMSO (30 
mL). The solution was cooled to 0 °C and NEt3 (12.1 mL, 86.4 mmol) was added. Sulfur 
trioxide pyridine complex (13.7 g, 86.4 mmol) was added in small portions, ensuring that 
the temperature did not rise above 5 °C. Once addition was complete, the solution was 
stirred for 1 h and then quenched with NH4Cl (50 mL). After warming to rt, the mixture 
was extracted with CH2Cl2 (3 × 30 mL). The combined organic layers were washed with 
brine (30 mL), dried (MgSO4) and concentrated in vacuo. The crude product was purified 
by flash column chromatography (1:4 EtOAc/PE) to afford aldehyde 55 as a colourless oil 
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Rf  0.25 (1:4 EtOAc/PE); 1H NMR (400MHz, CDCl3) &H 9.80 (1H, t, J = 0.9 Hz, CHO), 
3.76 (3H, s, OMe), 2.63 (2H, td, J = 6.9, 0.9 Hz, H6 × 2), 2.43 (2H, t, J = 6.9 Hz, H4 × 2), 
1.91 (2H, tt, J = 6.9, 6.9 Hz, H5 × 2).  







To a solution of dicyclohexylboron chloride (2.96 mL, 13.5 mmol) in Et2O (20 mL) at           
‒78 °C was added NEt3 (2.74 mL, 19.7 mmol), followed by a solution of ketone 42 (2.90 
g, 12.3 mmol) in Et2O (10 mL) via cannula. The reaction mixture was warmed to ‒20 °C 
and stirred for 1.5 h, before being cooled to ‒78 °C and a solution of aldehyde 55 (1.14 g, 
7.36 mmol) in Et2O (10 mL) was added. The mixture was stirred at ‒78 °C for 3 h then left 
at ‒20 °C for 16 h. After warming to 0 °C, the reaction was quenched with MeOH (40 mL) 
and pH 7.0 buffer solution (40 mL), followed by hydrogen peroxide (20 mL, 30% aq.). The 
mixture was stirred for 1 h at rt then poured into H2O (40 mL) and extracted with CH2Cl2 
(3 × 40 mL). The combined organics were washed with NaHCO3 (40 mL) and brine (40 
mL), then dried (MgSO4) and concentrated in vacuo. Purification by flash column 
chromatography (3:7 EtOAc/PE) gave aldol adduct 57 as a colourless oil (4.15 g, 88%, 
>95:5 dr).  
Rf  0.20 (7:3 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 7.20 (2H, d, J = 8.4 Hz, ArH), 
6.86 (2H, d, J = 8.6 Hz, ArH), 4.40 (2H, ABq, J = 11.6 Hz, OCH2Ar), 3.80 (3H, s, ArOMe), 
3.75 (3H, s, CO2Me), 3.70-3.64 (2H, m, H7, H11a), 3.39 (1H, dd, J = 8.9, 4.6 Hz, H11b), 
3.11-3.03 (1H, m, H10), 2.66 (1H, dq, J = 7.1, 7.1 Hz, H8), 2.34 (2H, t, J = 6.7 Hz, H4 × 2), 
1.80-1.71 (1H, m, H6a), 1.69-1.57 (2H, m, H5 × 2), 1.49-1.39 (1H, m, H6b), 1.14 (3H, d, J 
= 6.7 Hz, Me8), 1.03 (3H, d, J = 6.7 Hz, Me10).  
















To a solution of propionaldehyde (freshly distilled from CaCl2 1.10 mL, 15.2 mmol) in 
THF (12 mL) at 0 °C was added freshly prepared SmI2 (2.56 mL, 0.1 M in THF, 0.256 
mmol). The solution was stirred for 5 min until the deep blue colouration had subsided. A 
solution of aldol adduct 57 (1.00 g, 2.56 mmol) in THF (5 mL) was then added via cannula. 
The reaction was stirred at 0 °C for 1 h, before being quenched with NaHCO3 (10 mL) and 
extracted with Et2O (3 × 10 mL). The combined organic layers were dried (MgSO4), 
concentrated in vacuo and purified by flash column chromatography (3:7 EtOAc/PE) to 
give propionate ester 63 as a colourless oil (1.13 g, 98%, >95:5 dr).  
Rf  0.33 (7:3 EtOAc/PE); 1H NMR (400MHz, CDCl3) &H 7.23 (2H, d, J = 8.4 Hz, ArH), 
6.87 (2H, d, J = 8.6 Hz, ArH), 4.94 (1H, td, J = 8.3, 3.2 Hz, H7), 4.44 (2H, ABq, J = 11.6 
Hz, OCH2Ar), 3.80 (3H, s, ArOMe), 3.75 (3H, s, CO2Me), 3.57-3.48 (2H, m, H11 × 2), 3.44 
(1H, br d, J = 9.0 Hz, H9), 3.28 (1H, br s, OH), 2.41-2.30 (4H, m, H2’ × 2, H4 × 2), 1.93-
1.73 (3H, m, H6a, H8, H10), 1.70-1.53 (3H, m, H5 × 2, H6b), 1.15 (3H, t, J = 7.4 Hz, H3’ × 
3), 0.88 (3H, d, J = 6.7 Hz, Me10), 0.82 (3H, d, J = 6.7 Hz, Me8).  







To a solution of alkyne ester 63 (3.98 g, 8.88 mmol) in benzene (32 mL) was added PPh3 
(4.66 g, 17.8 mmol) and PhOH (1.75 g, 18.7 mmol). The reaction mixture was stirred at rt 
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with Et2O (3 × 30 mL). The combined organic layers were washed with brine (50 mL), 
dried (MgSO4) and concentrated in vacuo. Purification by flash column chromatography 
(1:4 EtOAc/PE) yielded dienoate 65 as a colourless oil (3.71 g, 93%).  
Rf  0.18 (1:4 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 7.25 (1H, dd, J = 15.6, 10.7 Hz, 
H3), 7.23 (2H, d, J = 8.6 Hz, ArH), 6.87 (2H, d, J = 8.6 Hz, ArH), 6.21 (1H, dd, J = 15.0, 
11.1 Hz, H4), 6.06 (1H, dt, J = 14.9, 8.1 Hz, H5), 5.80 (1H, d, J = 15.0 Hz, H2), 5.02 (1H, 
td, J = 8.1, 3.4 Hz, H7), 4.44 (2H, ABq, J = 11.6 Hz, OCH2Ar), 3.80 (3H, s, ArOMe), 3.74 
(3H, s, CO2Me), 3.54 (1H, dd, J = 9.0, 4.2 Hz, H11a), 3.51-3.46 (2H, m, H9, H11b), 3.36 (1H, 
br s, OH), 2.64 (1H, ddd, J = 15.4, 5.1, 5.1 Hz, H6a), 2.40 (1H, ddd, J = 15.4, 8.1, 8.1 Hz, 
H6b), 2.31 (1H, q, J = 8.1 Hz, H2’a), 2.31 (1H, q, J = 8.1 Hz, H2’b), 1.93-1.85 (1H, m, H10), 
1.82-1.75 (1H, m, H8), 1.12 (3H, t, J = 7.3 Hz, H3’ × 3), 0.89 (3H, d, J = 6.8 Hz, Me10), 
0.80 (3H, d, J = 6.8 Hz, Me8).  







Potassium carbonate (2.85 g, 20.6 mmol) was added to a solution of ester 65 (3.70 g, 8.25 
mmol) in MeOH (140 mL) and the solution was stirred at rt for 2 h. Once complete, the 
reaction mixture was poured into NaHCO3 (100 mL) and extracted with EtOAc (4 × 100 
mL). The combined organic extracts were dried (Na2CO3) and concentrated in vacuo. 
Purification by flash column chromatography (2:3 EtOAc/PE) gave diol 68 as a colourless 
oil (2.95 g, 93%).  
Rf  0.33 (1:1 EtOAc/PE); 1H NMR (400MHz, CDCl3) &H 7.27 (1H, dd, J = 15.4, 10.4 Hz, 
H3), 7.24 (2H, d, J = 8.6 Hz, ArH), 6.87 (2H, d, J = 8.6 Hz, ArH), 6.26 (1H, dd, J = 15.7, 
10.6 Hz, H4), 6.19 (1H, dt, J = 15.4, 7.1 Hz, H5), 5.80 (1H, d, J = 15.7 Hz, H2), 4.45 (2H, 
ABq, J = 11.4 Hz, OCH2Ar), 3.87 (1H, dd, J = 9.2, 7.1 Hz, H9), 3.80 (3H, s, ArOMe), 3.74 
(3H, s, CO2Me), 3.70-3.64 (1H, m, H7), 3.58 (1H, dd, J = 9.7, 3.6 Hz, H11a), 3.44 (1H, t, J 
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Hz, H6b), 2.02-1.94 (1H, m, H10), 1.63-1.57 (1H, m, H8), 1.00 (3H, d, J = 7.1 Hz, Me8), 
0.70 (3H, d, J = 7.1 Hz, Me10).  







To a solution of diol 68 (900 mg, 2.30 mmol) in CH2Cl2 (25 mL) at ‒78 °C was added 
TESOTf (1.15 mL, 5.08 mmol) and 2,6-lutidine (0.67 mL, 5.75 mmol). The reaction was 
stirred for 1 h before being quenched with NH4Cl (50 mL). The solution was warmed to rt 
and the layers were separated. The aqueous phase was extracted with CH2Cl2 (3 × 50 mL) 
and the combined organics were dried (MgSO4) and concentrated in vacuo. The crude 
material was purified by flash column chromatography (1:15 EtOAc/PE) to give 69 as a 
colourless oil (1.31 g, 92%). 
Rf  0.26 (1:15 EtOAc/PE); 1H NMR (400MHz, CDCl3) &H 7.27 (1H, dd, J = 15.4, 10.4 Hz, 
H3), 7.25 (2H, d, J = 8.8 Hz, ArH), 6.87 (2H, d, J = 8.8 Hz, ArH), 6.26 (1H, dd, J = 15.4, 
10.5 Hz, H4), 6.19 (1H, dt, J = 15.4, 7.0 Hz, H5), 5.79 (1H, d, J = 15.4 Hz, H2), 4.43 (2H, 
s, OCH2Ar), 3.80 (3H, s, ArOMe), 3.74 (3H, s, CO2Me), 3.73-3.68 (1H, m, H7), 3.64 (1H, 
dd, J = 5.1, 3.7 Hz, H11a), 3.48 (1H, dd, J = 9.2, 5.1 Hz, H11b), 3.21 (1H, dd, J = 9.1, 7.5 
Hz, H9), 2.30-2.21 (2H, m, H6 × 2), 2.00-1.93 (1H, m, H10), 1.80-1.75 (1H, m, H8), 0.99 
(3H, d, J = 7.0 Hz, Me10), 0.95 (9H, t, J = 7.7 Hz, Si(CH2CH3)3), 0.94 (9H, t, J = 7.7 Hz, 
Si(CH2CH3)3), 0.86 (3H, d, J = 7.1 Hz, Me8), 0.60 (6H, q, J = 7.7 Hz, Si(CH2CH3)3), 0.56 
(6H, q, J = 7.7 Hz, Si(CH2CH3)3). 

















To a solution of PMB ether 69 (1.66 g, 2.00 mmol) in CH2Cl2 (32 mL) and pH 7.0 buffer 
(16 mL) was added DDQ (910 mg, 4.00 mmol). The resulting dark green solution was 
stirred for 2 h before NaHCO3 (40 mL) was added. The mixture was diluted with H2O (200 
mL) and extracted with CH2Cl2 (3 × 100 mL). The combined organics were dried (Na2SO4), 
concentrated in vacuo and the crude purified by flash column chromatography (PhMe ® 
1:5 EtOAc/PE) to yield alcohol 70 as a colourless oil (1.19 g, 89%). 
Rf  0.56 (1:4 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 7.27 (1H, dd, J = 14.7, 10.0 Hz, 
H3), 6.21 (1H, dd, J = 15.7, 10.6 Hz, H4), 6.14 (1H, dt, J = 15.2, 6.9 Hz, H5), 5.81 (1H, d, 
J = 15.2 Hz, H2), 3.78-3.75 (2H, m, H9, H11a), 3.75 (3H, s, CO2Me), 3.73-3.69 (1H, m, H7), 
3.55 (1H, ddd, J = 12.0, 6.1, 6.1 Hz, H11b), 2.61 (1H, dd, J = 6.6, 5.3 Hz, OH), 2.34-2.22 
(2H, H6 × 2), 1.86-1.79 (1H, m, H8), 1.78-1.72 (1H, m, H10), 1.00 (3H, d, J = 7.6 Hz, Me10), 
0.98 (9H, t, J = 8.3 Hz, Si(CH2CH3)3), 0.95 (9H, t, J = 8.3 Hz, Si(CH2CH3)3), 0.89 (3H, d, 
J = 7.1 Hz, Me8), 0.65 (6H, q, J = 7.9 Hz, Si(CH2CH3)3), 0.60 (6H, q, J = 7.9 Hz, 
Si(CH2CH3)3). 
These data are in agreement with those previously reported.138 
 
Methyl (2E,4E,7R,8R,9S,10S)-11-iodo-8,10-dimethyl-7,9-bis((triethylsilyl)oxy) 




To a solution of alcohol 71 (1.19 g, 2.38 mmol) in Et2O/MeCN (1:1 50 mL) at 0 °C was 
added PPh3 (1.12 g, 4.28 mmol), imidazole (357 mg, 5.24 mmol) and, in small portions I2 
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stirred for 2 h, before being poured into NaHCO3 (50 mL). The layers were separated, and 
the aqueous phase was extracted with Et2O (3 × 50 mL). The combined organics were 
washed with brine (40 mL), dried (MgSO4) and concentrated in vacuo. Purification by flash 
column chromatography (1:6 EtOAc/PE) gave iodide 71 as a colourless oil (1.14 g, 82%).  
Rf  0.31 (1:4 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 7.27 (1H, dd, J = 15.5, 10.6 Hz, 
H3), 6.27-6.11 (2H, m, H4, H5), 5.81 (1H, d, J = 15.4 Hz, H2), 3.75 (3H, s, CO2Me), 3.72-
3.68 (1H, m, H7), 3.67-3.65 (1H, m, H9), 3.29 (1H, dd, J = 9.3, 3.9 Hz, H11a), 3.00 (1H, t, J 
= 9.6 Hz, H11b), 2.34-2.25 (2H, m, H6 × 2), 1.87-1.79 (1H, m, H10), 1.74-1.65 (1H, m, H8), 
1.05 (3H, d, J = 6.6 Hz, Me10), 0.96 (9H, t, J = 7.7 Hz, Si(CH2CH3)3), 0.95 (9H, t, J = 7.7 
Hz, Si(CH2CH3)3), 0.85 (3H, d, J = 7.0 Hz, Me8), 0.63 (6H, q, J = 7.7 Hz, Si(CH2CH3)3), 
0.60 (6H, q, J = 7.7 Hz, Si(CH2CH3)3). 







To a solution of ester 71 (1.14 g, 1.87 mmol) in CH2Cl2 (30 mL) was added DIBAL (5.59 
mL, 5.59 mmol, 1.0 M in CH2Cl2) at –78 °C. Upon completion after 3 h, the reaction was 
quenched with Na+/K+ tartrate (60 mL) and allowed to warm to rt. The layers were 
separated and the aqueous was extracted with CH2Cl2 (4 × 50 mL). The combined organics 
were dried (Na2SO4) and concentrated in vacuo. The crude was purified by flash column 
chromatography (1:2 EtOAc/PE) to afford alcohol 160 as a colourless oil (1.05 g, 96%). 
Rf  0.20 (1:2 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 6.23 (1H, dd, J = 15.1, 10.4 Hz, 
H3), 6.08 (1H, dd, J = 15.1, 10.4 Hz, H4),  5.79-5.68 (2H, m, H2, H5), 4.18 (2H, t, J = 6.1 
Hz, H1 × 2), 3.69-3.63 (2H, m, H7, H9), 3.32 (1H, dd, J = 9.9, 4.1 Hz, H11a), 2.99 (1H, t, J 
= 9.6 Hz, H11b), 2.24-2.19 (2H, m, H6 × 2), 1.89-1.78 (1H, m, H10), 1.73-1.64 (1H, m, H8), 
1.33 (1H, t, J = 5.2 Hz, OH), 1.05 (3H, d, J = 6.7 Hz, Me10), 0.96 (18H, t, J = 7.7 Hz, 
Si(CH2CH3)3), 0.85 (3H, d, J = 7.3 Hz, Me8), 0.63 (6H, q, J = 7.7 Hz, Si(CH2CH3)3), 0.60 
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To a solution of alcohol 160 (3.57 g, 6.13 mmol) in CH2Cl2 (100 mL) was added TBSCl 
(1.38 g, 9.19 mmol) and imidazole (834 mg, 12.3 mmol). The reaction was stirred for 3 h 
before being quenched with NH4Cl (100 mL). The layers were separated, the aqueous phase 
extracted with CH2Cl2 (3 × 70 mL) and the combined organics dried (MgSO4) and 
concentrated in vacuo. The crude material was purified by flash column chromatography 
(1:20 EtOAc/PE) to give 56 as a colourless oil (4.27 g, 100%). 
Rf  0.52 (1:20 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 6.19 (1H, dd, J = 15.5, 10.5 Hz, 
H3), 6.06 (1H, dd, J = 15.1, 10.5 Hz, H4),  5.71-5.62 (2H, m, H2, H5), 4.21 (2H, d, J = 5.1 
Hz, H1 × 2), 3.68-3.62 (2H, m, H7, H9), 3.33 (1H, dd, J = 9.6, 3.8 Hz, H11a), 2.98 (1H, t, J 
= 9.8 Hz, H11b), 2.24-2.17 (2H, m, H6 × 2), 1.88-1.79 (1H, m, H10), 1.74-1.66 (1H, m, H8), 
1.05 (3H, d, J = 6.3 Hz, Me10), 0.96 (18H, t, J = 7.8 Hz, Si(CH2CH3)3), 0.91 (9H, s, 
SiC(CH3)3, 0.85 (3H, d, J = 6.7 Hz, Me8), 0.63 (6H, q, J = 7.7 Hz, Si(CH2CH3)3), 0.60 (6H, 
q, J = 7.7 Hz, Si(CH2CH3)3), 0.07 (6H, s, Si(CH3)2). 






















To sodium hydride (60% in mineral oil, 1.18 g, 29.5 mmol) was added THF (30 mL) and 
the suspension was cooled to 0 °C before a solution of phosphonate 72 (4.83 mL, 25.3 
mmol) in THF (30 mL) was added via cannula. After stirring for 1 h, n-BuLi (15.8 mL, 1.6 
M in hexanes, 25.3 mmol) was added dropwise and the mixture was stirred for a further 30 
min. During this period of time the white slurry went into solution resulting in a yellow 
solution of dianion.  
A solution of iodide 56 (2.94 g, 4.21 mmol) in THF (30 mL) was added dropwise to the 
above dianion solution at 0 °C over 15 min. The reaction was stirred for 2 h, before being 
quenched with NH4Cl (100 mL) and warmed to rt. The aqueous phase was extracted with 
Et2O (3 × 70 mL) and the combined organics were dried (MgSO4) and concentrated in 
vacuo. Purification by flash column chromatography (1:9 ® 1:1.5 EtOAc/PE) gave 
phosphonate 36 and the undesired regioisomer 77 (2.25 g, 68%) as a 3:1 inseparable 
mixture.  
Rf  0.59 (1:1 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 6.18 (1H, dd, J = 14.9, 10.7 Hz, 
H3), 6.04 (1H, dd, J = 15.4, 11.8 Hz, H4),  5.74-5.60 (2H, m, H2, H5), 4.20 (2H, d, J = 5.1 
Hz, H1 × 2), 4.17-4.06 (4H, m, P(OCH2CH3)2), 3.67-3.55 (1H, m, H7), 3.55-3.50 (1H, m, 
H9), 3.25 (0.4H, dq, J = 21.3, 7.2 Hz, H14), 3.19 (0.4H, dq, J = 21.3, 7.2 Hz, H14†), 2.87 
(0.4H, ddd, J = 17.7, 10.1, 5.4 Hz, H12a†), 2.78-2.58 (0.8H, m, H12a, H12b), 2.46 (0.4H, ddd, 
J = 18.4, 9.7, 6.1 Hz, H12b†), [2.35] (0.7H, s, Me3’*), 2.25-2.12 (2H, m, H6 × 2), [1.88-1.80] 
(0.2H, m, H11a*), 1.79-1.60 (2H, m, H8, H11a, H11b*), 1.57-1.47 (1H, m, H10), 1.42-1.28 
(10H, m, H11b, Me14, P(OCH2CH3)2), 1.00-0.85 (33H, m, Me10, Me8, Me1’*, Si(CH2CH3)3 
× 2, SiC(CH3)3), [0.72] (0.8H, d, J = 6.9 Hz, Me8*), 0.65-0.54 (12H, m, Si(CH2CH3)3 × 2), 
0.07 (6H, s, Si(CH3)2). 
Distinguishable resonances of the minor regioisomer 77 are given in brackets and marked 
with an asterisk (*). The diastereomeric ratio of 36 at C14 is approximately 1:1 and 



















Chapter 6 – Experimental   
 
 158 
These data are in agreement with those previously reported.138 
 







To a solution of TiCl4 (175 µL, 1.78 mmol) in CH2Cl2 (8.4 mL) at 0 °C was added Ti(O-
iPr)4 (175 µL, 0.59 mmol). The mixture was stirred at 0 °C for 10 min, then at rt for 20 min. 
The resulting colourless solution was added dropwise to a solution of ketone 42 (500 mg, 
2.12 mmol, dried under vacuum for 2 h and stirred over CaH2 immediately prior to use) in 
CH2Cl2 (13 mL) at -78 °C. To the yellow solution was added i-PrNEt2 (0.41 mL) dropwise 
and the reaction mixture was allowed to enolise at -78 °C for 30 min. Acetaldehyde (1.12 
mL, 21.2 mmol, distilled from CaCl2 immediately prior to use) was dissolved in CH2Cl2 
(10 mL) and added to the reaction mixture dropwise, causing the deep red solution to 
gradually turn pale orange.  The mixture was stirred at  -78 °C for 30 min before MeOH 
(8 mL) was added. After warming to rt Na+/K+ tartrate was added (20 mL) and the biphasic 
mixture was vigorously stirred overnight. The layers were separated, and the organic phase 
washed with brine (20 mL) and the combined aqueous layers were extracted with CH2Cl2 
(3 ´ 20 mL). The combined organics were dried (Na2SO4) and concentrated in vacuo and 
purified by flash column chromatography (1:3 EtOAc/PE) to give aldol adduct 80 as a 
colourless oil (456 mg, 77%, 17:1 dr). 
 
Rf  0.24 (3:1EtOAc/PE); 1H NMR (400 MHz, CDCl3) dH 7.18 (2H, d, J = 8.6 Hz, ArH), 
6.87 (2H, d, J = 8.9 Hz, ArH), 4.39 (2H, ABq, J = 8.6 Hz, OCH2Ar), 4.19 (1H, qdd, J = 
6.6, 4.1, 3.2 Hz, H29), 3.80 (3H, s, OMe), 3.61 (1H, t, J = 9.1 Hz, H33a), 3.42 (1H, dd, J = 
8.7, 4.6 Hz, H33b), 3.15 (1H, dqd, J = 9.4, 7.0, 4.7 Hz, H32), 2.94 (1H, d, J = 4.2 Hz, OH), 
2.73 (1H, qd, J = 7.1, 3.0 Hz, H30), 1.12 (3H, d, J = 6.7 Hz, Me28), 1.08 (3H, d, J = 7.1 Hz, 
Me30), 1.00 (3H, d, J = 6.7 Hz, Me32). 
















To a solution of propionaldehyde (freshly distilled from CaCl2, 1.54 mL, 21.4 mmol) in 
THF (20 mL) at 0 °C was added freshly prepared SmI2 (2.56 mL, 0.1 M in THF, 0.256 
mmol). The solution was stirred for 5 min until the deep blue colouration had subsided. A 
solution of aldol adduct 80 (1.00 g, 3.57 mmol) in THF (10 mL) was then added via 
cannula. The reaction was stirred at 0 °C for 1 h, before being quenched with NaHCO3 (10 
mL) and extracted with Et2O (3 × 10 mL). The combined organic layers were dried 
(MgSO4), concentrated in vacuo and purified by flash column chromatography (1:4 
EtOAc/PE) to give propionate ester 82 as a colourless oil (1.17 g, 97%, >95:5 dr).  
Rf  0.31 (1:4 EtOAc/PE); 1H NMR (400MHz, CDCl3) &H  7.23 (2H, d, J = 8.4 Hz, ArH), 
6.87 (2H, d, J = 8.7 Hz, ArH), 5.40 (1H, qd, J = 6.6, 2.1 Hz, H29), 4.41 (2H, ABq, J = 11.6 
Hz, OCH2Ar), 3.80 (3H, s, OMe), 3.54-3.48 (2H, m, H33 × 2), 3.21-3.15 (2H, m, H31, OH), 
2.30 (2H, q, J = 7.7 Hz, H2’ × 2), 2.03-1.94 (1H, m, H32), 1.70-1.59 (1H, m, H30), 1.22 (3H, 
d, J = 6.7 Hz, Me28), 1.12 (3H, t, J = 7.5 Hz, H3’ × 3), 1.08 (3H, d, J = 7.0 Hz, Me32), 0.89 
(3H, t, J = 6.9 Hz, Me30). 









To a solution of Meerwein salt (Me3OBF4, 874 mg, 5.92 mmol) and proton sponge (1.90 
g, 8.88 mmol) in CH2Cl2 (50 mL) was added alcohol 82 (1.00 g, 2.96 mmol). The reaction 
was stirred for 4 h before being quenched with NH4Cl (100 mL). The layers were separated, 
and the aqueous phase extracted with CH2Cl2 (3 × 50 mL). The combined organic layers 
were dried (MgSO4), concentrated in vacuo and purified by flash column chromatography 
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Rf  0.29 (1:3 EtOAc/PE); 1H NMR (400MHz, CDCl3) &H  7.24 (2H, d, J = 8.6 Hz, ArH), 
6.87 (2H, d, J = 8.6 Hz, ArH), 5.27-5.20 (1H, m, H29), 4.41 (2H, ABq, J = 11.7 Hz, 
OCH2Ar), 3.80 (3H, s, OMe), 3.54 (1H, dd, J = 9.1, 4.9 Hz, H33a), 3.36 (3H, s, OMeAr), 
3.31 (1H, dd, J = 8.7, 2.3 Hz, H33b), 2.89 (1H, dd, J = 8.8, 3.2 Hz, H31), 2.30 (2H, q, J = 7.8 
Hz, H2’ × 2), 2.12-2.03 (1H, m, H32), 1.74-1.66 (1H, m, H30), 1.21 (3H, d, J = 6.0 Hz, Me28), 
1.21 (3H, t, J = 7.6 Hz, H3’ × 3), 1.10 (3H, d, J = 6.7 Hz, Me32), 0.94 (3H, t, J = 7.4 Hz, 
Me30). 
These data are in agreement with those previously reported.165 
 






To a solution of PMB ether 161 (380 mg, 1.08 mmol) in CH2Cl2 (12 mL) was added pH 
7.0 buffer (6 mL) and DDQ (490 mg, 2.16 mmol) at 0 °C. The reaction was warmed to rt 
and stirred for 1 h before being quenched with NaHCO3 (15 mL). The layers were 
separated, and the aqueous phase was extracted with EtOAc (3 × 15 mL). The combined 
organics were dried (Na2SO4) and concentrated in vacuo. The crude material was purified 
by flash column chromatography (1:3 EtOAc/PE) to yield alcohol 162 as a colourless oil 
(245 mg, 93%). 
 
Rf  0.21 (1:3 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 5.24 (1H, dq, J = 6.5, 2.5 Hz, 
H29), 3.84-3.78 (1H, m, H33a), 3.58-3.52 (1H, m, H33b), 3.47 (3H, s, OMe), 2.98 (1H, dd, J 
= 8.8, 3.2 Hz, H31), 2.78 (1H, br s, OH),  2.32 (2H, q, J = 7.8 Hz, H2’ × 2), 1.92-1.85 (1H, 
m, H32), 1.82-1.75 (1H, m, H30), 1.24 (3H, d, J = 6.5 Hz, Me28), 1.15 (3H, d, J = 7.2 Hz, 
Me32), 1.14 (3H, t, J = 7.5 Hz, H3’ × 3), 0.92 (3H, d, J = 7.0 Hz, Me30).  
 






















To a solution of ester 162 (233 mg, 1.00 mmol) in CH2Cl2 (10 mL) was added DIBAL (4 
mL, 4.00 mmol, 1.0 M in CH2Cl2) at – 78 °C. Upon completion, the reaction was quenched 
with Na+/K+ tartrate (20 mL) and allowed to warm to rt. The layers were separated and the 
aqueous was extracted with CH2Cl2 (4 × 30 mL) and the combined organics were dried 
(Na2SO4) and concentrated in vacuo. The crude was purified by flash column 
chromatography (1:1 EtOAc/PE) to afford diol 83 as a colourless oil (153 mg, 87%). 
 
Rf  0.20 (1:1 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 4.19 (1H, q, J = 6.7 Hz, H29), 
3.76-3.64 (2H, m, H33 × 2), 3.56 (3H, s, OMe), 3.18 (1H, dd, J = 7.7, 4.5 Hz, H31), 2.95 
(1H, br s, OH), 2.27 (1H, br s, OH), 2.02-1.95 (1H, m, H32), 1.71-1.64 (1H, m, H30), 1.56 
(3H, d, J = 6.4 Hz, Me28), 1.03 (3H, d, J = 7.2 Hz, Me32), 0.96 (3H, d, J = 6.7 Hz, Me30); 
13C NMR (125MHz, CDCl3) &C 90.6, 66.6, 65.3, 61.8, 39.7, 37.6, 20.7, 14.9, 11.0; [!]$"# 
+8.5 (c 1.00, CHCl3); IR (thin film) vmax  (cm-1) 3217, 2972, 2930, 1456, 1370, 1076, 1032, 






To a solution of DMSO (0.52 mL, 7.38 mmol) in CH2Cl2  (10 mL) at –78 °C was added 
oxalyl chloride (0.31 mL, 3.69 mmol). After stirring for 30 min, a solution of diol 83 (216 
mg, 1.23 mmol) in CH2Cl2 (10 mL) was added. The mixture was stirred for 30 min and 
then triethylamine (2.06 mL, 14.7 mmol) was added. The reaction mixture was stirred at –
78 °C for 30 min, then warmed to rt for 1 h before being quenched with NH4Cl solution 
(15 mL). The layers were separated, and the aqueous phase was extracted with Et2O (3 × 
15 mL). The combined organics were dried over MgSO4 and concentrated in vacuo to 
afford aldehyde 78 (180 mg, 85%) which was used immediately crude in the subsequent 
Wittig reaction.  
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3.74 (1H, dd, J = 8.4, 3.9 Hz, H31), 3.36 (3H, s, OMe), 2.94-2.83 (1H, m, H30), 2.70-2.60 








To a suspension of phosphonium salt 84 (4.48 g, 11.3 mmol) in THF (25 mL) at –78 °C 
was added freshly prepared LiHMDS (12.5 mL, 1.0 M in THF, 12.5 mmol). The ylide 
solution was stirred at –78 °C for 30 min, warmed to –40 °C and stirred for 30 min, warmed 
to –20 °C and stirred for 30 min and finally warmed to 0 °C for 20 min after which the 
yellow suspension was cooled back down to –78 °C. A solution of aldehyde 78 (976 mg, 
5.67 mmol, pre-dried over CaH2 for 1 h) in THF (25 mL) was added slowly. The reaction 
mixture was stirred at –78 °C for 2 h before being quenched with pH 7.0 buffer (50 mL) 
and diluted with Et2O (10 mL). The layers were separated and the aqueous layer extracted 
with EtOAc (3 × 50 mL). The combined organics were dried over MgSO4 and concentrated 
in vacuo. The crude material was purified by flash column chromatography (1:1 
EtOAc/PE) to afford enamide 86 as a pale yellow oil (800 mg, 62% over 2 steps, 3:1 Z/E).  
Rf  0.27 (1:1 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H  8.10 (0.85H, s, NCHO), [8.01] 
(0.1H, s, NCHO*), [6.19] (0.12H, d, J = 9.1 Hz, H34*), 5.92 (0.81H, d, J = 8.7 Hz, H34), 
5.27 (0.84H, dd, J = 10.8, 8.7 Hz, H33), [5.24-5.19] (0.13H, m, H33*), 3.32 (3H, s, OMe), 
3.20 (1H, dd, J = 9.4, 3.1 Hz, H31), [2.98] (0.15H, s, NMe*), 2.95 (2.45H, s, NMe), [2.74-
2.68] (0.16H, m, H32*), 2.67-2.57 (2H, m, H32, H30),  2.14 (3H, s, Me28), 1.09 (3H, d, J = 
7.0 Hz, Me30), [0.88] (0.67H, d, J = 7.0 Hz, Me32*), 0.84 (2.40H, d, J = 7.0 Hz, Me32); 13C 
NMR (125MHz, CDCl3) &C [212.4], 211.8, 162.5, [162.4], 127.7, 125.1, [124.5], [124.1], 
[87.2], 86.9, [61.2], 61.3, [49.7], 49.8, 36.2, [34.9], 33.8, 31.5, [31.1], 30.9, 19.0, [18.3], 
[13.4], 13.2; [!]$"# +11.0 (c 1.00, CHCl3); IR (thin film) vmax  (cm-1) 2972, 2929, 1682, 
1653, 1457, 1355, 1088, 1054; HRMS calc. for C12H21NO3Na [M+Na]+ 250.1414, found 
250.1412. 
 
Distinguishable resonances of the minor rotamer (3:1 ratio) are given in brackets and 














(Z)-Enamide 86 (810 mg, 3.56 mmol) was dissolved in CH2Cl2 (100 mL) and a solution of 
iodine (45 mg, 0.18 mmol) in CH2Cl2 (20 mL) was added. The reaction mixture was stirred 
in the dark at room temperature for 16 h before being quenched with sodium thiosulfate 
(100 mL, sat. aq.). The biphasic mixture was stirred rapidly for 2 h and the organic layer 
separated. The aqueous phase was extracted with CH2Cl2 (3 × 50 mL) and the combined 
organics dried (MgSO4) and concentrated in vacuo. The crude was purified by flash column 
chromatography (1:1 EtOAc/PE) to afford (E)-enamide 51 as a pale-yellow oil (700 mg, 
86%, >20:1 E/Z).   
Rf  0.27 (1:1 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 8.25 (0.59H, s, NCHO),  [8.04] 
(0.33H, s, NCHO*), [7.09] (0.32H, d, J = 14.5 Hz, H34*), 6.44 (0.59H, d, J = 14.5 Hz, H34), 
5.09 (1H, dd, J = 14.5, 8.5 Hz, H33), 3.34 (3H, s, OMe), 3.26 (1H, dd, J = 10.5, 2.7 Hz, 
H31), [3.04] (1H, s, NMe*), 3.00 (2H, s, NMe), 2.72-2.61 (1H, m, H32), 2.44-2.31 (1H, m, 
H30), 2.16 (3H, s, Me28), 1.12 (3H, d, J = 6.7 Hz, Me32), 0.92 (3H, d, J = 7.1 Hz, Me30); 13C 
NMR (125MHz, CDCl3) &C [212.4], 212.3, 162.1, 160.8, 128.7, 124.7, [113.1], 111.3, 
[87.4], 87.3, 61.2, 61.2, [49.7], 49.6, 37.6, 37.5, 33.0, [31.0], 30.9, 29.6, 27.5, 19.3, [13.4], 
13.3;  [!]$"# –74.4 (c 0.84, CHCl3); IR (thin film) vmax  (cm-1) 2964, 2928, 1691, 1651, 1457, 
1353, 1318, 1275, 1193, 1170, 1092, 1068, 956, 725; HRMS calc. for C12H21NO3Na 
[M+Na]+ 250.1414, found 250.1412.  
 
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 

























To a solution of alcohol 82 (1.17 g, 3.46 mmol) in CH2Cl2 (35 mL) at –78 °C was added 
TESOTf (1.20 mL, 5.2 mmol) and 2,6-lutidine (1.21 mL, 10.4 mmol). The reaction was 
stirred at this temperature for 2 h before being quenched with NH4Cl (35 mL). The reaction 
mixture was warmed to rt and the layers were separated. The aqueous phase was extracted 
with CH2Cl2 (3 × 40 mL) and the combined organics were dried (Na2SO4) and concentrated 
in vacuo. Purification via flash column chromatography (1:19 EtOAc/PE) yielded TES 
ether 92 (1.55g, 99%) as a colourless oil. 
 
Rf  0.60 (1:4 EtOAc/PE); 1H NMR (400MHz, CDCl3) &H  7.25 (2H, d, J = 8.6 Hz, ArH), 
6.87 (2H, d, J = 8.6 Hz, ArH), 5.05 (1H, qd, J = 6.5, 3.3 Hz, H29), 4.41 (2H, s, OCH2Ar), 
3.80 (3H,s, OMe), 3.59-3.50 (2H, m, H31, H33a), 3.25 (1H, dd, J = 9.2, 8.1 Hz, H33b), 2.28 
(2H, q, J = 7.5 Hz, H2’ × 2), 2.08-1.99 (1H, m, H30), 1.72-1.62 (1H, m, H32), 1.21 (3H, d, J 
= 7.8 Hz, Me28), 1.12 (3H, t, J = 7.6 Hz, H3’ × 3), 1.00 (3H, d, J = 7.0 Hz, Me32), 1.00-0.93 
(12H, m, Me30, Si(CH2CH3)3), 0.59 (6H, q, J = 8.0 Hz, Si(CH2CH3)3). 
 










To a solution of PMB ether 92 (4.00 g, 8.84 mmol) in CH2Cl2 (90 mL) was added pH 9.2 
buffer (22 mL) and DDQ (4.01 g, 17.7 mmol) at 0 °C. The reaction was warmed to rt and 
stirred for 2 h before being quenched with NaHCO3 (100 mL). The layers were separated, 
and the aqueous phase was extracted with CH2Cl2 (8 × 50 mL), dried (Na2SO4) and 
concentrated in vacuo. The crude material was purified by flash column chromatography 















Rf  0.18 (1:19 EtOAc/PE); 1H NMR (400MHz, CDCl3) &H 5.00 (1H, dq, J = 6.4, 24.1 Hz, 
H29), 3.78 (1H, ddd, J = 11.4, 4.1, 4.1 Hz, H33a), 3.66 (1H, dd, J = 6.9, 4.3 Hz, H31), 3.57 
(1H, ddd, J = 11.8, 5.2, 4.9 Hz, H33b), 2.64 (1H, dd, J = 6.9, 4.3 Hz, OH), 2.30 (2H, q, J = 
7.6 Hz,  H2’ × 2), 1.91-1.82 (1H, m, H30), 1.81-1.75 (1H, m, H32), 1.25 (3H, d, J = 6.4 Hz, 
Me28), 1.14 (3H, t, J = 6.8 Hz, H3’ × 3), 1.06 (3H, d, J = 7.0 Hz, Me32), 1.00-0.93 (12H, m, 
Me30, Si(CH2CH3)3), 0.59 (6H, q, J = 8.0 Hz, Si(CH2CH3)3). 
 








To a solution of ester 163 (5.00 g, 15.0 mmol) in CH2Cl2 (150 mL) was added DIBAL 
(60.2 mL, 60.2 mmol, 1.0 M in hexanes) at –78 °C. Upon completion, the reaction was 
quenched with Na+/K+ tartrate (240 mL) and allowed to warm to rt. The layers were 
separated and the aqueous was extracted with CH2Cl2 (3 × 60 mL) and the combined 
organics were dried (Na2SO4) and concentrated in vacuo. The crude was purified by flash 
column chromatography (1:3 EtOAc/PE) to afford diol 93 as a colourless oil (3.60 g, 87%). 
 
Rf  0.22 (1:3 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H  4.23 (1H, qdd, J = 6.4, 1.7, 1.7 
Hz, H29), 3.72 (1H, dd, J = 7.0, 3.5 Hz, H31), 3.66-3.62 (2H, m, H33 × 2), 2.97 (1H, br s, 
OH), 2.04-1.88 (2H, m, H32, OH), 1.64-1.56 (1H, m, H30), 1.13 (3H, d, J = 6.8 Hz, Me28), 
1.00 (3H, d, J = 6.8 Hz, Me30), 0.98 (9H, t, J = 8.1 Hz, Si(CH2CH3)3), 0.96 (3H, d, J = 7.0 
Hz, Me32), 0.69 (6H, q, J = 8.1 Hz, Si(CH2CH3)3). 
 




















To a solution of oxalyl chloride (920 µL, 10.9 mmol) in CH2Cl2 (50 mL) at –78 °C was 
added DMSO (1.54 mL, 21.7 mmol). After stirring for 30 min, a solution of diol 93 (1.00 
g, 3.62 mmol) in CH2Cl2 (20 mL) was added. The mixture was stirred for 30 min and then 
triethylamine (4.40 mL, 43.4 mmol) was added. The reaction mixture was stirred at –78 °C 
for 30 min, then warmed to rt for 1 h before being quenched with NH4Cl solution (50 mL). 
The layers were separated, and the aqueous phase was extracted with Et2O (3 × 50 mL). 
The combined organics were washed sequentially with 0.5 M HCl (25 mL) and brine (25 
mL) then dried over MgSO4 and concentrated in vacuo to afford aldehyde 164 (887 mg, 
90% which was used immediately in the subsequent Wittig reaction.  
Rf  0.63 (1:1 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 9.75 (1H, d, J = 1.9 Hz, CHO), 
4.29 (1H, dd, J = 8.0, 3.4 Hz, H31), 2.88-2.81 (1H, m, H30), 2.53-2.47 (1H, m, H32), 2.18 
(3H, s, Me28), 1.14 (3H, d, J = 6.9 Hz, Me32), 0.97 (3H, d, J = 6.9 Hz, Me30), 0.93 (9H, t, J 
= 8.0 Hz, Si(CH2CH3)3), 0.59 (6H, q, J = 8.0 Hz, Si(CH2CH3)3). 







To a suspension of phosphonium salt 84 (5.21 g, 14.1 mmol) in THF (45 mL) at –78 °C 
was added freshly prepared LiHMDS (13.2 mL, 1.0 M in THF, 13.2 mmol). The ylide 
solution was warmed to 0 °C and stirred for 30 min, after which the yellow suspension was 
cooled back down to –78 °C. A solution of aldehyde 164 (2.56 g, 9.4 mmol, pre-dried over 
CaH2 for 1 h) in THF (18 mL) was added slowly over 15 min. The reaction mixture was 
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separated, and the aqueous layer extracted with EtOAc (3 × 50 mL), dried over MgSO4 and 
concentrated in vacuo. The crude material was purified by flash column chromatography 
(1:1 EtOAc/PE) to afford enamide 94 as a colourless oil (2.00 g, 71% over 2 steps, 8:1 
Z/E).  
Rf  0.40 (1:1 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H  8.17 (0.9H, s, NCHO), [8.06] 
(0.1H, s, NCHO*), [6.26] (0.1H, d, J = 8.5 Hz, H34*), 5.96 (0.9H, d, J = 8.6 Hz, H34), 5.35 
(0.9H, dd, J = 10.9, 8.5 Hz, H33), [5.12] (0.1H, dd, J = 10.7, 8.8 Hz, H33*), 3.82 (1H, dd, J 
= 7.8, 3.0 Hz, H31), [3.19] (0.3H, s, NMe*), 3.00 (2.66H, s, NMe), 2.69-2.55 (2H, m, H30, 
H32), 2.15 (3H, s, Me28), 1.05 (3H, d, J = 6.7 Hz, Me30), 0.95 (9H, t, J = 7.8 Hz, 
Si(CH2CH3)3), 0.90 (3H, d, J = 7.0 Hz, Me32), 0.60 (6H, q, J = 7.8 Hz, Si(CH2CH3)3). 
 
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 
assignments denoted with an asterisk.  










A solution of TBAF (55.6 mL, 1M in THF, 55.6 mmol) and glacial acetic acid (2.04 mL, 
35.7 mmol) was stirred at 0 °C for 30 min before being added to TES ether 94 (2.61 g, 7.96 
mmol) via cannula. The reaction mixture was stirred at rt for 16 h. Upon completion, the 
reaction was quenched by the addition of NaHCO3 (100 mL) and then extracted with 
EtOAc (8 × 70 mL). The combined organics were dried (MgSO4) and concentrated in 
vacuo. The crude residue was purified by flash column chromatography (1:1 EtOAc/PE) 
to afford alcohol 95 (1.68 g, 99%, 8:1 Z/E) as a pale-yellow oil. 
 
Rf  0.12 (1:1 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H  8.17 (0.9H, s, NCHO), [8.04] 
(0.1H, s, NCHO*), [6.25] (0.1H, d, J = 8.6 Hz, H34*), 6.00 (1H, d, J = 8.6 Hz, H34), 5.32 
(1H, dd, J = 10.9, 8.5 Hz, H33), [5.11] (0.1H, dd, J = 10.5, 8.4 Hz, H33*), 3.66-3.58 (1H, m, 
H31), [3.13] (0.3H, s, NMe*), 3.00 (3H, s, NMe), 2.80-2.74 (1H, m, OH), 2.72-2.63 (1H, 
m, H32), 2.63-2.55 (1H, m, H30), 2.18 (3H, s, Me28), 1.15 (3H, d, J = 6.7 Hz, Me30), 1.05 






Chapter 6 – Experimental   
 
 168 
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 
assignments denoted with an asterisk.  
 
These data are in agreement with those previously reported.137  
 
 
6.5 Experimental procedures for Chapter 3 
6.5.1 Alternative coupling strategy  
(2S,3S,4R,5S)-13-((tert-butyldimethylsilyl)oxy)-1-hydroxy-3-methoxy-2,4-dimethyl 





To a solution of PMB-ether 98 (500 mg, 0.86 mmol) in CH2Cl2 (16 mL) was added pH 7.0 
buffer (8 mL) and the mixture was cooled to 0 °C. DDQ (390 mg, 1.72 mmol) was added, 
and the reaction was allowed to warm to rt. The biphasic mixture was vigorously stirred 
for 30 min, then quenched with NaHCO3 (20 mL) and extracted with EtOAc (4 × 20 mL). 
The combined organic layers were dried (MgSO4), concentrated in vacuo and purified by 
flash column chromatography (1:4 EtOAc/PE) to give alcohol 165 as a colourless oil (375 
mg, 95%).  
Rf  0.16 (1:4 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 5.17 (1H, app td, J = 6.5, 2.4 Hz, 
H23), 3.77 (1H, dd, J = 11.2, 3.0 Hz, H27a), 3.57 (2H, t, J = 7.4 Hz, H15 × 2), 3.55-3.50 (1H, 
m, H27b), 3.43 (3H, s, OMe), 2.93 (1H, dd, J = 8.6, 2.7 Hz, H25), 2.86 (1H, br s, OH), 2.30 
(2H, q, J = 7.4 Hz, H2’ × 2), 1.90-1.85 (2H, m, H24, H26), 1.66-1.58 (1H, m, H22a), 1.51-1.43 
(3H, m, H16 × 2, H22b), 1.32-1.22 (10H, m, H17-21), 1.15-1.09 (6H, m, H3’ × 3, Me26), 0.90-
0.84 (12H, m, SiC(CH3)3, Me24), 0.04 (6H, s, Si(CH3)2); 13C NMR (125MHz, CDCl3) &C 
174.1, 125.3, 88.6, 73.0, 64.7, 63.3, 61.7, 39.3, 36.2, 32.8, 32.8, 29.5, 29.3, 28.0, 26.0, 25.8, 
25.7, 18.4, 16.1, 10.6, 9.4, –5.2; [!]$"# –2.7 (c 1.01, CHCl3); IR (thin film) vmax (cm-1) 3300, 
2933, 2853, 1732, 1465, 1255, 1189, 1090, 832, 775; HRMS calc. for C25H53O5Si [M+H]+ 

















To a solution of oxalyl chloride (0.551 mL, 6.51 mmol) in CH2Cl2 (16 mL) at –78 °C was 
added DMSO (0.925 mL, 13.0 mmol) dropwise. After 30 min, a solution of alcohol 165 
(1.00 g, 2.17 mmol) in CH2Cl2 (8 mL) was added and the solution stirred for a further 30 
min. NEt3 (2.72 mL, 19.5 mmol) was added and the solution stirred at –78 °C before being 
warmed to rt over 1 h. The reaction was quenched by addition of NH4Cl (25 mL) and the 
layers were separated. The aqueous phase was extracted with Et2O (3 × 5 mL) and the 
combined organics were dried (MgSO4) and concentrated in vacuo to yield aldehyde 50 
(930 mg, 93%) as a colourless oil which was used immediately crude in the subsequent 
aldol reaction.  
Rf  0.80 (1:1 EtOAc/PE); 1H NMR (400MHz, CDCl3) &H 9.75 (1H, d, J = 1.7 Hz, CHO), 
5.26 (1H, dt, J = 5.8, 1.6 Hz, H23), 3.59 (2H, t, J = 6.0 Hz, H15 × 2), 3.39 (3H, s, OMe), 3.24 
(1H, dd, J = 8.8, 3.0 Hz, H25), 2.73-2.65 (1H, m, H26), 2.34 (2H, q, J = 6.7 Hz, H2’ × 2), 
1.86-1.77 (1H, m, H24), 1.69-1.58 (1H, m, H22a), 1.57-1.35 (3H, m, H16 × 2, H22b,), 1.30-
1.24 (10H, m, H17-21), 1.19-1.13 (6H, m, H3’ × 3, Me26), 0.89 (9H, s, SiC(CH3)3), 0.82 (3H, 


























Ketone 51 and aldehyde 50 were each azetropically dried with benzene and placed under 
vacuum for 3 h. To a solution of ketone 51 (574 mg, 2.52 mmol) in Et2O (6 mL) at 0 °C 
was added NEt3 (0.39 mL, 2.78 mmol) and dicyclohexylboron chloride (0.60 mL, 2.78 
mmol). The resulting cloudy yellow solution of enolate was stirred at 0 °C for 1 h before 
being cooled to –78 °C. A solution of aldehyde 50 (1.00 g, 2.18 mmol) in Et2O (10 mL) 
was added and the reaction mixture was stirred at –78 °C for 2 h, then warmed to –10 °C 
over 1 h before being quenched with SiO2 (ca. 5.00 g). The slurry was stirred for 1 h then 
filtered and rinsed with Et2O (20 mL) before being concentrated in vacuo. The crude 
material was purified by flash column chromatography (1:1 EtOAc/PE). All fractions 
containing aldol adduct 101 and ketone 51 were combined and used subsequently in the 
elimination reaction.  
To a solution of aldol adduct 101 and ketone 51 (ca. 1.40 g) in THF (12 mL) was added 
Burgess reagent (582 mg, 2.44 mmol). The reaction mixture was stirred at room 
temperature for 16 h then quenched with NH4Cl (50 mL) and extracted with EtOAc (3 × 
50 mL). The combined organic layers were washed with brine (25 mL), dried (MgSO4) and 
concentrated in vacuo. The crude product was purified by flash column chromatography 
(1:1 EtOAc/PE) yielding enone 102 (1.17 g, 85% over 2 steps, >20:1 E/Z) and recovered 
ketone 51 (97 mg).  
Rf  0.75 (1:1 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 8.28 (0.68H, s, NCHO), [8.08] 
(0.39H, s, NCHO*), [7.14] (0.34H, d, J = 14.6 Hz, H34*), 6.90-6.82 (1H, m, H27), 6.47 
(0.66H, d, J = 14.1 Hz, H34), 6.16-6.10 (1H, m, H28), 5.18-5.14 (1H, m, H23), 5.13 (1H, dd, 
J = 14.1, 9.6 Hz, H33), 3.57 (2H, t, J = 6.6 Hz, H15 × 2), 3.39 (3H, s, OMe), 3.27 (3H, s, 
OMe), 3.26-3.24 (1H, m, H31), [3.09] (1H, s, NMe*), 3.05 (2H, s, NMe), 3.04-2.98 (1H, m, 
H30), 2.86 (1H, m, H25), 2.65-2.57 (1H, m, H26), 2.49-2.36 (1H, m, H32), 2.31 (2H, q, J = 
7.7 Hz, H2’ × 2), 1.65-1.56 (2H, m H22a, H24), 1.52-1.44 (2H, m, H16 × 2), 1.44-1.36 (1H, 
m, H22b), 1.25 (10H, br s, H17-21), 1.17-1.11 (9H, m, H3’ × 3, Me26, Me32), 0.94 (3H, d, J = 
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Si(CH3)2); 13C NMR (125MHz, CDCl3) &C [203.8], 203.6, 174.1, [174.0], 162.1, [160.8], 
149.3, [149.1], 142.7, 131.0, [130.8], 128.8, [124.8], [113.3], 111.5, 87.8, [87.7], 86.1, 
[86.0], 73.1, 63.3, [61.2], 61.1, 45.6, 39.8, 39.4, 39.3, 38.0, [37.8], [33.0], 32.8, 32.5, 29.6, 
29.5, 29.4, 28.0, 27.5, 25.8, 25.6, 20.0, 17.5, 13.8, 13.6, 9.7, 9.5, –5.3; [!]$"# –12.0 (c 1.00, 
CHCl3); IR (thin film) vmax (cm-1) 2930, 2853, 1732, 1696, 1659,1462, 1369, 1254, 1191, 
1096, 1070, 835, 777; HRMS calc. for C37H73N2O7Si [M+NH4]+ 685.5182, found 
685.5173.  
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 








Stryker’s reagent solution (3.50 mL, 0.087 mmol, 0.025 M in PhMe) was added to enone 
102 (300 mg, 0.43 mmol) and the reaction mixture stirred at room temperature for 20 h. 
The solution was applied directly to a silica gel column and the product eluted with 
EtOAc/CH2Cl2 (3:17) to afford ketone 105 (268 mg, 93%) as a colourless oil.  
Rf  0.53 (3:17 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 8.29 (0.63H, s, NCHO), [8.08]  
(0.35H, s, NCHO*), [7.11] (0.35H, d, J = 14.5 Hz, H34*), 6.45 (0.61H, d, J = 14.2 Hz, H34), 
5.19 (1H, dt, J = 6.8, 1.8 Hz, H23), 5.10 (1H, dd, J = 14.1, 8.9 Hz, H33), 3.59 (2H, t, J = 6.5 
Hz, H15 × 2), 3.39 (3H, s, OMe), 3.35 (3H, s, OMe), 3.30 (1H, dd, J = 9.2, 2.3 Hz, H31), 
[3.08] (1H, s, NMe*), 3.04 (2H, s, NMe), 2.75 (1H, dd, J = 8.9, 2.4 Hz, H25), 2.71-2.61 
(1H, m, H30), 2.61-2.50 (1H, m, H28a), 2.50-2.35 (2H, m, H28b, H32), 2.32 (2H, q, J = 7.8 
Hz, H2’ × 2), 1.80-1.75 (1H, m, H24), 1.69-1.61 (2H, m, H22a, H26), 1.54-1.44 (3H, m, H16 × 
2, H22b), 1.44-1.32 (2H, m, H27 × 2), 1.26 (10H, br s, H17-21),1.16 (3H, d, J = 7.6Hz, Me32), 
1.14 (3H, t,  J = 7.7 Hz, H3’ × 3),0.97 (3H, d, J = 6.9 Hz, Me30), 0.92 (3H, d, J = 6.6 Hz, 
Me26), 0.89 (9H, s, SiC(CH3)3), 0.88 (3H, obs d, Me24), 0.04 (6H, s, Si(CH3)2); 13C NMR 
(125MHz, CDCl3) &C [214.2], 214.2, 174.1, 162.2, [160.9], 128.7, [124.7], [113.2], 111.4, 
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[33.1], 32.9, 32.8, 29.9, 29.6, 29.5, 28.0, 27.6, 25.7, 23.2, 19.4, 17.4, 13.5, 10.2, 9.4, –5.3; 
[!]$"# –10.4 (c 1.00, CHCl3); IR (thin film) vmax (cm-1) 2929, 2861, 1732, 1694, 1658, 1461, 
1371, 1255, 1193, 1095, 834, 775; HRMS calc. for C37H75N2O7Si [M+NH4]+ 687.5338, 
found 687.5330.  
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 









Zn(BH4)2 solution (10.1 mL, 0.175 M in Et2O, 1.80 mmol) was added to ketone 105 (200 
mg, 0.30 mmol) at 0 °C and the reaction stirred at this temperature for 2 h before being 
quenched with NH4Cl (15 mL) and Na+/K+ tartrate solution (30 mL). The quenching 
mixture was stirred vigorously for 1 h and extracted with CH2Cl2 (3 × 30 mL). The 
combined organics were dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by flash chromatography (1:4 EtOAc/CH2Cl2) to yield alcohol 109 as a 
colourless oil (136 mg, 68%, 2:1 dr).  
Rf  0.32 (1:4 EtOAc/CH2Cl2); 1H NMR (500MHz, CDCl3) &H 8.29 (0.60H, s, NCHO), 
[8.07] (0.28H, s, NCHO*), [7.15] (0.28H, d, J = 14.5 Hz, H34*), 6.50 (0.56H, d, J = 14.5 
Hz, H34), 5.20 (1H, t, J = 7.3 Hz, H23), [5.15] (0.32H, dd, J = 14.5, 8.6 Hz, H33*), 5.07 
(0.65H, dd, J = 14.2, 8.6 Hz, H33), 3.90-3.84 (1H, m, H29), 3.59 (2H, t, J = 6.6 Hz, H15 × 2), 
3.48 (3H, s, OMe), 3.40 (3H, s, OMe), [3.06] (1H, s, NMe*), 3.03 (1H, obs dd, H31), 3.02 
(2H, s, NMe), 2.86 (1H, br s, OH), 2.76 (1H, dd, J = 9.1, 2.2 Hz, H25), 2.58- 2.46 (1H, m, 
H32), 2.32 (2H, q, J = 7.6 Hz, H2’ × 2), 1.76-1.71 (1H, m, H24), 1.70-1.65 (2H, m, H26, H30), 
1.65-1.59 (2H, m, H22 × 2), 1.54-1.44 (6H, m, H16 × 2, H27 × 2, H28 × 2), 1.23-1.26 (10H, 
m, H17-21), 1.15 (3H, t, J = 7.8 Hz, H3’ × 3), [1.10] (1H, d, J = 7.0 Hz, Me32*), 1.07 (3H, d, 
J = 7.0 Hz, Me32), 1.01 (3H, d, J = 6.1 Hz, Me26), 0.95 (3H, d, J = 7.0 Hz, Me30), 0.90 (9H, 
s, SiC(CH3)3), 0.85 (3H, d, J = 7.0 Hz, Me24), 0.04 (6H, s, Si(CH3)2); 13C NMR (125MHz, 
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[71.5], 63.3, 61.9, 61.8, 61.4, 39.4, 38.8, 38.7, 38.1, 38.0, 35.5, [33.1], 32.9, 29.6, 29.5, 
29.4, 28.0, 27.5, 25.8, 18.8, 18.4, 17.7, 14.1, 10.9, 10.8, 10.4, 9.4, –5.3; [!]$"#  +21.6 (c 
0.454, CHCl3); IR (thin film) vmax (cm-1) 3487, 2931,2857, 1734, 1690, 1657, 1462, 1379, 
1193, 1093, 1072, 967, 878, 774, 712; HRMS calc. for C37H77N2O7Si 689.5487, found 
689.5495.  
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 








To a solution of alcohol 106 (3 mg, 0.013 mmol) in CH2Cl2 (0.10 mL) was added DMAP 
(1 crystal), DMAP hydrochloride (1 crystal), DCC (65 μL, 1M in CH2Cl2, 0.065 mmol) 
and (R)-(+)-MTPA OH (15 mg, 0.065 mmol) and the mixture was stirred at rt for 16 h. 
Once complete, the reaction mixture was filtered through a plug of silica (eluting with 
CH2Cl2) to give (R)-Mosher ester 107 as a colourless oil (4.7 mg, 81%).  
Rf  0.60 (1:4 EtOAc/CH2Cl2); 1H NMR (500MHz, CDCl3) &H 8.27 (0.57H, s, NCHO), 
[8.05] (0.33H, s, NCHO*), 7.60-7.54 (2H, m, ArH), 7.45-7.38 (3H, m, ArH), [7.12] (0.32H, 
d, J = 14.8 Hz, H34*), 6.44 (0.58H, d, J = 14.4 Hz, H34), 5.48 (1H, dq, J = 6.4, 1.4 Hz, H29), 
5.06 (1H, dd, J = 14.4, 9.0 Hz, H33), 3.51 (3H, s, OMe), 3.38 (3H, s, OMe), [3.04] (1H, s, 
NMe*), 3.00 (2H, s, NMe), 2.72 (1H, td, J = 9.8, 1.9 Hz, H31), 2.42 (1H, dqd, J = 9.7, 7.4, 
1.9 Hz, H32), 1.49-1.46 (1H, m, H30), 1.27 (3H, d, J = 6.7 Hz, Me28), 1.13 (3H, d, J = 6.9 
Hz, Me32), 0.83 (3H, d, J = 6.9 Hz, Me30).  
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 






















To a solution of alcohol 106 (3 mg, 0.013 mmol) in CH2Cl2 (0.10 mL) was added DMAP 
(1 crystal), DMAP hydrochloride (1 crystal), DCC (65 μL, 1M in CH2Cl2, 0.065 mmol) 
and (S)-(-)-MTPA OH (15 mg, 0.065 mmol) and the mixture was stirred at rt for 16 h. 
Once complete, the reaction was filtered through a plug of silica (eluting with CH2Cl2) to 
give (S)-Mosher ester 108 as a colourless oil (4.4 mg, 76%).  
Rf  0.61 (1:4 EtOAc/CH2Cl2); 1H NMR (500MHz, CDCl3) &H 8.26 (0.58H, s, NCHO), 
[8.05] (0.34H, s, NCHO*), 7.60-7.52 (2H, m, ArH), 7.43-7.37 (3H, m, ArH), [7.10] (0.33H, 
d, J = 14.6 Hz, H34*), 6.42 (0.58H, d, J = 14.2 Hz, H34), 5.48 (1H, dq, J = 6.3, 1.4 Hz, H29), 
5.05 (1H, dd, J = 14.4, 9.0 Hz, H33), 3.56 (3H, s, OMe), 3.38 (3H, s, OMe), [3.03] (1H, s, 
NMe*), 3.00 (2H, s, NMe), 2.68 (1H, td, J = 9.8, 1.9 Hz, H31), 2.38 (1H, dqd, J = 9.9, 7.6, 
1.9 Hz, H32), 1.49-1.46 (1H, m, H30), 1.35 (3H, d, J = 6.7 Hz, Me28), 1.11 (3H, d, J = 6.9 
Hz, Me32), 0.80 (3H, d, J = 6.9 Hz, Me30).  
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 









To a solution of alcohol 109 (2 mg, 2.98 μmol) in CH2Cl2 (0.10 mL) was added DMAP (1 
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(R)-(+)-MTPA OH (3.5 mg, 14.8 μmol) and the mixture was stirred at 24 for 16 h. Once 
complete, the reaction was filtered through a plug of silica (eluting with CH2Cl2) then 
purified by flash column chromatography (1:4 EtOAc/CH2Cl2) to give (R)-Mosher ester 
111 as a colourless oil (2.3 mg, 72%). 
Rf  0.75 (1:4 EtOAc/CH2Cl2); 1H NMR (500MHz, CDCl3) &H 8.26 (0.60H, s, NCHO), 
[8.05] (0.34H, s, NCHO*), 7.64-7.56 (2H, m, ArH), 7.45-7.36 (3H, m, ArH), [7.10] (0.30H, 
d, J = 15.2 Hz, H34*), 6.44 (0.60H, d, J = 14.6 Hz, H34), 5.38 (1H, app q, J = 6.1 Hz, H29), 
5.17 (1H, t, J = 6.9 Hz, H23), 5.05 (1H, dd, J = 14.5, 9.7 Hz, H33), 3.59 (2H, t, J = 6.6 Hz, 
H15 × 2), 3.50 (3H, s, OMe), 3.39 (3H, s, OMe), 3.37 (3H, s, OMe), [3.03] (1H, s, NMe*), 
3.00 (2H, s, NMe), 2.72 (1H, dd, J = 9.6, 2.5 Hz, H25), 2.66 (1H, td, J = 9.2, 2.2 Hz, H31), 
2.45-2.36 (1H, m, H32), 2.32 (2H, q, J = 7.4 Hz, H2’ × 2), 1.73-1.59 (7H, m, H22 × 2, H24, 
H26, H28 × 2, H30), 1.52-1.37 (4H, m, H16 × 2, H27 × 2), 1.32-1.21 (10H, m, H17-21), 1.14 (3H, 
t, J = 7.8 Hz, H3’ × 3), 1.11 (3H, d, J = 7.1 Hz, Me32), 0.99 (3H, d, J = 7.5 Hz, Me26), 0.89 
(9H, s, SiC(CH3)3), 0.81 (3H, d, J = 7.1 Hz, Me24), 0.78 (3H, d, J = 7.1 Hz, Me30), 0.04 
(6H, s, Si(CH3)2). 
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 









To a solution of alcohol 109 (2 mg, 2.98 μmol) in CH2Cl2 (0.10 mL) was added DMAP (1 
crystal), DMAP hydrochloride (1 crystal), DCC (15 μL, 1M in CH2Cl2, 14.8 μmol) and (S)-
(-)-MTPA OH (3.5 mg, 14.8 μmol) and the mixture was stirred at rt for 16 h. Once 
complete, the reaction was filtered through a plug of silica (eluting with CH2Cl2) then 
purified by flash column chromatography (1:4 EtOAc/CH2Cl2) to give (S)-Mosher ester 
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Rf  0.75 (1:4 EtOAc/CH2Cl2); 1H NMR (500MHz, CDCl3) &H 8.26 (0.60H, s, NCHO), 
[8.05] (0.34H, s, NCHO*), 7.63-7.56 (2H, m, ArH), 7.44-7.37 (3H, m, ArH), [7.10] (0.30H, 
d, J = 15.0 Hz, H34*), 6.41 (0.60H, d, J = 14.6 Hz, H34), 5.36 (1H, app q, J = 6.2 Hz, H29), 
5.17 (1H, t, J = 6.9 Hz, H23), 5.04 (1H, dd, J = 14.5, 9.7 Hz, H33), 3.59 (2H, t, J = 6.7 Hz, 
H15 × 2), 3.50 (3H, s, OMe), 3.40 (3H, s, OMe), 3.37 (3H, s, OMe), [3.03] (1H, s, NMe*), 
3.00 (2H, s, NMe), 2.72 (1H, dd, J = 8.8, 2.6 Hz, H25), 2.64 (1H, td, J = 9.4, 1.9 Hz, H31), 
2.41-2.34 (1H, m, H32), 2.32 (2H, q, J = 7.7 Hz, H2’ × 2), 1.72-1.58 (7H, m, H22 × 2, H24, 
H26, H28 × 2, H30), 1.52-1.45 (2H, m, H16 × 2), 1.44-1.32 (2H, m, H27 × 2), 1.30-1.19 (10H, 
m, H17-21), 1.14 (3H, t, J = 7.2 Hz, H3’ × 3), 1.09 (3H, d, J = 6.8 Hz, Me32), 1.01 (3H, d, J = 
7.2 Hz, Me26), 0.89 (9H, s, SiC(CH3)3), 0.82 (3H, d, J = 7.6 Hz, Me24), 0.76 (3H, d, J = 6.6 
Hz, Me30), 0.04 (6H, s, Si(CH3)2). 
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 









To a solution of alcohol 109 (84 mg, 0.12 mmol) in CH2Cl2 (2.00 mL) was added 2,6-
lutidine (20 μL, 0.15 mmol) and TBSOTf (34 μL, 0.15 mmol) at –78 °C. After stirring at 
this temperature for 30 min, the solution was quenched with NH4Cl (5 mL). The layers 
were separated and the aqueous was extracted with CH2Cl2 (3 × 5 mL). The combined 
organics were dried (Na2SO4) and concentrated in vacuo. The crude was purified by flash 
chromatography (CH2Cl2 → 1:4 EtOAc/CH2Cl2) to yield TBS ether 113 as a colourless oil 
(87 mg, 93%).  
Rf  0.79 (1:4 EtOAc/CH2Cl2); 1H NMR (500MHz, CDCl3) &H 8.27 (0.59H, s, NCHO), 
[8.05] (0.31H, s, NCHO*), [7.11] (0.29H, d, J = 14.6 Hz, H34*), 6.43 (0.57H, d, J = 14.3 
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m, H29), 3.59 (2H, t, J = 6.6 Hz, H15 × 2), 3.50 (3H, s, OMe), 3.38 (3H, s, OMe), 3.08 (1H, 
dd, J = 9.4, 1.8 Hz, H31), [3.03] (1H, s, NMe*), 3.00 (2H, s, NMe), 2.73 (1H, dd, J = 9.1, 
2.7 Hz, H25), 2.54-2.41 (1H, m, H32), 2.32 (2H, q, J = 7.6 Hz, H2’ × 2), 1.75-1.66 (2H, m, 
H24, H26), 1.66-1.59 (2H, m, H22 × 2), 1.53-1.33 (7H, H16 × 2, H27 × 2, H28 × 2, H30), 1.30-
1.24 (10H, m, H17-21), 1.16-1.14 (6H, m, H3’ × 3, Me32), 0.98 (3H, d, J = 7.2 Hz, Me26), 0.89 
(18H, s, SiC(CH3)3 × 2), 0.84 (3H, d, J = 7.2 Hz, Me24), 0.72 (3H, d, J = 7.2 Hz, Me30), 
0.08 (6H, s, Si(CH3)2), 0.04 (6H, s, Si(CH3)2); 13C NMR (125MHz, CDCl3) &C 174.1, 
162.2, [160.8], 128.3, [114.2], 112.4, [87.5], 86.4, 86.3, 73.4, 71.9, 63.3, 61.3, 61.2, 40.5, 
38.8, 37.6, 37.3, 35.5, 35.4, 33.8, [33.1], 32.9, 32.8, 28.0, 27.7, 25.8, 20.1, 20.0, 18.4, 17.7, 
17.6, 10.4, 9.4, 9.1, 9.0, –4.2, –5.3;	[!]$"#	–7.0 (c 0.410, CHCl3); IR (thin film) vmax (cm-1) 
2960, 2933, 2861, 1735, 1699,1660, 1462, 1453, 1364, 1274, 1255, 1192, 1059, 835, 774; 
HRMS calc. for C43H91N2O7Si2 [M+NH4]+ 803.6357, found 803.6359.  
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 









To a solution of bis TBS-ether 113 (87 mg, 0.11 mmol) in THF (1 mL) was added TBAF 
(120 μL, 0.12 mmol, 1M in THF). The reaction was stirred at rt for 8 h before being 
quenched with NH4Cl (2 mL). The layers were separated, and the aqueous phase was 
extracted with EtOAc (3 × 3 mL). The combined organics were dried (Na2SO4) and 
concentrated in vacuo. The crude was filtered through a small plug of silica (eluting with 
CH2Cl2) to give alcohol 114 as a colourless oil (74 mg, 100%).  
Rf  0.31 (1:4 EtOAc/CH2Cl2); 1H NMR (500MHz, CDCl3) &H 8.27 (0.56H, s, NCHO), 
[8.05] (0.27H, s, NCHO*), [7.11] (0.30H, d, J = 14.7 Hz, H34*), 6.43 (0.57H, d, J = 14.2 
Hz, H34), 5.21-5.16 (1H, m, H23), 5.15-5.10 (1H, m, H33), 3.99-3.94 (1H, m, H29), 3.63 (2H, 
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H31), [3.04] (1H, s, NMe*), 3.00 (2H, s, NMe), 2.73 (1H, dd, J = 6.3, 2.7 Hz, H25), 2.54-
2.41 (1H, m, H32), 2.32 (2H, q, J = 7.6 Hz, H2’ × 2), 1.74-1.68 (1H, m, H24), 1.66-1.59 (3H, 
m, H22 × 2, H26), 1.51-1.38 (4H, m, H16 × 2, H28 × 2), 1.38-1.21 (13H, m, H17-21, H27 × 2, 
H30), 1.18-1.12 (6H, m, H3’ × 3, Me32), 0.99 (3H, d, J = 7.1 Hz, Me26), 0.90 (9H, s, 
SiC(CH3)3), 0.83 (3H, d, J = 7.1 Hz, Me24), 0.72 (3H, d, J = 7.1 Hz, Me30), 0.07 (6H, s, 
Si(CH3)2); 13C NMR (125MHz, CDCl3) &C 174.1, 162.2, [160.8], 135.5, 128.3, 124.8, 
[124.3], [114.1], 112.0, [87.5], 86.5, 73.4, 71.9, 63.1, 61.4, 61.3, 40.4, 38.7, 37.6, 37.3, 
35.4, 33.8, [33.1], 32.8, 32.2, 31.0, 29.4, 29.2, 28.1, 27.6, 25.7, 23.4, 20.0, 18.4, 17.6, 10.3, 
9.4, 9.1, 9.0, –4.1;	[!]$"# –4.6 (c 0.310, CHCl3); IR (thin film) vmax (cm-1) 3476, 2948, 2932, 
2857, 1732, 1694, 1655, 1462, 1250, 1189, 1090, 1066, 834, 786; HRMS calc. for 
C37H74NO7Si1 [M+H]+ 672.5229, found 672.5224.  
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 
















Alcohol 114 (100 mg, 0.15 mmol) was dissolved in CH2Cl2 (3 mL) before DMP (220 mg, 
0.52 mmol) and NaHCO3 (151 mg, 1.8 mmol) were added. The reaction was stirred at rt 
for 2 h before being quenched with Na2S2O3 (10 mL) and NaHCO3 (5 mL). The quenching 
mixture was stirred for 30 min and the layers were separated. The aqueous phase was 
extracted with CH2Cl2 (3 × 10 mL) and the combined organics were dried (Na2SO4) and 
concentrated in vacuo to an oily solid. Aldehyde 54 (ca. 100 mg) was used immediately 
crude in the subsequent olefination reaction. 
To a suspension of Ba(OH)2 (281 mg, 0.13 mmol) in THF (1 mL) was added phosphonate 
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aldehyde 54 (100 mg, 0.15 mmol) in THF/H2O (40:1, 2 mL) was added and the reaction 
mixture was stirred for 72 h. Once complete, the solution was poured into NH4Cl (5 mL) 
and extracted with Et2O (3 × 5 mL). The combined organics were dried (MgSO4) and 
concentrated in vacuo. Purification by flash column chromatography (1:4 EtOAc/PE) 
yielded 116 as a colourless oil (146 mg, 85%).  
Rf  0.55 (1:3 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 8.27 (0.67H, s, NCHO), [8.05] 
(0.33H, s, NCHO*), [7.11] (0.33H, d, J = 15.3 Hz, H34*), 6.60 (1H, t, J = 7.1 Hz, H15), 6.44 
(0.67H, d, J = 15.3 Hz, H34), 6.18 (1H, dd, J = 15.1, 10.5 Hz, H3), 6.04 (1H, dd, J = 15.0, 
10.1 Hz, H4), 5.72-5.60 (2H, m, H2, H5), 5.20 (1H, t, J = 6.8 Hz, H23), [5.13] (0.3H, dd, J = 
14.7, 8.9 Hz, H33*), 5.11 (0.6H, dd, J = 14.3, 8.6 Hz, H33), 4.20 (2H, d, J = 5.2 Hz, H1 × 2), 
4.00-3.94 (1H, m, H29), 3.63 (1H, app q, J = 5.8 Hz, H7), 3.54 (1H, t, J = 4.3 Hz, H9), 3.50 
(3H, s, OMe), 3.38 (3H, s, OMe), 3.08 (1H, dd, J = 9.4, 1.8 Hz, H31), [3.03] (1H, s, NMe*), 
3.00 (2H, s, NMe), 2.77-2.70 (2H, m, H12a, H25 ), 2.60-2.51 (1H, m, H12b), 2.51-2.42 (1H, 
m, H32), 2.32 (2H, q, J = 7.8 Hz, H2’ × 2), 2.21 (2H, app q, J = 7.4 Hz, H16 × 2), 2.18-2.13 
(2H, m, H6 × 2), 1.76 (3H, s, Me14), 1.75-1.60 (6H, m, H8, H10, H11a, H22a, H24, H26), 1.54-
1.48 (2H, m, H28 × 2), 1.48-1.35 (7H, m, H11b, H17 × 2, H22b, H27 × 2, H30,), 1.35-1.28 (8H, 
m, H18-21), 1.16 (3H, t, J = 7.8 Hz, H3’ × 3), 1.15 (3H, t, J = 7.5 Hz, Me32), 0.99 (3H, d, J = 
6.9 Hz, Me26), 0.96 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.93 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 
0.92-0.82 (27H, m, SiC(CH3)3 × 2, Me8, Me10, Me24), 0.72 (3H, d, J = 7.0 Hz, Me30), 0.60 
(6H, q, J = 8.2 Hz, Si(CH2CH3)3), 0.57 (6H, q, J = 8.2 Hz, Si(CH2CH3)3), 0.07 (12H, s, 
Si(CH3)2); 13C NMR (125MHz, CDCl3) &C 202.1, 174.1, 162.2, [160.8], 142.2, [142.1], 
137.1, 131.4, 130.3, 130.2, 128.3, [124.3], [114.1], 112.3, [87.4], 86.4, 86.3, 74.4, 73.3, 
72.0, 71.9, 63.7, 61.3, [61.2], 53.4, 41.8, 40.6, 38.8, 38.1, 37.6, [37.3], 36.0, 35.4, 33.8, 
[33.1], 32.8, 29.5, 29.4, 29.1, 28.7, 28.0, 27.6, 26.9, 25.9, 25.8, 20.0, 18.3, 17.7, 16.2, 11.4, 
10.4, 10.3, 9.4, 9.1, 7.2, 7.0, 5.6, 5.2, –3.0, –4.1, –5.2;	[!]$"#  –3.3 (c 1.00, CHCl3); IR (thin 
film) vmax (cm-1) 2951, 2932, 2876, 1730, 1669, 1613, 1440, 1515, 1463, 1371, 1252, 1192, 
1083, 1001, 992, 832, 775, 725; HRMS calc. for C72H145N2O10Si4 [M+NH4]+ 1309.9971, 
found 1309.9978.  
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 




















NaOH (45 mg, 0.89 mmol) was dissolved in MeOH (25 mL) and 3 mL of this stock solution 
was added to ester 116 (60 mg, 0.046 mmol). The solution was heated to 65 °C and stirred 
at this temperature for 1 h. The reaction was cooled to rt and quenched with NH4Cl (3 mL) 
and brine (2 mL). The layers were separated, and the aqueous phase extracted with EtOAc 
(3 × 5 mL). The combined organics were dried (Na2SO4) and concentrated in vacuo. 
Purification via flash column chromatography (1:4 EtOAc/PE) yielded alcohol 119 as a 
colourless oil (25 mg, 50%, 87% brsm). 
Rf  0.50 (1:2 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 8.27 (0.67H, s, NCHO), [8.04] 
(0.33H, s, NCHO*), [7.11] (0.33H, d, J = 14.9 Hz, H34*), 6.60 (1H, t, J = 7.0 Hz, H15), 6.44 
(0.67H, d, J = 14.1 Hz, H34), 6.18 (1H, dd, J = 15.0, 10.7 Hz, H3), 6.04 (1H, dd, J = 15.0, 
10.7 Hz, H4), 5.76-5.60 (2H, m, H2, H5), 5.13 (1H, dd, J = 14.1, 9.0 Hz, H33), 4.20 (2H, d, 
J = 5.8 Hz, H1 × 2), 4.00-3.95 (1H, m, H29), 3.90-3.86 (1H, m, H23), 3.65-3.59 (1H, m, H7), 
3.56-3.52 (1H, m, H9), 3.50 (3H, s, OMe), 3.46 (3H, s, OMe), 3.07 (1H, d, J = 9.8 Hz, H31), 
[3.03] (1H, s, NMe*), 2.99 (2H, s, NMe), 2.90 (1H, dd, J = 7.5, 3.2 Hz, H25 ), 2.77-2.69 
(1H, m, H12a), 2.60-2.50 (1H, m, H12b), 2.49-2.41 (1H, m, H32), 2.22 (2H, app q, J = 7.4 Hz, 
H16 × 2), 2.18-2.13 (2H, m, H6 × 2), 1.76 (3H, s, Me14), 1.75-1.60 (5H, m, H8, H11a, H26, 
H10, H24), 1.59-1.49 (4H, m, H22 × 2, H28a, H11b), 1.49-1.38 (6H, m, H17 × 2, H27 × 2, H28b, 
H30), 1.36-1.28 (8H, m, H18-21), 1.17 (3H, d, J = 7.1 Hz, Me32), 1.00 (3H, d, J = 6.9 Hz, 
Me26), 0.95 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.93 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.92-
0.82 (27H, m, SiC(CH3)3 × 2), Me24, Me8, Me10), 0.72 (3H, d, J = 6.7 Hz, Me30), 0.60 (6H, 
q, J = 8.0 Hz, Si(CH2CH3)3), 0.58 (6H, q, J = 8.3 Hz, Si(CH2CH3)3), 0.07 (12H, s, 
Si(CH3)2);13C NMR (125MHz, CDCl3) &C 202.1, 162.2, [160.8], 142.2, 137.1, 131.4, 
130.2, 128.2, [124.5], [114.3], 112.5, 92.4, [86.4], 86.3, 74.5, 71.8, 71.0, 63.7, 61.9, 41.8, 
40.4, 38.1, 37.6, 36.0, 35.4, 34.7, 33.4, [33.1], 29.7, 29.5, 29.1, 28.7, 27.6, 26.9, 25.9, 20.0, 
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CHCl3); IR (thin film) vmax (cm-1) 3867, 2954, 2922, 2856, 1660, 1615, 1431, 1517, 1443, 
1390, 1249, 1172, 1083, 1038, 991, 832, 778; HRMS calc. for C69H141N2O9Si4 [M+NH4]+ 
1253.9709, found 1253.9703.  
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 














To a solution of 119 (30 mg, 24.3 μmol) in CH2Cl2 (1 mL) and pH 7 buffer solution (1.00 
mL) at 0 °C was added DDQ (6.6 mg, 29 μmol). The mixture was warmed to rt and stirred 
in the dark for 2 h before being quenched with NaHCO3 (2 mL). The solution was diluted 
with H2O (5 mL) and extracted with CH2Cl2 (3 × 5 mL). The combined organics were dried 
(Na2SO3) and concentrated in vacuo. The crude material was purified by flash column 
chromatography (3:7 EtOAc/PE) to give aldehyde 120 as a colourless oil (20 mg, 74%). 
Rf  0.28 (3:7 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 9.55 (1H, d, J = 8.2 Hz, H1), 8.27 
(0.60H, s, NCHO), [8.04] (0.30H, s, NCHO*), 7.15-7.05 (1.3H, m, H3, H34*), 6.60 (1H, t, 
J = 6.5 Hz, H15), 6.43 (0.6H, d, J = 14.4 Hz, H34), 6.38-6.29 (2H, m, H4, H5), 6.08 (1H, dd, 
J = 14.9, 7.9 Hz, H2), 5.13 (1H, dd, J = 14.1, 9.0 Hz, H33), 4.00-3.94 (1H, m, H29), 3.93-
3.85 (1H, m, H23), 3.76-3.70 (1H, m, H7), 3.55 (1H, app t, J = 3.8 Hz, H9), 3.50 (3H, s, 
OMe), 3.46 (3H, s, OMe), 3.07 (1H, d, J = 9.9 Hz, H31), [3.03] (1H, s, NMe*), 2.99 (2H, s, 
NMe), 2.90 (1H, dd, J = 7.7, 3.5 Hz, H25), 2.79-2.70 (1H, m, H12a), 2.62-2.53 (1H, m, H12b), 
2.52-2.42 (1H, m, H32), 2.38-2.26 (2H, m, H6 × 2), 2.21 (2H, app q, J = 7.0 Hz, H16 × 2), 
1.75 (3H, s, Me14), 1.74-1.69 (2H, m, H8, H11a) 1.66-1.59 (3H, m, H24, H26, H28a), 1.58-1.49 
(4H, m, H10, H22 × 2 H30,), 1.49-1.39 (6H, m, H11b, H17 × 2, H27 × 2, H28b,), 1.36-1.28 (8H, 
m, H18-21), 1.17 (3H, d, J = 8.0 Hz, Me32), 1.02-0.82 (39H, m, Si(CH2CH3)3) × 2, SiC(CH3)3, 
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Si(CH2CH3)3), 0.56 (6H, q, J = 7.5 Hz, Si(CH2CH3)3), 0.09 (6H, s, Si(CH3)2);13C NMR 
(125MHz, CDCl3) &C 201.9, 194.0, 162.2, [160.7], 152.5, 144.5, 142.2, 137.1, 130.2, 128.2, 
[114.2], 112.4, 92.4, [86.3], 74.0, 71.8, 71.0, 61.8, 61.7, [61.3], 61.2, 53.4, 41.6, 40.4, 38.3, 
37.6, 37.4, 36.6, 36.0, 35.1, 34.7, 33.3, [33.1], 29.7, 29.1, 28.7, 28.4, 27.5, 27.0, 23.8, 19.9, 
18.3, 16.3, 16.0, 14.2, 11.7, 11.4, [10.3], 9.0, 7.1, 6.9, 5.6, 5.2, –3.0, –4.2;	[!]$"#  –1.9 (c 
0.72, CHCl3); IR (thin film) vmax (cm-1) 3848, 2952, 2932, 2876, 1684, 1640, 1612, 1458, 
1447, 1378, 1248, 1172, 1080, 1038, 995, 820; HRMS calc. for C63H121NO9Si3 [M+H]+ 
1120.8422, found 1120.8424.  
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 
assignments denoted with an asterisk.  
 
6.5.2 Established coupling strategy  
(2S,3S,4R,5S)-13-hydroxy-3-methoxy-1-((4-methoxybenzyl)oxy)-2,4-dimethyl 








To a solution of TBS ether 98 (2.67 g, 4.60 mmol) in THF (62.5 mL) was added H2O (25 
mL) and HCl (3.0 M, 12.5 mL). The reaction was stirred for 2 h before being cooled to       
0 °C and quenched with NaHCO3 (100 mL, portionwise addition). The mixture was 
extracted with Et2O (3 × 100 mL) and the combined organics were dried (Na2SO4) and 
concentrated in vacuo. Purification via flash column chromatography (1:3 EtOAc/PE) gave 
alcohol 166 (2.19 g, 100%) as a colourless oil. 
 
Rf 0.17 (1:3 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 7.24 (2H, d, J = 8.4 Hz, ArH), 
6.86 (2H, d, J = 8.4 Hz, ArH), 5.18 (1H, t, J = 7.2 Hz, H23), 4.41 (2H, ABq, J = 10.2 Hz, 
OCH2Ar), 3.80 (3H, s, OMe), 3.63 (2H, q, J = 6.1 Hz, H15 × 2), 3.54 (1H, dd, J = 9.7, 5.2 
Hz, H27a), 3.38 (3H, s, OMe), 3.32 (1H, t, J = 8.5 Hz, H27b), 2.86 (1H, dd, J = 8.9, 4.0 Hz, 
H25), 2.31 (2H, q, J = 7.9 Hz, H2’ × 2), 2.12-2.06 (1H, m, H26), 1.78 (1H, dqd, J = 8.3, 7.9, 
1.8 Hz, H24), 1.66-1.59 (1H, m, H22a), 1.55 (2H, app quint, J = 7.0 Hz, H16 × 2), 1.48-1.39 
(1H, m, H22b), 1.37-1.19 (10H, m, H17-21), 1.14 (3H, t, J = 7.4 Hz, H3’ × 3), 1.05 (3H, d, J = 
























To a solution of oxalyl chloride (707 μL, 8.35 mmol) in CH2Cl2 (35 mL) at –78 °C was 
added DMSO (1.19 mL, 15.1 mmol) and the mixture stirred for 15 min. A solution of 
alcohol 166 (1.30 g, 2.79 mmol) in CH2Cl2 (20 mL) was added and the solution stirred for 
30 min. Triethylamine (3.50 mL, 25.1 mmol) was added and the reaction was warmed to rt 
and stirred for 1.5 h before being quenched by the addition of NH4Cl (75 mL). The layers 
were separated, and the aqueous phase was extracted with CH2Cl2 (2 × 50 mL) and the 
combined organics were concentrated in vacuo. The organic residue was dissolved in Et2O 
(100 mL) and washed with brine (50 mL) before being dried (Na2SO4) and concentrated in 
vacuo. Flash column chromatography (1:3 EtOAc/PE) yielded aldehyde 52 (1.10 g, 85%) 
as a colourless oil.  
 
Rf 0.35 (1:3 EtOAc/PE); 1H NMR (400MHz, CDCl3) &H 9.75 (1H, t, J = 1.9 Hz, H15), 7.24 
(2H, d, J = 8.2 Hz, ArH), 6.86 (2H, d, J = 8.2 Hz, ArH), 5.17 (1H, t, J = 7.0 Hz, H23), 4.42 
(2H, ABq, J = 10.1 Hz, OCH2Ar), 3.80 (3H, s, OMe), 3.53 (1H, dd, J = 9.5, 4.9 Hz, H27a), 
3.38 (3H, s, OMe), 3.32 (1H, dd, J = 9.0, 7.4 Hz, H27b), 2.86 (1H, dd, J = 8.9, 3.9 Hz, H25), 
2.40 (2H, td, J = 7.4, 1.9 Hz, H16 × 2), 2.31 (2H, q, J = 7.6 Hz, H2’ × 2), 2.12-2.06 (1H, m, 
H26), 1.78 (1H, dqd, J = 8.8, 7.6, 1.9 Hz, H24), 1.66-1.58 (3H, m, H22a, H17 × 2 ), 1.47-1.40 
(1H, m, H22b), 1.34-1.20 (8H, m, H18-21), 1.14 (3H, t, J = 7.5 Hz, H3’ × 3), 1.05 (3H, d, J = 
7.0 Hz, Me26), 0.90 (3H, d, J = 7.0 Hz, Me24). 
 

























To Ba(OH)2 (592 mg, 3.46 mmol) was added a solution of phosphonate 36 (2.24 g, 2.88 
mmol, 3:1 mixture with regioisomer 77) in THF (40 mL) and the suspension was stirred 
for 1 h at rt. Aldehyde 52 (1.10 g, 2.37 mmol) in THF/H2O (40:1, 25 mL) was added and 
the reaction was stirred for 72 h. The reaction was quenched by the addition of NH4Cl (75 
mL) and the layers separated. The aqueous phase was extracted with EtOAc (3 × 100 mL) 
and the combined organics were dried (MgSO4) and concentrated in vacuo. The crude 
material was purified by flash column chromatography (1:5 ® 1:4 EtOAc/PE) to yield 
enone 121 (1.96 g, 85% >20:1) as a colourless oil. 
 
Rf 0.76 (1:3 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 7.24 (2H, d, J = 8.5 Hz, ArH), 
6.86 (2H, d, J = 8.5 Hz, ArH), 6.59 (1H, t, J = 7.1 Hz, H15), 6.18 (1H, dd, J = 14.9, 10.5 
Hz, H3), 6.04 (1H, dd, J = 15.2, 10.5 Hz, H4), 5.68 (1H, dt, J = 14.7, 7.5 Hz, H5), 5.64 (1H, 
dt, J = 14.7, 5.7 Hz, H2), 5.18 (1H, td, J = 6.7, 2.0 Hz, H23), 4.41 (2H, ABq, J = 11.0 Hz, 
OCH2Ar), 4.20 (2H, d, J = 5.1 Hz, H1 × 2), 3.80 (3H, s, OMe), 3.66-3.60 (1H, m, H7), 3.56-
3.51 (2H, m, H9, H27a), 3.38 (3H, s, OMe), 3.32 (1H, dd, J = 8.9, 7.2 Hz, H27b), 2.87 (1H, 
dd, J = 8.8, 3.8 Hz, H25), 2.73 (1H, ddd, J = 15.7, 9.7, 6.0 Hz, H12a), 2.56 (1H, ddd, J = 
15.7, 9.7, 6.0 Hz, H12b), 2.31 (2H, q, J = 7.6 Hz, H2’ × 2), 2.21 (2H, q, J = 7.4 Hz, H16 × 2), 
2.18-2.14 (2H, m, H6 × 2), 2.11-2.06 (1H, m, H26), 1.81-1.70 (3H, m, H8, H11a, H24), 1.76 
(3H, s, Me14), 1.67-1.58 (1H, m, H22a), 1.48-1.37 (4H, m, H11b, H22b, H17 × 2 ), 1.34-1.20 
(8H, m, H18-21), 1.14 (3H, t, J = 7.6 Hz, H3’ × 3), 1.06 (3H, d, J = 7.1 Hz, Me26), 0.95 (9H, 
t, J = 8.2 Hz, Si(CH2CH3)3), 0.93 (9H, t, J = 8.2 Hz, Si(CH2CH3)3), 0.92-0.89 (15H, m, 
SiC(CH3)3, Me24, Me10), 0.86 (3H, d, J = 6.9 Hz, Me8), 0.61 (6H, q, J = 7.8 Hz, 
Si(CH2CH3)3), 0.56 (6H, q, J = 7.5 Hz, Si(CH2CH3)3), 0.07 (6H, s, Si(CH3)2). 
 



























To a solution of enone 121 (1.96 g, 1.80 mmol) in THF (47 mL) was added (R)-Me-CBS 
catalyst (2.16 mL, 1 M in PhMe, 2.16 mmol) at –10 °C and the solution stirred for 5 min 
before dropwise addition of BH3×SMe2 (188 μL, 1.98 mmol). The solution was stirred at     
–10 °C for 1.5 h then carefully quenched by the addition of MeOH (50 mL). The solution 
was warmed to rt and concentrated in vacuo. The residue was re-dissolved in MeOH (40 
mL) and was again concentrated in vacuo. This process was repeated twice further. 
Purification via flash column chromatography (1:6 EtOAc/PE) gave alcohol 122 (1.79 g, 
93%, >20:1 dr) as a colourless oil. 
 
Rf 0.72 (1:3 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 7.24 (2H, d, J = 8.5 Hz, ArH), 
6.86 (2H, d, J = 8.5 Hz, ArH), 6.18 (1H, dd, J = 15.2, 10.4 Hz, H3), 6.04 (1H, dd, J = 15.3, 
10.2 Hz, H4), 5.68 (1H, dt, J = 14.7, 7.4 Hz, H5), 5.64 (1H, dt, J = 15.3, 5.6 Hz, H2), 5.36 
(1H, t, J = 6.4 Hz, H15), 5.18 (1H, td, J = 7.2, 1.8 Hz, H23), 4.41 (2H, ABq, J = 11.1 Hz, 
OCH2Ar), 4.20 (2H, d, J = 5.2 Hz, H1 × 2), 3.94 (1H, td, J = 6.6, 2.5 Hz, H13), 3.80 (3H, s, 
OMe), 3.62-3.58 (1H, m, H7), 3.53 (1H, dd, J = 9.2, 4.8 Hz, H27a), 3.50 (1H, dd, J = 5.1, 
3.5 Hz, H9), 3.38 (3H, s, OMe), 3.32 (1H, dd, J = 9.1, 7.4 Hz, H27b), 2.87 (1H, dd, J = 8.6, 
3.4 Hz, H25), 2.31 (2H, q, J = 7.7 Hz, H2’ × 2), 2.18-2.12 (2H, m, H6 × 2), 2.12-2.06 (1H, 
m, H26), 2.03-1.94 (2H, m, H16 × 2), 1.82-1.70 (2H, m, H8, H24), 1.66-1.60 (2H, m, H12a, 
H22a), 1.58 (3H, br s, Me14), 1.54-1.48 (1H, m, H10), 1.48-1.37 (4H, m, H11 × 2, H12b, H22b), 
1.35-1.29 (2H, m, H17 × 2), 1.29-1.24 (8H, m, H18-21), 1.14 (3H, t, J = 7.6 Hz, H3’ × 3), 1.05 
(3H, d, J = 7.0 Hz, Me26), 0.96 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.93 (9H, t, J = 7.9 Hz, 
Si(CH2CH3)3), 0.91 (9H, s, SiC(CH3)3), 0.90-0.84 (9H, m, Me8, Me24, Me10), 0.60 (6H, q, 
J = 8.0 Hz, Si(CH2CH3)3), 0.57 (6H, q, J = 7.8 Hz, Si(CH2CH3)3), 0.07 (6H, s, Si(CH3)2). 
 

























To a solution of Meerwein salt (143 mg, 0.96 mmol) and proton sponge (309 mg, 1.44 
mmol) in CH2Cl2 (30 mL) was added alcohol 122 (525 mg, 0.48 mmol). The reaction was 
stirred for 4 h at rt before being quenched with NH4Cl (50 mL). The layers were separated, 
and the aqueous phase extracted with CH2Cl2 (3 × 50 mL). The combined organic layers 
were dried (MgSO4), concentrated in vacuo and purified by flash column chromatography 
(1:20 ® 1:9 EtOAc/PE) to give methyl ether 167 as a colourless oil (445 mg, 87%). 
Rf 0.79 (1:3 EtOAc/PE); 1H NMR (400MHz, CDCl3) &H 7.24 (2H, d, J = 8.7 Hz, ArH), 
6.86 (2H, d, J = 8.7 Hz, ArH), 6.18 (1H, dd, J = 14.9, 10.6 Hz, H3), 6.03 (1H, dd, J = 15.3, 
10.6 Hz, H4), 5.68 (1H, dt, J = 14.8, 7.1 Hz, H5), 5.64 (1H, dt, J = 14.8, 5.9 Hz, H2), 5.31 
(1H, t, J = 7.2 Hz, H15), 5.18 (1H, td, J = 7.2, 1.7 Hz, H23), 4.41 (2H, ABq, J = 11.6 Hz, 
OCH2Ar), 4.20 (2H, d, J = 5.0 Hz, H1 ´ 2), 3.80 (3H, s, OMe), 3.62-3.56 (1H, m, H7), 3.53 
(1H, dd, J = 8.9, 4.5 Hz, H27a), 3.48 (1H, dd, J = 5.0, 3.2 Hz, H9), 3.38 (3H, s, OMe), 3.36-
3.30 (2H, m, H13, H27b), 3.14 (3H, s, OMe), 2.87 (1H, dd, J = 8.2, 3.9 Hz, H25), 2.31 (2H, 
q, J = 7.6 Hz, H2’ × 2), 2.19-2.12 (2H, m, H6 × 2), 2.12-1.93 (3H, m, H16 × 2, H26), 1.83-
1.68 (2H, m, H8, H24), 1.68-1.57 (2H, m, H12a, H22a), 1.54-1.40 (4H, m, H10, H12 × 2, H22b), 
1.49 (3H, s, Me14), 1.39-1.31 (4H, m, H11 × 2, H17 × 2), 1.31-1.24 (8H, m, H18-21), 1.14 (3H, 
t, J = 7.4 Hz, H3’ × 3), 1.06 (3H, d, J = 7.1 Hz, Me26), 0.94 (9H, t, J = 8.1 Hz, Si(CH2CH3)3), 
0.93 (9H, t, J = 8.1 Hz, Si(CH2CH3)3), 0.91 (9H, s, SiC(CH3)3), 0.90-0.83 (9H, m, Me8, 
Me10, Me24), 0.60 (6H, q, J = 7.6 Hz, Si(CH2CH3)3), 0.57 (6H, q, J = 7.6 Hz, Si(CH2CH3)3), 
0.07 (6H, s, Si(CH3)2). 
 
























To a solution of ester 167 (1.58 g, 1.43 mmol) in CH2Cl2 (28 mL) was added DIBAL (2.86 
mL, 2.86 mmol, 1.0 M in hexanes) at –78 °C. After 1.5 h, the reaction was quenched with 
NH4Cl (25 mL) and Na+/K+ tartrate (25 mL) and allowed to warm to rt. The layers were 
separated and the aqueous was extracted with CH2Cl2 (3 × 25 mL) and the combined 
organics were dried (Na2SO4) and concentrated in vacuo. The crude was purified by flash 
column chromatography (1:4 EtOAc/PE) to afford alcohol 123 as a colourless oil (1.51 g, 
99%). 
 
Rf 0.62 (1:3 EtOAc/PE); 1H NMR (400MHz, CDCl3) &H 7.26 (2H, d, J = 8.9 Hz, ArH), 
6.88 (2H, d, J = 8.6 Hz, ArH), 6.18 (1H, dd, J = 15.2, 10.7 Hz, H3), 6.04 (1H, dd, J = 15.2, 
10.7 Hz, H4), 5.68 (1H, dt, J = 14.4, 7.0 Hz, H5), 5.64 (1H, dt, J = 15.2, 5.0 Hz, H2), 5.31 
(1H, t, J = 7.0 Hz, H15), 4.44 (2H, s, OCH2Ar), 4.20 (2H, d, J = 5.4 Hz, H1 × 2), 3.89 (1H, 
t, J = 6.6 Hz, H23), 3.80 (3H, s, OMe), 3.62-3.56 (1H, m, H7), 3.54-3.50 (1H, m, H27a), 3.50-
3.46 (3H, m, H9, H27b, OH,), 3.44 (3H, s, OMe), 3.34 (1H, t, J = 7.1 Hz, H13), 3.19 (1H, dd, 
J = 9.0, 3.0 Hz, H25), 3.14 (3H, s, OMe), 2.19-2.10 (2H, m, H6 × 2), 2.10-1.97 (3H, m, H26, 
H16 × 2), 1.76-1.70 (2H, m, H8, H24), 1.55-1.44 (4H, m, H10, H12 × 2, H22a), 1.49 (3H, s, 
Me14), 1.41-1.31 (5H, m, H11 × 2, H17 × 2, H22b), 1.31-1.26 (8H, m, H18-21), 1.04 (3H, d, J 
= 6.9 Hz, Me24), 0.95 (9H, t, J = 8.1 Hz, Si(CH2CH3)3), 0.94 (9H, t, J = 8.1 Hz, 
Si(CH2CH3)3), 0.94-0.91 (3H, obs m, Me26), 0.91 (9H, s, SiC(CH3)3), 0.87 (3H, d, J = 7.5 
Hz, Me10), 0.85 (3H, d, J = 7.6 Hz, Me8), 0.60 (6H, q, J = 8.0 Hz, Si(CH2CH3)3), 0.57 (6H, 
q, J = 8.1 Hz, Si(CH2CH3)3), 0.07 (6H, s, Si(CH3)2). 
 
 



























To a solution of TBS ether 123 (836 mg, 0.80 mmol) in CH2Cl2 (12 mL) and pH 9.2 buffer 
(3 mL) at 0 °C was added DDQ (200 mg, 0.88 mmol). The solution was stirred at this 
temperature for 15 min, then quenched with NaHCO3 (60 mL) and warmed to rt. The 
mixture was extracted with CH2Cl2 (3 × 50 mL) and the combined organics were dried 
(Na2SO4) and concentrated in vacuo. Purification via flash column chromatography (1:6 
EtOAc/PE) gave aldehyde 124 (560 mg, 75%, 91% brsm) as a colourless oil.  
 
Rf 0.62 (1:3 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 9.55 (1H, d, J = 7.9 Hz, H1), 7.25 
(2H, d, J = 7.8 Hz, ArH), 7.08 (1H, dd, J = 15.3, 10.1 Hz, H3), 6.88 (2H, d, J = 8.5 Hz, 
ArH), 6.34-6.28 (2H, m, H4, H5), 6.08 (1H, dd, J = 15.4, 8.2 Hz, H2), 5.31 (1H, t, J = 7.0 
Hz, H15), 4.43 (2H, s, OCH2Ar), 3.90 (1H, app t, J = 6.6 Hz, H23), 3.81 (3H, s, OMe), 3.70-
3.63 (1H, m, H7), 3.55-3.45 (4H, m, H9, H27 ´ 2, OH), 3.44 (3H, s, OMe), 3.34 (1H, t, J = 
6.1 Hz, H13), 3.18 (1H, dd, J = 9.3, 3.7 Hz, H25), 3.14 (3H, s, OMe), 2.37-2.24 (2H, m, H6 
× 2), 2.11-1.93 (3H, m, H16 × 2, H26), 1.80-1.71 (1H, m, H8), 1.71-1.64 (1H, m, H24), 1.57-
1.51 (4H, m, H10, H22a, H12 × 2), 1.49 (3H, s, Me14), 1.45-1.33 (5H, m, H17 × 2, H11 × 2, 
H22b), 1.33-1.25 (8H, m, H18-21), 1.04 (3H, d, J = 7.1 Hz, Me24), 0.95 (9H, t, J = 7.9 Hz, 
Si(CH2CH3)3), 0.94 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.93 (3H, obs d, J = 7.8 Hz, Me26), 
0.88 (3H, d, J = 6.8 Hz, Me10), 0.87 (3H, d, J = 6.8 Hz, Me8), 0.60 (6H, q, J = 7.8 Hz, 
Si(CH2CH3)3), 0.57 (6H, q, J = 7.8 Hz, Si(CH2CH3)3); HRMS calc. for C54H102NO8Si2 
[M+NH4]+ 948.7138, found 948.7133.  
 



























To aldehyde 124 (510 mg, 0.55 mmol) was added 2-methyl-2-butene (8.71 mL, 82.6 mmol) 
and the solution was cooled to 0 °C. NaClO2 (1.86 g, 80% technical grade, 16.4 mmol) and 
NaH2PO4×H2O (3.43 g, 22 mmol) were dissolved in H2O/t-BuOH (34 mL, 1:1) and added 
to the reaction mixture. The reaction was warmed to rt and stirred for 16 h before being 
diluted with EtOAc (50 mL) and brine (50 mL). The mixture was extracted with EtOAc (3 
× 10 mL) and the combined organics were dried (Na2SO4) and concentrated in vacuo to 
give seco-acid 125 (ca. 521 mg) as a pale-yellow oil. The crude material was used directly 
in the next reaction without further purification.  
 
Rf 0.21 (1:4:1 EtOAc/PE/AcOH); 1H NMR (500MHz, CDCl3) &H 7.32 (1H, dd, J = 15.2, 
9.9 Hz, H3), 7.25 (2H, d, J = 8.5 Hz, ArH), 6.88 (2H, d, J = 8.5 Hz, ArH), 6.27-6.12 (2H, 
m, H4, H5), 5.79 (1H, d, J = 15.5 Hz, H2), 5.31 (1H, t, J = 7.0 Hz, H15), 4.44 (2H, s, 
OCH2Ar), 3.98-3.91 (1H, t, J = 7.1 Hz,  H23), 3.81 (3H, s, OMe), 3.67-3.60 (1H, m, H7), 
3.55-3.40 (2H, m, H9, H27b), 3.49-3.45 (1H, m, H27b), 3.45 (3H, s, OMe), 3.35 (1H, t, J = 
6.9 Hz, H13), 3.19 (1H, dd, J = 8.8, 3.1 Hz, H25), 3.14 (3H, s, OMe), 2.31-2.22 (2H, m, H6 
× 2), 2.12-2.06 (2H, m, H16a, H26), 2.01-1.93 (1H, m, H16b), 1.76-1.70 (2H, m, H8, H24), 
1.65-1.54 (4H, m, H10, H12 × 2, H22a,), 1.50 (3H, s, Me14), 1.40-1.20 (13H, m, H11 × 2, H17-
21, H22b), 1.04 (3H, d, J = 7.3 Hz, Me24), 0.95 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.94 (9H, 
t, J = 7.9 Hz, Si(CH2CH3)3), 0.94 (3H, obs d, J = 8.0 Hz, Me26), 0.88 (3H, d, J = 6.8 Hz, 
Me10), 0.84 (3H, d, J = 7.1 Hz, Me8), 0.59 (6H, q, J = 7.1 Hz, Si(CH2CH3)3), 0.57 (6H, q, 
J = 7.8 Hz, Si(CH2CH3)3); HRMS calc. for C54H102NO9Si2 [M+NH4]+ 964.7081, found 
964.7088.  
 


























Crude seco-acid 125 (ca. 568 mg, 0.60 mmol) was dissolved in THF (15 mL) and NEt3 
(836 μL, 6.00 mmol) and TCBC (656 μL, 4.20 mmol) were added. The mixture was stirred 
at rt for 1 h, then diluted with PhMe (100 mL) and the resulting cloudy orange solution 
added to a solution of DMAP (733 mg, 6.00 mmol) in PhMe (50 mL) via syringe pump at 
a rate of 4.6 mL/h. Once complete the reaction was stirred for a further 16 h before being 
quenched with NH4Cl (100 mL). The layers were separated, and the aqueous phase was 
extracted with EtOAc (3 × 100 mL) and the combined organics were dried (Na2SO4) and 
concentrated in vacuo. Flash column chromatography (1:50 ® 1:9 EtOAc/PE) yielded 
macrocycle 126 (386 mg, 70%) as a colourless oil. 
 
Rf 0.52 (1:5 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 7.28 (1H, dd, J = 15.3, 10.0 Hz, 
H3), 7.24 (2H, d, J = 8.9 Hz, ArH), 6.86 (2H, d, J = 8.5 Hz, ArH), 6.25-6.15 (2H, m, H4, 
H5), 5.83 (1H, d, J = 15.7 Hz, H2), 5.38 (1H, dt, J = 10.8, 2.3 Hz, H23), 5.24 (1H, dd, J = 
8.0, 6.0 Hz, H15), 4.41 (2H, ABq, J = 11.4 Hz, OCH2Ar), 3.80 (3H, s, OMe), 3.67-3.61 
(1H, m, H7), 3.56-3.50 (2H, m, H9, H27a), 3.45 (3H, s, OMe), 3.32 (1H, dd, J = 9.2, 7.2 Hz, 
H27b), 3.31 (1H, t, J = 8.7 Hz, H13), 3.13 (3H, s, OMe), 2.90 (1H, dd, J = 8.3, 3.8 Hz, H25), 
2.35-2.26 (1H, m, H6a), 2.18-2.03 (3H, m, H6b, H16a, H26), 1.88-1.80 (1H, m, H16b), 1.78-
1.73 (1H, m, H24), 1.73-1.64 (2H, m, H8, H22a), 1.62-1.57 (2H, m, H10, H12a), 1.53-1.48 (1H, 
m, H12b), 1.48 (3H, s, Me14), 1.43-1.33 (3H, m, H11a, H21a, H22b), 1.33-1.20 (10H, m, H11b, 
H17-20, H21b,), 1.06 (3H, d, J = 7.1 Hz, Me26), 0.96 (9H, t, J = 8.2 Hz, Si(CH2CH3)3), 0.95 
(9H, t, J = 8.2 Hz, Si(CH2CH3)3), 0.94 (9H, m, Me8, Me10, Me24), 0.61 (6H, q, J = 7.8 Hz, 
Si(CH2CH3)3), 0.58 (6H, q, J = 7.8 Hz, Si(CH2CH3)3); 13C NMR (125MHz, CDCl3) &C 
167.1, 158.9, 144.8, 141.8, 133.2, 130.8, 130.0, 129.9, 119.7, 113.6, 88.0, 85.6, 73.1, 72.6, 
71.5, 61.0, 55.5, 55.1, 40.9, 40.7, 36.4, 35.9, 33.8, 31.3, 28.9, 28.5, 28.4, 28.2, 27.8, 27.7, 
27.6, 24.5, 23.8, 20.7, 17.4, 17.2, 16.1, 14.6, 11.7, 11.1, 9.7, 7.0, 6.9, 5.3, 5.1;	[!]$"#  +10.9 
(c 1.00, CHCl3); IR (thin film) vmax (cm-1) 2930, 2876, 1711, 1643, 1614, 1580, 1513, 1458, 
1367, 1300, 1245, 1171, 1134, 1091, 1038, 1001; HRMS calc. for C54H96O8Si2Na [M+Na]+ 























To a solution of PMB ether 126 (335 mg, 0.36 mmol) in CH2Cl2 (20 mL) and pH 7.0 buffer 
(10 mL) was added DDQ (164 mg, 0.72 mmol). The reaction was stirred for 2 h before 
being quenched with NaHCO3 (50 mL). The solution was diluted with H2O (100 mL) and 
the layers were separated. The aqueous phase was extracted with CH2Cl2 (3 × 100 mL) and 
the combined organics dried (Na2SO4) and concentrated in vacuo. The crude residue was 
purified by flash column chromatography (1:50 EtOAc/PhMe ® 1:2 EtOAc/PE) to give 
alcohol 127 (238 mg, 82%) as a colourless oil.  
 
Rf 0.21 (1:5 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 7.28 (1H, dd, J = 15.1, 10.3 Hz, 
H3), 6.23-6.18 (2H, m, H4, H5), 5.84 (1H, d, J = 14.8 Hz, H2), 5.38 (1H, dt, J = 10.9, 2.6 
Hz, H23), 5.25 (1H, dd, J = 8.4, 5.7 Hz, H15), 3.80 (1H, dd, J = 10.9, 3.5 Hz, H27a), 3.68-
3.62 (1H, m, H7), 3.59-3.55 (2H, m, H9, H27b), 3.53 (3H, s, OMe), 3.31 (1H, dd, J = 8.4, 
5.8 Hz, H13), 3.14 (3H, s, OMe), 3.00 (1H, dd, J = 8.1, 3.5 Hz, H25), 2.87 (1H, br s, OH), 
2.35-2.27 (1H, m, H6a), 2.23-2.06 (2H, m, H6b, H16a), 1.94-1.80 (3H, m, H16b, H24, H26), 
1.77-1.64 (2H, m, H8, H22a), 1.64-1.49 (4H, m, H10, H12 × 2, H22b), 1.47 (3H, s, Me14), 1.45-
1.36 (2H, m, H11a, H21a) 1.35-1.18 (10H, m, H11b, H17-20, H21b,), 1.13 (3H, d, J = 7.2 Hz, 
Me26), 0.96 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.95 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.93 
(3H, obs d, Me24), 0.91 (3H, d, J = 7.6 Hz, Me10), 0.89 (3H, d, J = 7.0 Hz, Me8), 0.60 (6H, 
q, J = 7.8 Hz, Si(CH2CH3)3), 0.58 (6H, q, J = 7.8 Hz, Si(CH2CH3)3); 13C NMR (125MHz, 
CDCl3) &C 167.3, 145.1, 141.8, 133.3, 130.1, 129.9, 129.1, 128.7, 119.6, 88.7, 88.1, 77.2, 
73.4, 73.1, 65.1, 61.5, 41.7, 41.1, 39.6, 36.2, 36.2, 33.6, 31.4, 29.0, 28.6, 28.3, 27.9, 27.8, 
27.7, 24.5, 16.2, 14.5, 11.7, 11.2, 9.8, 7.1, 7.0, 5.4, 5.2; [!]$"#  +19.2 (c 1.00, CHCl3); IR 
(thin film) vmax (cm-1) 3452, 2935, 2876, 1712, 1642, 1458, 1415, 1367, 1300, 1238, 1134, 

























To a solution of alcohol 127 (144 mg, 0.18 mmol) in CH2Cl2 (17 ml) was added DMP (377 
mg, 0.89 mmol) and NaHCO3 (74 mg, 0.89 mmol). The mixture was stirred for 2 h before 
being quenched with Na2S2O3 (50 mL). The quenching mixture was stirred for 1 h and the 
layers were separated. The aqueous phase was extracted with CH2Cl2 (3 × 50 mL) and the 
combined organics were dried (Na2SO4) and concentrated in vacuo. Aldehyde 53 was used 
immediately and crude subsequent aldol reaction.  
 
Rf 0.68 (1:1 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 9.74 (1H, d, J = 1.4 Hz, CHO), 
7.29 (1H, dd, J = 15.0, 10.0 Hz, H3), 6.27-6.15 (2H, m, H4, H5), 5.84 (1H, d, J = 14.4 Hz, 
H2), 5.45 (1H, dt, J = 10.8, 2.2 Hz, H23), 5.25 (1H, dd, J = 8.4, 5.7 Hz, H15), 3.68-3.61 (1H, 
m, H7), 3.56-3.49 (1H, m, H9), 3.44 (3H, s, OMe), 3.34-3.26 (2H, m, H13, H25), 3.13 (3H, 
s, OMe), 2.74-2.64 (1H, m, H26), 2.37-2.25 (1H, m, H6a), 2.25-2.04 (2H, m, H6b, H16a), 
1.90-1.78 (2H, m, H16b, H24), 1.78-1.65 (2H, m, H8, H22a), 1.65-1.49 (3H, m, H10, H12 × 2,) 
1.47 (3H, s, Me14), 1.45-1.35 (3H, m, H11a, H21a, H22b), 1.35-1.19 (10H, m, H11b, H17-20, 
H21b), 1.16 (3H, d, J = 7.0 Hz, Me26), 0.96 (18H, t, J = 7.6 Hz, Si(CH2CH3)3 × 2), 0.93 (3H, 
d, J = 7.2 Hz, Me10), 0.89 (3H, d, J = 7.0 Hz, Me8), 0.83 (3H, d, J = 7.0 Hz, Me24), 0.61 
(6H, q, J = 7.9 Hz, Si(CH2CH3)3), 0.57 (6H, q, J = 7.9 Hz, Si(CH2CH3)3). 
 
 

































Ketone 51 was azeotropically dried with benzene and placed under vacuum for 16 h. To a 
solution of ketone 51 (125 mg, 0.55 mmol) in Et2O (5 mL) at 0 °C was added a freshly 
prepared solution of BCy2Cl×NEt3 (275 µL, 0.55 mmol, 2.0 M in Et2O). The resulting 
cloudy yellow solution of enolate was stirred at 0 °C for 1 h before being cooled to –78 °C. 
A solution of crude aldehyde 53 (ca. 140 mg) in Et2O (3 mL) was added and the reaction 
mixture was stirred at –78 °C for 2 h, then warmed to –10 °C over 1 h before being 
quenched with SiO2 (ca. 1 g). The slurry was stirred for 1 h then filtered and rinsed with 
Et2O (10 mL) before being concentrated in vacuo. The crude material was purified by flash 
column chromatography (3:1®1:1 EtOAc/PE). All fractions containing aldol adduct 128 
and ketone 51 were combined and used subsequently in the elimination reaction.  
To a solution of aldol adduct 128 and ketone 51 (ca. 184 mg) in THF (6 mL) was added 
Burgess reagent (83 mg, 0.36 mmol). The reaction mixture was stirred at room temperature 
for 16 h then quenched with NH4Cl (10 mL) and extracted with EtOAc (3 × 10 mL). The 
combined organic layers were washed with brine (15 mL), dried (MgSO4) and concentrated 
in vacuo. The crude product was purified by flash column chromatography (2:1®1:1 
EtOAc/PE) yielding enone 129 (117 mg, 65% over 3 steps) and recovered ketone 51 (75 
mg).  
Rf 0.89 (1:1 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 8.30 (0.60H, s, NCHO), [8.08] 
(0.30H, s, NCHO*), 7.30 (1H, dd, J = 15.4, 9.1 Hz, H3), [7.15] (0.33H, d, J = 14.6 Hz, 
H34*), 6.91 (1H, dd, J = 15.1, 8.1 Hz, H27),  6.48 (0.67H, d, J = 14.3 Hz, H34), 6.25-6.10 
(3H, m, H4, H5, H28), 5.83 (1H, d, J = 15.2 Hz, H2), 5.40 (1H, br d, J = 10.7 Hz, H23), 5.24 
(1H, t, J = 6.0 Hz, H15), 5.15 (1H, dd, J = 13.5, 9.9 Hz, H33), 3.68-3.61 (1H, m, H7), 3.56-
3.51 (1H, m, H9), 3.49 (3H, s, OMe), 3.33-3.27 (5H, m, H13, H31, OMe), 3.13 (3H, s, OMe), 
[3.10] (1H, s, NMe*), 3.06 (2H, s, NMe), 3.03-2.95 (1H, m, H30), 2.95-2.89 (1H, m, H25), 
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H6b, H16a), 1.89-1.79 (1H, m, H16b), 1.74-1.65 (2H, m, H8, H22a), 1.64-1.57 (3H, m, H10, 
H12a, H24,) 1.47 (3H, s, Me14), 1.44-1.33 (2H, m, H11a, H22b), 1.32-1.19 (11H, m, H11b,        
H17-21), 1.18-1.12 (6H, m, Me26, Me32), 0.96 (18H, t, J = 7.7 Hz, Si(CH2CH3)3) ´ 2), 0.95 
(3H,  d, Me30), 0.92 (3H, d, J = 7.1 Hz, Me10), 0.89 (3H, d, J = 7.1 Hz, Me8), 0.83 (3H, d, 
J = 7.4 Hz, Me24), 0.60 (6H, q, J = 7.4 Hz, Si(CH2CH3)3), 0.58 (6H, q, J = 7.4 Hz, 
Si(CH2CH3)3); 13C NMR (125MHz, CDCl3) &C [203.5], 203.4, [167.2], 162.2, [160.9], 
149.3, [149.2], 145.1, 141.9, 133.2, [130.5], 130.1, 129.9, 128.8, [124.7], 119.5, [113.3], 
111.4, 88.0, [87.6], 87.5, 86.0, 77.1, 73.4, 72.9, 61.2, 61.1, 55.4, [46.1], 46.0, 41.4, 39.6, 
39.5, [37.9], 37.7, 36.5, 33.5, [33.0], 31.4, 29.0, 28.6, 28.3, 27.9, 27.8, 27.7, 27.5, 24.6, 
19.5, 17.4, 14.5, 13.8, [13.7], 11.7, 10.4, [10.3], 9.8, 7.1, 7.0, 5.4, 5.2; [!]$"#  -39.7 (c 1.00, 
CHCl3); IR (thin film) vmax (cm-1) 2924, 2875, 1696, 1656, 1458, 1370, 1237, 1134, 1095, 
1069, 1003, 913; HRMS calc. for C58H105NO9Si2Na [M+Na]+ 1038.7220, found 
1038.7230. 
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 














Stryker’s reagent solution (104 µL, 0.0026 mmol, 0.025 M in PhMe) was added to enone 
129 (54 mg, 0.052 mmol) and the reaction mixture stirred at room temperature for 1 h. 
Further aliquots of Stryker’s reagent solution (100 µL) were added every hour for a further 
4 h. The solution was applied directly to a silica gel column and the product eluted with 
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Rf 0.88 (1:1 EtOAc/PE); 1H NMR (500MHz, CDCl3) &H 8.29 (0.67H, s, NCHO), [8.08] 
(0.33H, s, NCHO*), 7.28 (1H, dd, J = 15.4, 10.6 Hz, H3), [7.15] (0.33H, d, J = 14.6 Hz, 
H34*), 6.46 (0.67H, d, J = 14.6 Hz, H34), 6.24-6.12 (2H, m, H4, H5), 5.83 (1H, d, J = 15.3 
Hz, H2), 5.42 (1H, d, J = 11.5 Hz, H23), 5.23 (1H, t, J = 8.4 Hz, H15), 5.15 (1H, dd, J = 14.6, 
9.8 Hz, H33), 3.67-3.59 (1H, m, H7), 3.55-3.49 (1H, m, H9), 3.47 (3H, s, OMe), 3.33 (3H, 
s, OMe), 3.23-3.27 (2H, m, H13, H31), 3.14 (3H, s, OMe), [3.07] (1H, s, NMe*), 3.03 (2H, 
s, NMe), 2.82-2.74 (1H, m, H25), 2.72-2.62 (1H, m, H30), 2.61-2.50 (1H, m, H28a), 2.50-
2.35 (2H, m, H28b, H32), 2.35-2.26 (1H, m, H6a), 2.16-1.97 (2H, m, H6b, H16a), 1.88-1.79 
(1H, m, H16b), 1.78-1.49 (8H, m, H8, H10, H12 ´ 2, H22a, H24, H26, H27a), 1.47 (3H, s, Me14), 
1.43-1.33 (3H, m, H11a, H22b, H27b), 1.32-1.19 (11H, m, H17-21, H11b), 1.15 (3H, d, J = 7.5 
Hz, Me32), 0.96-0.87 (33H, m, Me8, Me10, Me24, Me26, Me30, Si(CH2CH3)3), 0.60 (6H, q, J 
= 7.7 Hz, Si(CH2CH3)3), 0.58 (6H, q, J = 7.7 Hz, Si(CH2CH3)3); 13C NMR (125MHz, 
CDCl3) &C [214.3], 214.2, 167.2 162.1, [160.8], 144.9, 134.9, 133.2, 130.2, 130.0, 128.9, 
[124.5], 119.8, [113.2], 111.3, 88.0, 87.4, 87.3, 74.4, 73.4, 73.2, 61.4, 61.3, 55.5, [49.2], 
49.1, 42.0, 41.0, 40.4, [37.7], 37.5, 36.5, 34.4, 33.7, [33.1], 31.4, 29.7, 29.0, 28.6, 28.3, 
28.0, 27.8, 27.7, [27.4], 24.6, 23.4, [19.4], 19.3, 17.4, 14.5, 13.6, 13.5, 10.8, 9.8, 7.1, 7.0, 
5.4, 5.2; [!]$"#  -22.5 (c 1.00, CHCl3); IR (thin film) vmax (cm-1) 2934, 2869, 1706, 1657, 
1458, 1369, 1238, 1068, 1004, 725; HRMS calc. for C58H107NO9Si2Na [M+Na]+ 
1040.7377, found 1040.7353. 
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 
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6.5 Experimental procedures for Chapter 4  










A stock solution of HF·pyridine was prepared by adding HF·pyridine (100 μL) to a solution 
of pyridine (200 μL) in THF (1 mL) at 0 °C before warming to rt and stirring for 30 min. 
This solution was added to bis-TES ether 130 (8 mg, 7.9 μmol) in a plastic reaction vessel 
at 0 °C and the reaction stirred at rt overnight. The reaction was quenched at 0 °C with 
NaHCO3 solution (5 mL), stirred vigorously at rt for 30 min and the aqueous phase 
extracted with EtOAc (3 × 5 mL). The combined organics were dried (Na2SO4) and 
concentrated in vacuo. Purification via flash column chromatography (1:1:0 ® 10:10:1 
EtOAc/CH2Cl2/MeOH) yielded diol 132 (5.3 mg, 85%) as a colourless oil.  
Rf 0.52 (5:5:1 EtOAc/CH2Cl2/MeOH); 1H NMR (500MHz, CDCl3) &H 8.29 (0.67H, s, 
NCHO), [8.07] (0.33H, s, NCHO*), 7.27 (1H, obs dd, H3), [7.13] (0.33H, d, J = 14.8 Hz, 
H34*), 6.46 (0.67H, d, J = 13.6 Hz, H34), 6.28 (1H, dd, J = 15.4, 11.1 Hz, H4), 6.11 (1H, dt, 
J = 15.1, 7.4 Hz, H5), 5.84 (1H, d, J = 15.0 Hz, H2), 5.35 (1H, td, J = 10.2, 2.6 Hz, H23), 
5.30 (1H, t, J = 7.9 Hz, H15), 5.11 (1H, dd, J = 14.3, 9.5 Hz, H33), 3.89-3.82 (1H, m, H7), 
3.70-3.64 (1H, m, H9), 3.46 (3H, s, OMe), 3.38-3.35 (1H, m, H13), 3.34 (3H, s, OMe), 3.31 
(1H, br d, J = 9.3 Hz, H31), 3.15 (3H, s, OMe), [3.08] (1H, s, NMe*), 3.04 (2H, s, NMe), 
2.82-2.74 (2H, m, H25, OH), 2.71-2.62 (1H, m, H30), 2.59-2.52 (3H, m, H6 × 2, H28a), 2.49-
2.32 (3H, m, H28b, H32, OH), 2.09-1.94 (2H, m, H16 × 2), 1.80-1.54 (8H, m, H8, H10, H12 ´ 
2, H22a, H24, H26, H27a), 1.53-1.47 (1H, m, H11a), 1.47 (3H, s, Me14), 1.47-1.33 (2H, m, H22b, 
H27b), 1.32-1.19 (11H, m, H11b, H17-21,), 1.16 (3H, d, J = 6.8 Hz, Me32), 1.04 (3H, d, J = 7.1 
Hz, Me24), 0.97 (3H, d, J = 6.8 Hz, Me8), 0.90 (3H, d, J = 7.1 Hz, Me30), 0.90 (3H, d, J = 
7.1 Hz, Me26), 0.79 (3H, d, J = 7.2 Hz, Me10); 13C NMR (125MHz, CDCl3) &C [214.3], 
214.2, 167.0 162.2, [160.9], 144.3, 138.9, 133.7, 131.0, 129.9, 128.8, [124.7], 120.6, 
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[37.7], 37.5, 37.0, 34.5, 33.7, [33.1], 30.9, 29.7, 28.8, 28.7, 28.5, 27.8, 27.6, 27.3, 25.1, 
23.5, 19.5, 17.4, 15.8, 13.5, 11.6, 10.9, 10.3; [!]$"#  -46.8 (c 0.21, CHCl3); IR (thin film) 
vmax (cm-1) 3349, 2939, 2853, 1703, 1655, 1461, 1360, 1277, 1134, 1065, 1002, 970, 800, 
725; HRMS calc. for C46H79NO9Na [M+Na]+ 812.5647, found 812.5643. 
 
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 















(S)-Trimethyl serine (3.9 mg, 26.5 μmol) and DMAP (3.2 mg, 26.3 μmol) were dissolved 
in CH2Cl2 (3 mL), then TCBC (8 μL, 51.1 μmol) and NEt3 (11 μL, 78.9 μmol) were added 
to form a stock solution of mixed anhydride. Diol 132 (2 mg, 2.65 μmol) was dissolved in 
benzene (0.30 mL) and an aliquot of the stock solution (0.30 mL) was added at 0 °C. Further 
aliquots of stock solution (0.15 mL) were added hourly for 4 h. The reaction was then 
quenched with MeOH (0.5 mL) and concentrated in vacuo. The crude residue was purified 
by preparative thin layer chromatography (4:4:1 EtOAc/CH2Cl2/MeOH) to give ester 133 
as a colourless oil (1.5 mg, 62%). 
 
Rf 0.57 (4:4:1 EtOAc/CH2Cl2/MeOH); 1H NMR (500MHz, CDCl3) &H 8.29 (0.67H, s, 
NCHO), [8.07] (0.33H, s, NCHO*), 7.23 (1H, obs dd, H3), [7.12] (0.33H, d, J = 14.8 Hz, 
H34*), 6.45 (0.67H, d, J = 14.2 Hz, H34), 6.26 (1H, dd, J = 14.7, 11.2 Hz, H4), 6.04 (1H, dt, 
J = 14.7, 6.7 Hz, H5), 5.86 (1H, d, J = 15.1 Hz, H2), 5.38 (1H, br d, J = 10.8 Hz, H23), 5.28 
(1H, t, J = 7.5 Hz, H15), 5.11 (1H, dd, J = 14.5, 9.6 Hz, H33), 5.00-4.95 (1H, m, H7), 3.67 
(1H, dd, J = 9.9, 2.8 Hz, H3’a), 3.64 (1H, dd, J = 8.3, 4.0 Hz, H3’b), 3.61-3.58 (1H, m, H9), 
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OMe), 3.31 (1H, br d, J = 9.1 Hz, H31), 3.14 (3H, s, OMe), [3.08] (1H, s, NMe*), 3.04 (2H, 
s, NMe), 2.78 (1H, dt, J = 9.1, 2.5 Hz, H25), 2.72-2.61 (1H, m, H30), 2.61-2.51 (2H, m, H6a, 
H28a), 2.50-2.40 (3H, m, H6b, H28b, H32), 2.40-2.35 (7H, m, OH, C2’NMe2), 1.95-1.90 (2H, 
m, H16 × 2), 1.80-1.70 (3H, m, H24, H26, H27a) 1.65-1.58 (3H, m, H10, H12 ´ 2), 1.50 (3H, s, 
Me14), 1.46-1.35 (4H, m, H11a, H22 ´ 2, H27b), 1.35-1.19 (11H, m, H11b, H17-21,), 1.16 (3H, 
d, J = 6.9 Hz, Me32), 0.99-0.95 (6H, m, Me8, Me10), 0.92 (3H, d, J = 6.5 Hz, Me30), 0.90 
(3H, d, J = 6.1 Hz, Me24), 0.88 (3H, d, J = 6.9 Hz, Me26); 13C NMR (125MHz, CDCl3) &C 
[214.3], 214.2, 170.2, 167.0, 162.2, [160.9], 144.0, 137.8, 133.8, 131.4, 129.9, 128.7, 128.2,  
[124.7], 121.2, [113.2], 111.4, 87.8, 87.4, 87.4, 87.3, 74.0, 73.7, 70.5, 67.6, 67.4, 61.4, 
[61.3], 59.2, 55.6, [49.2], 49.1, 42.5, 42.4, 42.1, [40.8], 40.8, [37.7], 37.5, 36.7, 36.4, 34.6, 
34.5, 33.8, [33.1], 31.6, 29.7, 29.4, 28.9, 28.4, 28.1, 27.7, 27.6, 27.4, 22.7, [22.7], [19.4], 
19.4, 17.4, 15.5, 13.5, 11.8, 10.9, 10.1; [!]$"#  -22.1 (c 0.032, CHCl3); IR (thin film) vmax 
(cm-1) 3390, 2451, 2896, 2853, 1711, 1678, 1651, 1462, 1360, 1272, 1220, 1079, 1002, 
957, 891, 829, 701; HRMS calc. for C52H90N2O11K [M+K]+ 957.6176, found 957.6189. 
 
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 




















(R)-Trimethyl serine (3.9 mg, 26.5 μmol) and DMAP (3.2 mg, 26.3 μmol) were dissolved 
in CH2Cl2 (3 mL), then TCBC (8 μL, 51.1 μmol) and NEt3 (11 μL, 78.9 μmol) were added 
to form a stock solution of mixed anhydride. Diol 132 (2.1 mg, 2.67 μmol) was dissolved 
in benzene (0.30 mL) and an aliquot of the stock solution (0.30 mL) was added at 0 °C. 
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reaction was then quenched with MeOH (1.00 mL) and concentrated in vacuo. The crude 
residue was purified by flash column chromatography (1:1:0 ® 4:4:1 EtOAc/CH2Cl2 
/MeOH) to give ester 134 as a colourless oil (1.8 mg, 73%). 
 
Rf 0.42 (5:5:1 EtOAc/CH2Cl2/MeOH); 1H NMR (500MHz, CDCl3) &H 8.29 (0.67H, s, 
NCHO), [8.07] (0.33H, s, NCHO*), 7.26 (1H, obs dd, H3), [7.13] (0.33H, d, J = 14.0 Hz, 
H34*), 6.46 (0.67H, d, J = 14.1 Hz, H34), 6.26 (1H, dd, J = 14.6, 11.9 Hz, H4), 6.06-6.00 
(1H, m, H5), 5.86 (1H, d, J = 15.5 Hz, H2), 5.38 (1H, br d, J = 10.7 Hz, H23), 5.32-5.26 (1H, 
m, H15), 5.09 (1H, dd, J = 14.3, 9.1 Hz, H33), 4.99-4.95 (1H, m, H7), 3.69 (2H, app d, J = 
6.4 Hz, H3’ ´ 2), 3.59-3.56 (1H, m, H9), 3.46 (3H, s, OMe), 3.46-3.40 (1H, m, H2’), 3.37-
3.35 (4H, m, H13, OMe), 3.34 (3H, s, OMe), 3.31 (1H, br d, J = 10.9 Hz, H31), 3.14 (2H, s, 
OMe), [3.12] (1H, s, OMe*), [3.08] (1H, s, NMe*), 3.04 (2H, s, NMe), 2.78 (1H, dt, J = 
8.2, 3.1 Hz, H25), 2.72-2.62 (1H, m, H30), 2.61-2.42 (5H, m, H6 ´ 2, H28 ´ 2, H32), 2.40-
2.35 (7H, m, OH, C2’NMe2), 1.96-1.90 (2H, m, H16 × 2), 1.82-1.71 (3H, m, H24, H26, H27a) 
1.65-1.59 (3H, m, H10, H12 ´ 2), 1.51 (3H, s, Me14), 1.43-1.35 (4H, m, H11a, H22 ´ 2, H27b), 
1.35-1.17 (11H, m, H11b, H17-21,), 1.15 (3H, d, J = 7.0 Hz, Me32), 0.99-0.95 (6H, m, Me8, 
Me10), 0.92 (3H, d, J = 6.6 Hz, Me30), 0.90 (3H, d, J = 6.4 Hz, Me24), 0.88 (3H, d, J = 7.0 
Hz, Me26); 13C NMR (125MHz, CDCl3) &C [214.3], 214.2, 169.9, 166.9, 162.2, [160.8], 
143.8, 138.8, 137.6, 133.8, 132.1, 131.5, 129.9, 128.7, 128.5, 127.7, 125.0, [124.7], 121.2, 
[113.2], 111.4, 87.8, 87.4, 87.4, 87.3, 74.0, 73.7, 71.3, 67.2, 61.4, [61.4], 61.3, 59.1, 55.6, 
[49.2], 49.1, 42.3, 42.1, 40.8, [37.7], 37.5, 36.6, 36.3, 34.6, 34.5, 33.8, [33.1], 30.5, 29.7, 
29.4, 29.0, 28.4, 28.2, 27.7, 27.6, 27.5, 22.7, [19.4], 19.4, 17.4, 15.5, [13.6], 13.5, 11.6, 
10.9, [10.9], 10.1; [!]$"#  -7.1 (c 0.028, CHCl3); IR (thin film) vmax  (cm-1) 3392, 2896, 
2846, 1710, 1675, 1651, 1461, 1343, 1288, 1221, 1082, 1003, 960, 892, 829, 700; HRMS 
calc. for C52H90N2O11Na [M+Na]+ 941.6442, found 941.6402. 
 
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 





























Zn(BH4)2 solution (1.12 mL, 0.175 M in Et2O, 0.196 mmol) was added to ketone 130 (20 
mg, 0.0196 mmol) at 0 °C and the reaction stirred at this temperature for 5 h before being 
quenched with NH4Cl (5 mL) and Na+/K+ tartrate solution (10 mL). The quenching mixture 
was stirred vigorously for 3 h then extracted with CH2Cl2 (3 × 10 mL). The combined 
organics were dried over Na2SO4 and concentrated in vacuo. The crude product was 
purified by flash chromatography (1:0 ® 4:1 ® 1:1 CH2Cl2/EtOAc) to yield alcohol 135 
as a colourless oil (11.5 mg, 58%, 2:1 dr).  
Rf  0.45 (1:2 EtOAc/CH2Cl2); 1H NMR (500MHz, CDCl3) &H 8.29 (0.66H, s, NCHO), 
[8.07] (0.33H, s, NCHO*), 7.28 (1H, dd, J = 15.2, 9.8 Hz, H3), [7.15] (0.33H, d, J = 14.7 
Hz, H34*), 6.49 (0.66H, d, J = 14.3 Hz, H34), 6.24-6.14 (2H, m, H4, H5), 5.84 (1H, d, J = 
15.1 Hz, H2), 5.42 (1H, dd, J = 10.9, 2.0 Hz, H23), 5.24 (1H, t, J = 7.8 Hz, H15), [5.15] 
(0.37H, dd, J = 15.2, 8.8 Hz, H33*), 5.07 (0.60H, dd, J = 14.2, 8.3 Hz, H33), 3.90-3.83 (1H, 
m, H29), 3.67-3.61 (1H, m, H7), 3.55-3.40 (1H, m, H9), 3.48 (3H, s, OMe), 3.46 (3H, s, 
OMe), 3.30 (1H, dd, J = 8.1, 5.9 Hz, H13), [3.06] (1H, s, NMe*), 3.02 (2H, s, NMe), 3.01 
(1H, obs dd, H31), 2.79 (1H, dd, J = 11.0, 2.1 Hz, H25), 2.60-2.46 (1H, m, H32), 2.38-2.27 
(1H, m, H6a), 2.17-2.00 (3H, m, H6b, H16 ´ 2), 1.88-1.77 (1H, m, H22a), 1.75-1.61 (4H, m, 
H8, H22b, H24, H26), 1.61-1.55 (4H, m, H10, H12 ´ 2, H30), 1.51-1.48 (2H, m, H28 ´ 2), 1.47 
(3H, s, Me14), 1.43-1.33 (4H, m, H11 ´ 2, H27 ´ 2), 1.31-1.20 (10H, m, H17-21), [1.10] (1H, 
d, J = 6.7 Hz, Me32*), 1.07 (2H, d, J = 6.7 Hz, Me32), 1.00 (3H, d, J = 6.7 Hz, Me26), 0.97 
(3H, obs d, Me8), 0.96 (9H, t, J = 8.3 Hz, Si(CH2CH3)3), 0.95 (9H, t, J = 8.3 Hz, 
Si(CH2CH3)3), 0.92-0.86 (9H, m, Me10, Me24, Me30), 0.60 (6H, q, J = 8.0 Hz, Si(CH2CH3)3), 
0.58 (6H, q, J = 8.0 Hz, Si(CH2CH3)3); 13C NMR (125MHz, CDCl3) &C 167.3, 162.2, 
[160.8], 144.9, 135.2, 134.5, 133.1, 132.1, 131.9, 130.1, 129.9, 128.5, 125.0, [124.5], 122.3, 
119.8, 114.5, [113.0], 90.5, 90.1, 88.0, [87.6], 87.5, 74.3, 73.6, 73.3, 71.8, 71.5, 61.9, 
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29.6, 29.1, 28.9, 28.7, 28.3, 27.9, 27.7, 27.5, 26.6, 25.7, 24.6, 23.4, 22.7, 18.8, 17.7, 14.5, 
14.1, [10.9], 10.8, 9.8, 9.7, 7.1, 7.0, 5.4, 5.2; [!]$"#  -15.1 (c 0.46, CHCl3); IR (thin film) 
vmax (cm-1) 3445, 2933, 2876, 1698, 1657, 1461, 1240, 1225, 1006, 727, 669; HRMS calc. 
for C58H109NO9Si2Na [M+Na]+ 1042.7533, found 1042.7539. 
 
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 















To a solution of alcohol 135 (2 mg, 1.96 μmol) in CH2Cl2 (0.10 mL) was added DMAP (1 
crystal), DMAP hydrochloride (1 crystal), DCC (7 μL, 1M in CH2Cl2, 9.82 μmol) and (R)-
(-)-MTPA OH (2 mg, 9.82 μmol) and the mixture was stirred for 16 h. Once complete, the 
reaction was purified by flash column chromatography (1:4 EtOAc/CH2Cl2) to give (R)-
Mosher ester 136 as a colourless oil (1.5 mg, 63%).  
Rf  0.78 (1:3 EtOAc/CH2Cl2); 1H NMR (500MHz, CDCl3) &H 8.27 (0.66H, s, NCHO), 
[8.05] (0.33H, s, NCHO*), 7.61-7.56 (2H, m, ArH), 7.44-7.37 (3H, m, ArH), 7.30 (1H, obs 
dd, H3), [7.11] (0.33H, d, J = 14.7 Hz, H34*), 6.43 (0.66H, d, J = 14.5 Hz, H34), 6.24-6.14 
(2H, m, H4, H5), 5.84 (1H, d, J = 15.1 Hz, H2), 5.38 (1H, dd, J = 10.9, 2.1 Hz, H23), 5.36 
(1H, app q, J = 8.4 Hz, H29), 5.24 (1H, t, J = 7.4 Hz, H15), [5.13] (0.47H, dd, J = 15.2, 8.8 
Hz, H33*), 5.06 (1H, dd, J = 13.9, 7.9 Hz, H33), 3.68-3.61 (1H, m, H7), 3.56-3.51 (1H, m, 
H9), 3.49 (3H, s, OMe), 3.47 (3H, s, OMe), 3.38 (3H, s, OMe), 3.31 (1H, dd, J = 8.2, 5.9 
Hz, H13), 3.15 (3H, s, OMe), [3.04] (1H, s, NMe*), 3.00 (2H, s, NMe), 2.74 (1H, dt, J = 
8.8, 2.7 Hz, H25), 2.65 (1H, td, J = 9.6, 1.7 Hz, H31), 2.43-2.22 (3H, m, H6 ´ 2, H32), 2.15-
2.08 (2H, m, H16 ´ 2), 1.91-1.71 (2H, m, H8, H22a), 1.65-1.55 (7H, m, H10, H12 ´ 2, H22b, 
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1.22 (10H, m, H17-21,), 1.10 (3H, d, J = 6.8 Hz, Me32), 0.99 (3H, d, J = 7.0 Hz, Me26), 0.97 
(3H, obs d, Me8), 0.96 (9H, t, J = 8.0 Hz, Si(CH2CH3)3), 0.95 (9H, t, J = 8.0 Hz, 
Si(CH2CH3)3), 0.87 (3H, d, J = 6.6 Hz, Me24), 0.84 (3H, d, J = 6.6 Hz, Me10), 0.78 (3H, d, 
J = 6.6 Hz, Me30), 0.60 (6H, q, J = 8.1 Hz, Si(CH2CH3)3), 0.58 (6H, q, J = 8.1 Hz, 
Si(CH2CH3)3). 
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 














To a solution of alcohol 135 (1.8 mg, 1.77 μmol) in CH2Cl2 (0.10 mL) was added DMAP 
(1 crystal), DMAP hydrochloride (1 crystal), DCC (7 μL, 1M in CH2Cl2, 9.82 μmol) and 
(S)-(-)-MTPA OH (2 mg, 9.82 μmol) and the mixture was stirred for 16 h. Once complete, 
the reaction was purified by flash column chromatography (1:4 EtOAc/CH2Cl2) to give (S)-
Mosher ester 137 as a colourless oil (1.6 mg, 72%). 
Rf  0.78 (1:3 EtOAc/CH2Cl2); 1H NMR (500MHz, CDCl3) &H 8.27 (0.66H, s, NCHO), 
[8.05] (0.33H, s, NCHO*), 7.62-7.56 (2H, m, ArH), 7.43-7.37 (3H, m, ArH), 7.29 (1H, obs 
dd, H3), [7.10] (0.33H, d, J = 14.5 Hz, H34*), 6.41 (0.66H, d, J = 14.5 Hz, H34), 6.24-6.14 
(2H, m, H4, H5), 5.83 (1H, d, J = 15.5 Hz, H2), 5.39 (1H, dd, J = 10.7, 2.4 Hz, H23), 5.35 
(1H, app q, J = 8.4 Hz, H29), 5.24 (1H, t, J = 8.2 Hz, H15), [5.10] (0.37H, dd, J = 14.3, 8.2 
Hz, H33*), 5.04 (0.6H, dd, J = 14.7, 8.2 Hz, H33), 3.67-3.59 (1H, m, H7), 3.57 (3H, s, OMe), 
3.55-3.40 (1H, m, H9), 3.45 (3H, s, OMe), 3.39 (3H, s, OMe), 3.31 (1H, dd, J = 8.4, 5.7 
Hz, H13), 3.15 (3H, s, OMe), [3.03] (1H, s, NMe*), 3.00 (2H, s, NMe), 2.75 (1H, dt, J = 
8.9, 2.2 Hz, H25), 2.64 (1H, td, J = 9.6, 1.7 Hz, H31), 2.41-2.24 (3H, m, H6 ´ 2, H32), 2.17-
2.08 (2H, m, H16 ´ 2), 1.90-1.72 (2H, m, H8, H22a), 1.65-1.55 (7H, m, H10, H12 ´ 2, H22b, 
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1.22 (10H, m, H17-21,), 1.09 (3H, d, J = 6.8 Hz, Me32), 1.00 (3H, d, J = 7.0 Hz, Me26), 0.97 
(3H, obs d, Me8), 0.96 (9H, t, J = 8.2 Hz, Si(CH2CH3)3), 0.95 (9H, t, J = 8.2 Hz, 
Si(CH2CH3)3), 0.89 (3H, d, J = 6.6 Hz, Me24), 0.84 (3H, d, J = 6.6 Hz, Me10), 0.76 (3H, d, 
J = 6.6 Hz, Me30), 0.60 (6H, q, J = 8.2 Hz, Si(CH2CH3)3), 0.58 (6H, q, J = 8.2 Hz, 
Si(CH2CH3)3). 
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 














DMAP (11 mg, 8.8 µmol), DMAP hydrochloride (14 mg, 8.8 µmol), dimethylglycine (9 
mg, 8.8 µmmol) and alcohol 135 (9 mg, 8.8 µmmol) were dissolved in CH2Cl2 (0.50 mL). 
DCC (88 µL, 8.8 µmol, 1M in CH2Cl2) was added and the reaction stirred for 16 h before 
being quenched with NaHCO3 (2 mL). The layers were separated, and the aqueous phase 
extracted with CH2Cl2 (3 × 5 mL). The combined organics were dried (Na2SO4), 
concentrated in vacuo and the crude material transferred to a plastic reaction vessel.  
A stock solution of HF·pyridine was prepared by adding HF·pyridine (100 μL) to a solution 
of pyridine (200 μL) in THF (1 mL) at 0 °C before warming to rt and stirring for 30 min. 
This solution was added the crude material 0 °C and the reaction stirred at rt overnight. The 
reaction was quenched at 0 °C with NaHCO3 solution (5 mL), stirred vigorously at rt for 
30 min and the aqueous phase extracted with EtOAc (3 × 5 mL). The combined organics 
were dried (Na2SO4) and concentrated in vacuo. Purification via flash column 
chromatography (1:1:0 ® 4:4:1 EtOAc/CH2Cl2/MeOH) yielded diol 138 (5.3 mg, 69%) as 
a colourless oil.  
Rf 0.45 (4:4:1 EtOAc/CH2Cl2/MeOH); 1H NMR (500MHz, CDCl3) &H 8.28 (0.66H, s, 
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H34*), 6.45 (0.66H, d, J = 14.5 Hz, H34), 6.28 (1H, dd, J = 15.3, 11.0 Hz, H4), 6.12 (1H, dt, 
J = 15.2, 7.8 Hz, H5), 5.84 (1H, d, J = 15.7 Hz, H2), 5.35-5.27 (2H, m, H23, H29), 5.24 (1H, 
t, J = 6.9 Hz, H15), 5.11 (1H, dd, J = 14.5, 10.0 Hz, H33), 3.88-3.80 (1H, m, H7), 3.70-3.59 
(1H, m, H9), 3.53-3.46 (2H, m, H2’’ ´ 2), 3.44 (3H, s, OMe), 3.43 (3H, s, OMe), 3.41 (1H, 
obs dd, H13), 3.15 (3H, s, OMe), [3.05] (1H, s, NMe*), 3.00 (2H, s, NMe), 2.81 (1H, dd, J 
= 9.8, 2.1 Hz, H25), 2.75 (1H, dd, J = 8.4, 2.4 Hz, H31), 2.59-2.42 (3H, m, H6 ´ 2, H32), 2.39 
(6H, s, C2’’NMe2), 2.10-1.99 (2H, m, H16 ´ 2), 1.73-1.65 (6H, m, H8, H22a, H24, H26, H28 ´ 
2), 1.64-1.51 (5H, m, H10, H12 ´ 2, H22b, H30), 1.38-1.31 (4H, m, H11 ´ 2, H27 ´ 2), 1.48 (3H, 
s, Me14), 1.30-1.19 (10H, m, H17-21,), 1.16 (3H, d, J = 6.6 Hz, Me32), 1.04 (3H, d, J = 6.6 
Hz, Me8), 0.97 (3H, d, J = 7.4 Hz, Me26), 0.88-0.82 (6H, m, Me10, Me24), 0.79 (3H, d, J = 
7.4 Hz, Me30); 13C NMR (125MHz, CDCl3) &C 170.2, 167.0, 162.2, [160.9], 156.7, 144.3, 
139.0, 133.7, 130.9, 129.9, 128.8, 128.6, [124.6], 120.5, [113.4], 111.7, 87.9, 87.3, 86.6, 
75.3, 74.0, 73.9, 61.3, [61.1], 60.3, 55.6, 49.1, 45.2, 40.6, [39.3], 39.1, 39.0, 38.1, [37.8], 
37.0, 36.9, 35.2, 33.9, 33.6, [33.1], 30.9, 29.7, 28.8, 28.7, 28.5, 27.8, 27.6, 27.3, 24.9, 20.3, 
[17.4], 17.3, 15.7, [11.6], 11.1, 10.3, 9.8, 9.7; [!]$"#  -13.9 (c 0.16, CHCl3); IR (thin film) 
vmax (cm-1) 3325, 2952, 2853, 1708, 1690, 1656, 1635, 1559, 1448, 1254, 1159, 1091 975; 
HRMS calc. for C50H88N2O10Na [M+Na]+ 899.6337, found 899.6324. 
 
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 




















(S)-Trimethyl serine (6.7 mg, 46.1 μmol) and DMAP (5.6 mg, 46.1 μmol) were dissolved 
in CH2Cl2 (3 mL) and TCBC (15 μL, 92.3 μmol) and NEt3 (13 μL, 92.3 μmol) were added 
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benzene (0.30 mL) and an aliquot of the stock solution (0.40 mL) was added at 0 °C. Further 
aliquots of stock solution (0.40 mL) were added every 30 min for 2 h. The reaction was 
then quenched with MeOH (1.5 mL) and concentrated in vacuo. The crude residue was 
purified by flash column chromatography (1:0:0 ® 1:1:0 ® 4:4:1CH2Cl2/EtOAc/MeOH) 
to give ester 44 as a colourless oil (1.4 mg, 65%). 
 
Rf 0.31 (4:4:1 EtOAc/CH2Cl2/MeOH); 1H NMR (500MHz, CDCl3) &H 8.28 (0.66H, s, 
NCHO), [8.06] (0.33H, s, NCHO*), 7.24 (1H, obs dd, H3), [7.12] (0.33H, d, J = 14.4 Hz, 
H34*), 6.46 (0.66H, d, J = 14.2 Hz, H34), 6.28 (1H, dd, J = 14.8, 11.1 Hz, H4), 6.03 (1H, dt, 
J = 15.2, 7.8 Hz, H5), 5.86 (1H, d, J = 15.4 Hz, H2), 5.34 (1H, dt, J = 9.5, 2.4 Hz, H15), 
5.31-5.25 (2H, m, H23, H29), 5.08 (1H, dd, J = 14.6, 9.4 Hz, H33), 5.01-4.95 (1H, m, H7), 
3.82-3.68 (2H, m, H3’ ´ 2, H2’’ ´ 2), 3.60-3.55 (1H, m, H9), 3.44 (3H, s, OMe), 3.43 (3H, 
s, OMe), 3.37 (3H, s, OMe) 3.42-3.38 (1H, m, H2’), 3.35 (1H, br d, J = 6.4 Hz, H13), 3.15 
(3H, s, OMe), [3.05] (1H, s, NMe*), 3.00 (2H, s, NMe), 2.81 (1H, dd, J = 9.1, 2.5 Hz, H25), 
2.76 (1H, dd, J = 8.4, 2.7 Hz, H31), 2.58 (6H, s, C2’ NMe2), 2.52 (7H, s, C2’’NMe2, H32), 
2.50-2.41 (2H, m, H6 ´ 2), 1.96-1.86 (2H, m, H16 ´ 2), 1.72-1.66 (4H, m, H8, H22a, H24, 
H26,), 1.64-1.53 (7H, m, H10, H12 ´ 2, H22b, H28 ´ 2, H30), 1.38-1.29 (4H, m, H11 ´ 2, H27 ´ 
2), 1.50 (3H, s, Me14), 1.28-1.19 (10H, m, H17-21,), 1.15 (3H, d, J = 6.6 Hz, Me32), 0.98 (6H, 
d, J = 7.4 Hz, Me8, Me26), 0.88 (3H, d, J = 6.8 Hz, Me10), 0.86 (3H, d, J = 6.8 Hz, Me24),  
0.83 (3H, d, J = 7.0 Hz, Me30); 13C NMR (125MHz, CDCl3) &C 169.1, [168.5], 166.9, 
162.2, 160.9, 143.9, 137.7, 135.2, 133.8, 131.4, 129.9, 128.7, 127.6, 125.0, [124.7], 121.1, 
[113.6], 111.7, 87.7, [87.3], 86.6, 74.1, 73.7, 70.3, 67.0, 61.9, 61.3, [61.3], 59.2, 55.6, 49.2, 
45.2, 42.2, 40.8, 39.2, 39.0, 38.1, 37.8, 36.5, 35.2, 34.3, 33.9, 33.7, [33.1], 30.4, 29.7, 29.4, 
29.0, 28.4, 28.1, 27.8, 27.6, 27.5, 26.4, 25.9, 23.4, 22.7, 20.1, 17.6, [17.5], 15.5, 14.1, 
[11.6], 11.1, 10.2, 9.9, 9.8; [!]$"#  -4.5 (c 0.056, CHCl3); IR (thin film) vmax (cm-1) 3456, 
2940, 2925, 2912, 1714, 1692, 1649, 1613, 1546, 1454, 1368, 1258, 1218, 1129, 1094, 852, 
820, 780, 731; HRMS calc. for C55H98N3O11 [M+H]+ 992.7151 found 992.7126. 
 
Distinguishable resonances of the minor rotamer (2:1 ratio) are given in brackets and 
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6.5.2 Linker synthesis 









To a solution of Fmoc-Val-OH 147 (500 mg, 1.47 mmol) in THF (4 mL) at 0 °C was added 
N-hydroxysuccinimide (254 mg, 2.21 mmol) and DCC (303 mg, 1.47 mmol). The reaction 
was stirred at this temperature for 2 h before warming to rt for 16 h. The suspension was 
filtered and the solid was washed with THF (3 × 4 mL). The filtrate was concentrated in 
vacuo to produce Fmoc-Val-OSuc 148 as a glassy solid (580 mg, 90%) which was used in 
the next reaction without further purification. 
 
1H NMR (400 MHz, DMSO-d6) δH 8.14 (1H, d, J = 8.5 Hz, CONHVal), 7.89 (2H, d, J = 
7.8 Hz, ArH), 7.74 (2H, t, J = 8.8 Hz, ArH), 7.42 (2H, t, J = 7.8 Hz, ArH), 7.33 (2H, t, J = 
8.3 Hz, ArH), 4.39-4.20 (4H, m, Fmoc CH2, Fmoc CH, HαVal), 2.82 (4H, s, NCOCH2), 
2.28-2.15 (1H, m, HβVal), 1.03 (6H, d, J = 6.1 Hz, CH3 × 2 Val); 13C NMR (101 MHz, 
DMSO-d6) δC 170.0, 167.9, 156.3, 143.8, 143.6, 140.7, 127.7, 127.1, 125.3, 125.3, 120.1, 
66.1, 58.0, 46.6, 30.1, 25.5, 25.2, 18.6, 18.0. 
 















To a solution of Fmoc-Val-OSuc 148 (3.50 g, 8.02 mmol) in DME (26 mL) at 0 °C was 
added a solution of L-citrulline (1.96 g, 11.2 mmol) and NaHCO3 (944 mg, 11.2 mmol) in 
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warmed to rt and stirred for 48 h. K2CO3 (20 ml, sat. aq.) was added and the aqueous layer 
extracted with EtOAc (2 × 40 mL). The aqueous phase was then acidified to pH 3-4 with 
10% HCl (30 mL) upon which a gelatinous material formed. The material was extracted 
with 10% IPA/EtOAc (7 × 300 mL) and the organics were dried (MgSO4) and concentrated 
in vacuo. The resulting white solid was washed with MTBE (3 × 50 mL) and dried under 
vacuum at 40 °C for 72 h to give Fmoc-Val-Cit-OH 149 as a free-flowing white solid (3.55 
g, 89%).  
1H NMR (400 MHz, DMSO-d6) δH 12.5 (1H, br s, COOH), 8.17 (1H, d, J = 7.4 Hz, 
CONHCit), 7.89 (2H, d, J = 8.1 Hz, ArH), 7.75 (2H, t, J = 8.1 Hz, ArH), 7.41 (3H, q, J = 
7.4 Hz, ArH, CONHVal), 7.35-7.29 (2H, m, ArH), 5.94 (1H, t, J = 5.7 Hz, NHCit), 5.37 
(2H, s, NH2Cit), 4.32-4.18 (3H, m, Fmoc CH2, Fmoc CH), 4.18-4.11 (1H, m, Hα’Cit), 3.92 
(1H, dd, J = 9.0, 7.2 Hz, HαVal), 2.99-2.90 (2H, m, NCH2Cit), 2.03-1.93 (1H, m, HβVal), 
1.74-1.64 (1H, m, CH2Cit), 1.62-1.50 (1H, m, CH2Cit), 1.45-1.33 (2H, m, CH2Cit), 0.89 
(3H, d, J = 6.7 Hz, CH3Val), 0.86 (3H, d, J = 6.7 Hz, CH3Val); 13C NMR (101 MHz, 
DMSO-d6) δC 173.4, 171.3, 158.7, 156.0, 143.9, 143.8, 140.7, 127.6, 127.0, 125.4, 120.1, 
65.7, 59.8, 51.9, 46.7, 38.7, 30.5, 28.3, 26.7, 19.2, 18.2. 

















Fmoc-Val-Cit-OH 149 (630 mg, 1.27 mmol), PABOH (250 mg, 2.02 mmol) and EEDQ 
(500 mg, 2.02 mmol) were dissolved in CH2Cl2/MeOH (2:1, 24 mL) and stirred in the dark 
for 72 h. The reaction was concentrated in vacuo and the residue suspended in MTBE (50 
mL) before being filtered to yield Fmoc-Val-Cit-PABOH 153 as a yellow solid (565 mg, 
74%). 
1H NMR (400 MHz, DMSO-d6) δH 9.97 (1H, s, PABNH), 8.09 (1H, d, J = 7.2 Hz, 
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(2H, d, J = 8.8 Hz, ArHPAB), 7.41 (3H, t, J = 7.2 Hz, ArHFmoc, CONHVal), 7.32 (2H, t, 
J = 8.0 Hz, ArHFmoc), 7.23 (2H, d, J = 8.8 Hz, ArHPAB), 5.97 (1H, t, J = 5.7 Hz, NHCit), 
5.40 (2H, s, NH2Cit), 5.08 (1H, t, J = 5.5 Hz, PABOH), 4.43 (2H, d, J = 5.5 Hz, 
ArCH2PAB), 4.35-4.19 (4H, m, Fmoc CH2, Fmoc CH, HαCit), 3.93 (1H, t, J = 7.2 Hz, 
HαVal), 3.08-2.88 (2H, m, NCH2Cit), 2.07-1.92 (1H, m, HβVal), 1.76-1.64 (1H, m, 
CH2Cit), 1.64-1.51 (1H, m, CH2Cit), 1.50-1.30 (2H, m, CH2Cit), 0.92-0.81 (6H, m, 2 × 
CH3Val); 13C NMR (101 MHz, DMSO-d6) δC 171.2, 170.4, 158.9, 156.1, 143.9, 143.8, 
140.7, 137.5, 137.4, 127.6, 127.1, 126.9, 125.4, 120.1, 118.8, 65.7, 62.6, 60.1, 53.0, 46.7, 
38.6, 30.4, 29.5, 26.8, 19.2, 18.3. 











To a solution of Alloc-Val-Ala-PABOH 154 (3.00 g, 7.95 mmol) in MeOH (78 mL) was 
added Pd(PPh3)4 (92 mg, 0.0795 mmol) and the mixture was stirred for 5 min. K2CO3 (6.59 
g, 47.7 mmol) was added and the reaction stirred for 30 min before being concentrated in 
vacuo. The residue was dissolved in H2O (50 mL) and the aqueous extracted with EtOAc 
(6 × 100 mL). The combined organics were dried (MgSO4) and concentrated in vacuo to 
yield Val-Ala-PABOH 155 as a pale yellow solid (2.00 g, 85%). 
 
1H NMR (400 MHz, DMSO-d6): δH 10.03 (1H, s, PABNH), 8.20 (1H, br s, NHAla), 7.54 
(2H, d, J = 8.3 Hz, ArH), 7.24 (2H, d, J = 8.3 Hz, ArH), 4.51-4.45 (1H, m, Hα’Ala), 4.43 
(2H, s, ArCH2PAB), 3.03 (1H, d, J = 5.0 Hz, HαVal), 1.97-1.88 (1H, m, HβVal), 1.30 (3H, 
d, J = 6.8 Hz, CH3Ala), 0.89 (3H, d, J = 6.8 Hz, CH3Val), 0.79 (3H, d, J = 6.8 Hz, CH3Val);         
13C NMR (101 MHz, DMSO-d6): δC 174.1, 171.0, 137.5, 137.5, 126.9, 119.0, 62.6, 59.6, 
48.6, 31.4, 19.5, 18.7, 16.9. 
 




























HATU (373 mg, 0.98 mmol) and 6-maleimidohexanoic acid (190 mg, 0.98 mmol) were 
dissolved in DMF (8 mL) before the addition of i-Pr2NEt (5.00 mL, 0.98 mmol). The 
solution was stirred for 1 h. Amine 155 (240 mg, 0.82 mmol) was dissolved in DMF (3 
mL) and added to the reaction mixture, which was left to stir for a further 16 h. The reaction 
was quenched with 5% aq. LiCl (20 mL) and extracted with EtOAc (6 × 50 mL). The 
combined organics were washed with H2O (100 mL) and brine (100 mL), dried (MgSO4) 
and concentrated in vacuo. Purification via flash column chromatography (1:19 
MeOH/CH2Cl2) gave Mc-Val-Ala-PABOH 156 as a pale orange solid (300 mg, 78%). 
 
1H NMR (500 MHz, DMSO-d6) δH 9.85 (1H, s, PABNH), 8.14 (1H, d, J = 7.0 Hz, NHAla), 
7.82 (1H, d, J = 8.2 Hz, NHVal), 7.54 (2H, d, J = 8.6 Hz, ArH), 7.23 (2H, d, J = 8.6 Hz, 
ArH), 7.00 (2H, s, CH-Mal), 5.10 (1H, br s, PABOH), 4.43 (2H, s, ArCH2PAB), 4.39 (1H, 
t, J = 7.3 Hz, Hα’Ala), 4.17 (1H, dd, J = 8.6, 7.0 Hz, HαVal), 3.40-3.34 (2H, m, H1 × 2), 
2.25-2.09 (2H, m, H5 × 2), 2.01-1.92 (1H, m, HβVal), 1.57-1.43 (4H, m, H2 × 2, H4 × 2), 
1.31 (3H, d, J = 7.0 Hz, CH3Ala), 1.23-1.15 (2H, m, H3 × 2), 0.86 (3H, d, J = 7.0 Hz, 
CH3Val), 0.82 (3H, d, J = 7.0 Hz, CH3Val); 13C NMR (126 MHz, DMSO-d6) δC 172.4, 
171.1, 171.0, 171.0, 137.6, 137.4, 134.5, 126.9, 119.9, 62.6, 57.6, 49.0, 37.1, 35.0, 30.4, 
27.8, 25.8, 24.9, 19.3, 18.2, 18.0. 
 









































To a solution of Mc-Val-Ala-PABOH 156 (50 mg, 0.11 mmol) in DMF (500 µL) at 0 °C 
was added SOCl2 (9 µL, 0.12µmol). The reaction was stirred at this temperature for 5 min 
before being quenched by the addition of H2O (1 mL). The resulting precipitated solid was 
collected by filtration and washed with H2O (2 mL) and MTBE (2 mL), then dried under 
vacuum for 2 h to yield Mc-Val-Ala-PABCl 157 as a brown solid (30 mg, 61%). 
 
1H NMR (500 MHz, DMSO-d6) δH 10.00 (1H, s, PABNH), 8.16 (1H, d, J = 6.7 Hz, 
NHAla), 7.81 (1H, d, J = 8.0 Hz, NHVal), 7.60 (2H, d, J = 8.0 Hz, ArH), 7.36 (2H, d, J = 
8.3 Hz, ArH), 7.00 (2H, s, CH-Mal), 4.71 (2H, s, ArCH2PAB), 4.38 (1H, t, J = 7.4 Hz, 
Hα’Ala), 4.16 (1H, dd, J = 8.5, 7.0 Hz, HαVal), 3.36 (2H, t, J = 7.4 Hz, H1 × 2), 2.22-2.10 
(2H, m, H5 × 2), 2.03-1.94 (1H, m, HβVal), 1.53-1.42 (4H, m, H2 × 2, H4 × 2), 1.30 (3H, d, 
J = 7.5 Hz, CH3Ala), 1.22-1.14 (2H, m, H3 × 2), 0.86 (3H, d, J = 6.9 Hz, CH3Val), 0.82 
(3H, d, J = 6.9 Hz, CH3Val); 13C NMR (126 MHz, DMSO-d6) δC 172.2, 171.1, 171.0, 
171.0, 139.0, 134.4, 129.4, 119.1, 63.3, 57.5, 52.3, 49.0, 37.0, 34.9, 30.3, 27.7, 25.7, 24.8, 
19.2, 18.2, 17.9; [!]$"#  +18.2  (c 1.00, CHCl3); IR (thin film) vmax (cm-1) 3285, 2940, 1701, 
1655, 1604, 1515, 1441, 1409, 1371, 1318, 1247, 1181, 1140, 1098, 1022, 946, 826; 
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Appendix: Selected 1H and 13C NMR 
spectra
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